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Abstract
This study focused on the chemistry of Urginavia altissima (L.F) Speta, Ornithogalum 
duhium ‘Hybrid’ and Ornithogalum ponticum ‘Sochi’ of the Scilloideae subfamily (formerly 
Hyacinthaceae) of the Asparagaceae family. Plants belonging to the Scillodeae subfamily are 
widely used as medicinal plants in South Africa, Asia and Mediterranean regions for the 
treatment of various diseases including cancers. The compounds isolated previously from the 
species of the Scilloideae subfamily possess various biological activities including anticancer. 
In this study the bulbs of Urginavia altissima gave ten new bufadienolides (UA.1-UA.3, 
UA.5-UA.10 and UA.12), a known bufadienolide (UA.11), two known eudesmanes (UA.13, 
UA.14), a known 3 -benzyl-4-chromanone type homoisoflavonoid (UA.15), a known 
polyhydroxylated compound, polybotrin (UA.16), a purine nucleoside, adenosine (UA.17) 
and a di-unsaturated hydroxylated fatty acid ethyl ester (UA.18). The bulbs of Ornithogalum 
dubium ‘Hybrid’ yielded three new (ODH.4-6) and three known (ODH. 1-3) 3-benzyl-4- 
chromanone type homoisoflavonoids while the bulbs of Ornithogalum ponticum ‘Sochi’ gave 
three known cardenolide glycosides (OPS.l, 3, 5) with a rhamnose sugar attached at the C-3 
position and oxidation occurring at the C-19 position. The structures of these compounds 
were determined using FTIR, MS, ID, 2D NMR studies and CD analysis.
This study also investigated the anticancer activity and possible mode of actions of 
compounds isolated from Urginavia altissima by utilising the Computerised Pattem- 
recognition Algorithm (COMPARE) programme provided by the National Cancer Institute, 
USA, and molecular docking studies using Molecular Operating Environment (MOE 2012) 
software. The bufadienolides (UA.1-UA.10) were tested against the NCI 59 cancer cell lines. 
Compounds UA.1-UA.9 showed significant growth inhibition of cancer cell lines at five dose 
concentration level with good responses at the GI50, TGI and LC50 parameters. From 
COMPARE the bufadienolides correlated with standard agents that are DNA interacting, 
topoisomerase I and II inhibitors and DNA antimetabolites. Docking studies showed that 
bufadienolides (UA.1-5, 7-8, 12) interacted with B-DNA as groove binders and 
bufadienolides (UA.1-5, 7-8, 12) interacted with topoisomerase I and bufadienolides (UA.2- 
5, 8, 12) interacted with topoisomerase II. From the binding free energy results obtained 
from docking studies and the anticancer in vitro screen results, it can be concluded that the 
changes in the functionality of bufadienolides affect their anticancer activity and their binding 
affinities to DNA and topoisomerase I/II-DNA complexes.
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CHAPTER ONE: MEDICINAL PLANTS AND DRUG DISCOVERY
1.0 Background information
Medicinal plants have been used to alleviate diseases for thousands of years. Before the 
introduction of synthetic drugs, 80% of medicines were obtained from roots, barks, fruits and 
leaves of plants.^ These medicines were used in crude forms such as teas, powders and herbal 
formulations. The use of plants as medicines has progressed from the crude formulations to 
the isolation of active molecules, with the first being the isolation of morphine (1) from 
Papaver somniferum in 1804. This led to further isolation of early drugs such as cocaine (2) 
from the leaves of Erythroxylum sp., codeine (3) from Papaver somniferum, digitoxin (4) 
from Digitalis purpurea and quinine (5) from the bark of Cinchona sp. Plants are known to 
provide compounds directly useful as drugs or as lead compounds. This has allowed the 
design, biomimetic synthesis and discovery of new therapeutic properties not yet attributed to 
known compounds.^ An example of a drug synthesised from a natural product is aspirin (6), 
made by acétylation of salicin extracted from the willow tree."^
The development of organic chemistry in the first half of the 19* century resulted in a 
preference for synthetic products for pharmaceuticals. This was because pure compounds 
were easily obtained from synthesis, the possibility of structural modification to produce 
potentially more pharmacologically active and safer drugs and also due to increasing 
economic power of pharmaceutical companies at the time.^ However medicinal plants still 
remain an important source of drugs and their phytochemical studies have led to the isolation 
of a number of modem dmgs.^ Examples of plant derived dmgs and/or dmg leads introduced 
to the market recently include arteether (7) a potent anti-malarial dmg derived from 
artemisinin, a sesquiterpene lactone isolated from Artemisia annua, a plant used in traditional 
Chinese medicine, galanthamine (8), isolated from Galanthus woronowii Losinsk for the 
treatment of Alzheimer's disease and slowing the process of neurological degeneration, the 
anticancer agents vinblastine (9) and vincristine (10) isolated from Catharanthus roseus and 
paclitaxel (11) isolated from Taxus brevifoliaJ
R = H: 1: Morphine 
R = CH3 : 3: Codeine
5: Quinine Q y
2: Cocaine
4: Digitoxin
OCH2CH3
7: Arteether
6 : Aspirin
— O
O
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Figure 1.1: Drugs obtained from natural sourees
1.1 South Africa, a biodiversity hotspot
South Africa is one of the countries in the world characterised by vast biodiversity with 
approximately 30,000 species of vascular plants, many of which are endemic to the region.^ 
In South Africa, traditional herbal medicine forms the backbone of rural healthcare and the 
majority of South Africa’s population consult traditional healers.^ The use of these herbal 
medicines in South Africa is prevalent in regions where western medicines are inaccessible 
due to their high cost and also in regions where traditional medicine remains of cultural 
significance. A large number of plant species are used for medicinal purposes with an 
estimation of 3000 plant species being used as medicines. Of these plant species about 500 
species are traded in large quantities in informal medicinal markets.^ Due to the high level of 
biodiversity in South Africa, the study of the phytochemistry of medicinal plants is far from 
being exhausted.
1.2 Objectives of the study
The objectives of this study include:
• To determine the chemical constituents of Urginavia altissima, Ornithogalum dubium 
‘Hybrid’ and Ornithogalum ponticum ‘Sochi’
• To compare the chemical constituents of Urginavia altissima and those of Urginea 
altissima and Drimia altissima, previously investigated and thought to be 
synonymous to Urginavia altissima
• To investigate the biological activities of the compounds isolated from Urginavia 
altissima
• To determine the mode of action of compounds isolated from Urginavia altissima by 
utilising COMPARE programme provided by NCI and molecular docking studies 
using Molecular Operating Environment (MOE 2012).
CHAPTER TWO: THE URGINEEAE TRIBE, ITS BOTANICAL ASPECTS AND 
CHEMICAL CONSTITUENTS 
2.1 The Scilloideae subfamily of the Asparagaceae family (formerly Hyacinthaceae APG 
II)
The Hyacinthaceae family {sensu APG II) includes about 1000 species of bulbous plants 
grouped into over 70 g e n e r a . T h e  well-known members of the Hyacinthaceae family 
include horticultural species such as bluebells (Hyacinthoides Heist.ex Fabr.), hyacinths 
{Hyacinthus Toum. ex L.), squills {Scilla L.) and pineapple lilies {Eucomis L’Her.). The 
Hyacinthaceae family is mainly distributed through Europe, Africa and south-west Asia, with 
a small genus in western South America^^, with some members also in Madagascar. Species 
richness and endemism in the Hyacinthaceae family is highest in sub-Saharan Africa (528 
species, 80.5% endemism) followed by the Mediterranean region (262 species, 68.7% 
endemism), the Cape (184 species, 45.6% endemism). Middle East (134 species, 38% 
endemism). South America (5 species, 100% endemism) and Madagascar (<100 species). 
Molecular studies of several species of the Hyacinthaceae family by Pfosser and Speta and 
Manning et aL, led to the subdivision of the family into four subfamilies: the Hyacinthoideae, 
the Omithogaloideae, the Urgineoideae and the Oziroeoideae.^^’^ "^ Recently the 
Hyacinthaceae family has been transferred to the Scilloideae subfamily of the expanded 
Asparagaceae family, with its four subfamilies treated as tribes, namely the Hyacintheae, 
Omithogaleae, Urgineeae and Ozirëeae.^^ Several members of the Scilloideae subfamily have 
been evaluated phytochemically and a trend in their chemistry observed with the Hyacintheae 
predominantly yielding homoisoflavanones and spirocyclic nortriterpenoids, the 
Omithogaleae characterised by the presence of cardenolides and cholestane glycosides and 
the Urgineeae tribe predominantly yielding bufadienolides. None of the five species of the 
Ozirëeae tribe have been evaluated phytochemically. Urginavia altissima that is being 
evaluated in this study, belongs to the Urgineeae tribe (Asparagaceae Family). Botanical 
aspects, distribution, traditional uses and the chemistry of members of the Urgineeae tribe are 
reviewed in this chapter.
2.2 Botanical aspects and distribution of the Urgineeae tribe
The Urgineeae tribe is characterised by flattened or winged seeds with brittle, loosely 
adhering testa and are largely distributed in sub-saharan Africa, with several species in 
Eurasia. It comprises the three main African genera, Bowiea, Urginea and Drimia. The two
4
core genera Urginea and Drimia are traditionally separated by the degree of fusion of the 
perianth and the orientation of the tepals and the stamens but have been, at times, regarded as 
same g e n u s . T h e  number of genera in the Urgineeae tribe is constantly under revision. 
Wetsching in a lecture presented at the Hyacinthaceae Symposium held at the University of 
Surrey in May 2012 showed how the Urgineeae tribe has been revised over the y e a r s . I n  
1993, Reid recognised eight genera under the Urgineeae t r i b e . T h e s e  were Urginea, 
Drimia, Tenicroa, Thuranthos, Litanthus, Rhadamanthus, Schizobasis and Bowiea. 
However, Speta in 1998, subdivided the genus Urginea into Urgineopsis and Urginea, 
Radamanthus into Rhadamanthopsis and Rhadamanthus and added a new genus, Igidia, 
bringing the new number to eleven genera. In the same year, Speta proposed that the genus 
Urginea be subdivided further to another three genera, Charybdis, Ebertia and Urginavia and 
the genus Drimia to be subdivided to two genera, Drimia and Fusifilum bringing the new 
number to 15 genera. In 2001, 21 genera were suggested by Pfosser and Speta with six 
new additions, Boosia, Ledurgia and Sekanama split further from the Urginea genus, 
Gescholia split from the DrimiagQvms and Indurgia and Duthiea split from the Thuranthos 
genus. Surprisingly, in 2004, Manning and Fay lumped nineteen of these genera onto the 
Drimia genus leaving Drimia, Igidia and Bowiea, as the only three genera. According to 
Wetsching in his unpublished review presented at the University of Surrey, he proposed 23 
genera under the Urgineeae tribe.
2.3 The chemistry and ethnomedicinal properties of the Urgineeae tribe
Several species of the currently-accepted three genera, Urginea, Drimia and Bowiea, of the 
Urgineeae tribe have been analysed for their chemistry and pharmacological activities. It has 
been found that bufadienolides, C-24 steroids and their glycosides, characterise the Urgineeae 
tribe.^^ These support the use of these plants from as far back as the ancient Egyptians in the 
treatment of heart diseases. Other classes of compounds reported from this tribe include 
alkaloids.However, this finding is questionable and is thought that the plant investigated 
may have been confused with some members of the Amaryllidaceae. Other compounds 
include flavonoid,^"  ^cardenolide^^, sesquiterpenoid^^ and homoisoflavonoid classes.
2.3.3 Bufadienolides isolated from members of the Urgineeae tribe
2.3.3.1 Urginea genus
Urginea species are bulbous plants widely distributed throughout the world. It is one of the 
interesting and polytypic genera with about one hundred species occurring in Africa, India 
and the Mediterranean region. It is a well-known Southern African genus and is used for the 
treatment of various ailments such as treatment of venereal diseases, abdominal pain, 
backache and asthma. The sap of leaves and bulbs of Urginea species are irritating to the 
skin and some species produce such marked topical stinging and itching effects that they are 
used by young Xhosa boys during pain-endurance games.
2.3.3.1.1 Urginea altissima (L. f.) Baker, (syn. Urginavia altissima (L. f) Speta, Drimia 
altissima (L. f) Ker Gawl)
U. altissima occurs throughout most of sub-saharan Africa. In South Africa, the bulb 
preparations of U altissima are used in the treatment of gout, rheumatism and a range of 
respiratory conditions including asthma, influenza and bronchitis.^^ Several compounds 
including urginin (12)^ ,^ gamabufatalin-3 -0-a-L-rhamnopyranoside (13), hellebrigenin (14), 
hellebrigenin-3-O-P-D-glucopyranoside (15), scilliglaucosidin (nabogenin) (16), 
scilligalucosidin-3 -one (17), scilliglaucosidin-3-O-a-L-rhamnopyranoside (18) and
scilliglaucosidin-3p-(9-P-D-glucopyranoside (altoside) (19)^  ^ have been reported from U 
altissima.
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2.3.3.1.2 Urginea depressa Baker (syn. Drimia depressa (Baker) Jessop)
There is no report on the ethnomedicinal usage of U. depressa, however it has been reported 
to contain the known bufadienolides urginin (12) hellebrigenin-3-O-P-D-glucopyranoside 
(15), scilliglaucosidin-3p-0-P-D-glucopyranoside (altoside) (19) and hellebrigenol-3-O-p-D- 
glucopyranoside (20)?^ Other bufadienolides isolated recently by Dai et ah, include urginin B 
(21) and urginin C (12)?^ The bufatrienolides, altoside, urginin, urginin B and urginin C were 
tested for their antiprolifearive activity against A2780 ovarian cancer, A2058 melanoma and 
H522-T1 human non-small lung cancer cell lines. All were respectively found to show 
significant antiproliferative activity with IC50 values of 24, 11, 111 and 41 nM against the 
A2780 ovarian cancer cell line.^°
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2.3.3.1.3 Urginea epigea R. A. Dyer (syn. Urginavia epigea R. A. Dyer)
U. epigea is restricted to Namibia, Swaziland, and the northern and eastern provinces of 
South Africa, where it grows in semi-arid and often rocky grassland.^^ In Swaziland the 
bulbs are used as soaps and also for the treatment of backaches,^ ^ while in South Africa the 
smoke from smouldering bulbs of U. epigea is inhaled for treatment of headaches and 
colds.^^ A phytoehemieal investigation of U. epigea yielded a bufadienolide with a 3,5-diene 
system, 14p-hydroxybufa-3,5,20,22-tetraenolide (23).^  ^ This unusual 3,5-diene system is not 
commonly isolated from plant sources, however its easily obtained synthetically.^^
2.3.3.1.4 Urginea lydenburgensis R. A. Dyer
U. lydenburgensis occurs in the Mpumalanga Province of South Africa, particularly the
Lydenburg Distriet.^"  ^ It is a highly toxic species responsible for stock losses."*  ^ Its 
phytoehemieal investigation led to the isolation of two bufadienolides 16P-aeetoxy-3p,14P- 
dihydroxy-19-formyl-bufa-4,20,22-trienolide (16P-aeetoxyberseillogenin) (24) and 
4p,8p, 11 a, 14p-tetrahydroxybufa-5,20,22-trienolide-12-one-2a,3p-0-glyeoside 
(lydenburgenin) (25).^^
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2.3.3.1.5 Urginea maritima (L.) Baker (syn. Scilla maritima L, Drimia maritima (L.) 
Stearn)
U. maritima, commonly known as the white squill, has long been used in medicine due to its 
strong cardiotonic properties.^^ It is native to the Mediterranean basin and is well adapted to 
this type of climate.^^ Several compounds have been reported from U. maritima. These 
include gamabufatalin-3-O-a-L-rhamnopyranoside (13) and scilliglaucosidin-3-O-a-L- 
rhamnopyranoside (18), also isolated from U. altissima^^ 11 a-hydroxy-scilliglaucosidin-3-0- 
a-L-rhamnoside (26), scillicyanoside (27), lla-acetylgamabufotalin-3-0-(4-0-P-D- 
glucosyl)-a-L-rhamnoside (28), lla-hydroxyscilliglaucoside (29) and scillaglaucoside 
(scillaren F) (30)^  ^ and compounds 31 -  70.^ ^
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Table 2.1: Compounds 31 -  57 isolated from U, maritima39
0^ . Name Ri R2 Ri R4 R5 R6
H Proscillaridin A a-L-rhamnose H H H H H
12 Scillaren A p-D-glucopyranosyl-( 1 -^4)-a- 
L-rhamnose
H H H H H
13 Glucoscillaren A P-D-glucopyranosyl-( 1 —>4)-P- 
D- glucopyranosyl-(l—>4)-a-L- 
rhamnose
H H H H H
14 Scillarenin 3-0-P-D-glucopyranoside P-D-glucose H H H H H
15 Scillarenin-3-O-P-D-glucopyranosyl- 
1 ’ >4’-P-D-glucoside
p-D-glucopyranosyl-l’ ’-^4’-P- 
D-glucose
H H H H H
6 Scillimbrosidin-3-(9-P-D- 
glucopyranosyl-r ’-^4’-p-D-glucoside
p-D-glucopyranosyl-r ’-^4’~P- 
D-glucose
H OH H H H
7 Scillimbrosidin-3-O-p-D- 
rhamnopyranosyl-1 ’ ’-^4” p-D-
P-D-rhamnopyranosyl- 
1 ” -^4” p-D-glucopyranosyl-
H OH H H H
10
glucopyranosyl-l’ >4’-P-D-glucoside 1 ’ ’^ 4 ’-P-D-glucose
38 Scilliphaeoside a-L-rhamnose H H P-OH H H
39 Scilliphaeosidin-3-(9-P-D-glucose P-D-glucose H H p-OH H H
40 Glucoscilliphaeoside P-D- glucopyranosyl-(1^4)-a- 
L-rhamnose
H H P-OH H H
41 6-Desacetyl-scilliroside p-D-glucose OH OH H H H
42 Scilliroside P-D-glucose P-
OAc
OH H H H
43 Glucoscilliroside p-D-glucopyranosyl-( 1 —>4)-P- 
D-glucose
P-
OAc
OH H H H
44 12p-Hydroxyscillirosidine H P-
OAc
OH OH H H
15 12p-Hydroxyscilliroside P-D-glucose P-
OAc
OH OH H H
16 6-Desacetyl-12p-hydroxyscilIiroside P-D-glucose OH OH OH H H
17 12p-Hydroxyscillirubrosidln-3-0-a-L-
rhamnoside
a-L-rhamnose H OH OH H H
18 16p-Hydroxyproscillaridin A a-L-rhamnose H H H OH H
19 16P-HydroxysciIlarenin-3-0-P-D- 
glucoside
p-D-glucopyranosyl H H H OH H
50 16 P-Hydroxyglucoscillaren A p-D-glucopyranosyl-( 1 -^4)-p- 
D- glucopyranosyl-(1^4)-a-L- 
rhamnose
H H H OH H
51 16p-(9-Acetylproscillaridin A a-L-rhamnose H H H OAc H
52 16p-0-Acetylscillarenin- 3-0-P-D- 
glucoslde
p-D-glucose H H H OAc H
53 16 P-O-Acetylscillarenln-3-G-P-D 
glucosido-1" 4"- glucoside
p-D-glucopyranosyl-(l" —> 4” )- 
p-D glucose
H H H OAc H
54 16p-0-Acelyglucoscillaren A P-D-glucopyranosyl-( 1 -^4)-P- 
D- glucopyranosyl-(l-^4)-a-L- 
rhamnose
H H H OAc H
55 16p-0-Acetylscillarenln- 3-0- a- L- 
glucomethylosido-l” ^  4” -p-D- 
glucosido-
1’” ^  4” _P_D-glucoside
a- L-glucomethyl-1” ^  4” -P-D- 
glucopyranosyl-
1 ” ’ ^  4"-p-D-glucose
H H H OAc H
56 16P-0-Acetylscillirubroslde p-D-glucopyranosyl H OH H OAc H
57 9-Hydroxyscilliphaeosilde a-L-rhanmose H H P-OH H OH
11
OH
OH
RiO'
OAc
Table 2.2: Compounds 58 -  70 isolated from U. maritima39
No. Name Ri R2 Rs
58 5a-4,5-Dihydroscillirosidin-3-0-a-L-
glucomethyloside
a-L-glucomethyl H H
59 5a-4,5-Dihydroscillirosidin-3-0-a-L-
thevetoside
a-L-thevetose H H
60 5a-4,5-Dihydroscillirosidin-3-0-P -D- 
glucoside
P-D-glucose H H
61 5a-4,5-Dihydroscillirosidin-3-0-a-L-
rhamnosido-4’-P-D-glucoside
a-L-rhamnopyranosyl-4 ’ - 
p-D-glucose
H H
62 5a-4,5-Dihydroscillirosidin-3-(9-a-L-
glucomethylosido-4’-P-D-glucoside
a-L-glucomethyl-4’-p-D-
glucose
H H
63 5 a-4,5 -Dihydroscillirosidin-3-0-a-L- 
thevetosido-4’-P-D-glucoside
a-L-thevetopyranosyl-4 ’ - 
P-D-glucose
H H
64 5a-4,5-Dihydroscillirosidin-3-0-a-L- 
glucomethylosido-r ’ —>4 ’-p-D-glucosido- 
1 ’ >4” -P-D-glucoside
a-L-glucomethyl-1 ’ ’ -^4 ’ -
P-D-glucopyranosyl-
l ’” ^ 4 ” .p_D-glucose
H H
65 5 a-4,5 -Dihydroscillirosidin-3 -0-a-L- 
rhamnosido - l ” ^ 4 ’-P-D-glucosido - 
1 ’ ” -^4” -P-D-glucoside
a-L- rhamnopyranosyl -
glucopyranosyl -1 ” ’-^4’’- 
P-D-glucose
H H
66 5 a-4,5 -Dihydroscillirosidin-3 - 0-a-L- 
thevetosido - l ” ^ 4 ’-P-D-glucosido - 
1 ’ ” -^4” -P-D-glucoside
a-L- thevetopyranosyl - 
l ” ^ 4 ’.p_D-
glucopyranosyl - r ” ^ 4 ” - 
P-D-glucose
H H
67 5a-4,5-Dihydro-12p-hydroxy- scillirosidin-3- 
0-a-L-thevetoside
a-L-thevetose P-OH H
68 5a-4,5-Dihydro-12P-hydroxy- scillirosidin-3- 
0-a-L-thevetosido-4’-P-D-glucoside
a-L-thevetopyrano syl-4 ’ - 
P-D-glucose
P-OH H
69 5a-4,5-Dihydro-l6 p-hydroxy- scillirosidin-3- 
0-a-L-thevetoside
a-L-thevetose H OH
70 5a-4,5-Dihydro-l6P-0-acetyl- scillirosidin-3- 
0-a-L-thevetosido-4’-P-D-glucoside
a-L-thevetopyranosyl-4 ’ - 
P-D-glucose
H OAc
12
2.3.3.1.6 Urginea indica (Roxb) Kunth (syn. Drimia indica (Roxb) Jessop)
U. indica, also commonly known as the Indian Squill, has long been used for its cardiotonic, 
expectorate and digestive promoting properties in small doses and treatment of asthma, 
rheumatism, leprosy and other skin ailments?"^ The phytoehemieal studies on U. indica 
yielded several compounds including scilliglaucosidin-3-O-a-L-rhanmopyranoside (18), 
proscillaridin A (31), scillaren A (32) also isolated from U. altissima and U. maritima and 
scilliphaeoside (38) also isolated from U. altissima, U maritima, U hesperia and U. 
aphylla.^^ Kopp and Danner also found the bulbs to eontain seillarenin (71), scillarenin-3-0- 
a-L-rhamnoside (72), scillarenin-3-O-a-L-rhamnopyranosyl-P-D-glucoside (73), 
scilliphaesidin-3-O-a-L-rhamnoside (74), seilliglaueosidin-3-O-P-D-glucoside (19) and 
scilliglaucosidin-3 - (9-a-L-rhamnopyranoside (18)."^ ^
OH
RiO'
Table 2.3: Compounds 71 -  74 isolated from U, indica,41
No Name Ri R2
71 Seillarenin H CH]
72 Scillarenin 3-0-a-L-rhamnoside a-L-rhamnose H
73 Scillarenin 3 -0-a-L-rhamnopyranosyl-P-D- 
glueoside
a-L-rhamnopyranosyl-p-D-
glucose
H
74 Scilliphaesidin 3-0-a-L-rhamnoside a-L-rhamnose OH
2.3.3.1.6 Urginea riparia Baker
U. riparia Baker is a poorly understood bulbous species found both in the Midlands and 
coastal regions of KwaZulu-Natal and the Transkei of the Eastern Cape. It frequents rocky, 
exposed stream and riverside habitats, growing in clumped colonies with its bulbs submerged 
and leaves erect and emergent. Its phytoehemieal study led to the isolation of riparianin 
(75).""
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HQ
OCRHO, OH OCCH3
OH
2.3.3.1.7 Urginea rubella Baker
U. rubella Baker is used for the treatment of colie and the phytoehemieal investigation of U. 
rubella led to the isolation of rubellin (76)/^
HO...
OH
""OH OH
OH
76
2.3.3.1.8 Urginea sanguinea Schinz (syn. Drimia sanguined)
U. sanguinea Schinz is known in South Africa for its poisonous effects on livestock, but 
despite this, it is widely used as a herbal medicine by traditional healers. It is frequently used 
in South Africa as a blood purifier, as a treatment for venereal diseases, abdominal pain, 
backache and hypertension.'^'^ Several bufadienolides (77-82/^ have been isolated including 
scillaren A (32) and 12p-hydroxyscilliroside (45), also isolated from U. maritima. 4,Sp- 
Dihydroscillaren A (83)'^  ^has also been isolated from U. sanguinea.
14
OH
OH
R
Table 2.4: Compounds 77 -  82 isolated from U. sanguined,45
No. Name Ri R2 Rs
77 Seillirosidin OH OAc H
78 Deaeetylscillirosidin OH OH H
79 12p-Hydroxyseillirosidin OH OAc OH
80 12(3-Hydroxydeacetylseillirosidin OH OH OH
81 12p-Hydroxyseillirosidin-3 -one =0 OAc OH
82 12P-Hydroxyseillirubrosidin-3-one =0 H OH
RO'
H
83: R = p-D-gIucopyranosyI-(1^4)-a-L-rhamnose
2.3.3.1.9 Urginea physodes (Jacq.) Baker (syn. Drimia physodes (Jacq) Jessop)
U. physodes (Jacq.) Baker is thought to be related to or possibly synonymous with U. pusilla 
(Jaeq.) Baker It is used to treat genealogieal ailments and to facilitate delivery during 
birth."^  ^ Phytoehemieal studies yielded four bufadienolides (84-87) with two of them 
representing the first examples of natural 14-dehydroxybufadienolides (86-87).'^^
15
OHC
OH
OH
Table 2.5: Compounds 84 -  85 isolated from U, physodes,49
No. Name Ri R2
84 Physodine A H a-D-galaetopyranosyl
85 Physodine B OAc P-D-glueopyranosyl-(l—>4)-0-(2-0-aeetyl-a-L-thevetose)
AcO
RiO'
Table 2.6: Compounds 8 6  -  87 isolated from U, physodes49
No. Name Ri
8 6 Physodine C P-D-xylopyranosyl-(l—>4)-0- a-L-rhamnose
87 Physodine D P-D-glueopyranosyl-( 1 ^ 3 )-0-(4 ’ -0-aeetyl- a-L-rhamnose)
2.3.3.1.10 Urginea aphylla (Forssk.) Speta (syn. Drimia aphylla (Forssk.) J. C. Manning 
and Goldblatt
Phytoehemieal studies of U. aphylla led to the isolation of eleven bufadienolides ineluding 
the known seillaglaueoside (35), proseillaridin A (31), seilliphaeosidin-3-O-p-D-glueoside 
(39) and gamabufatalin 3-0-a-L-rhamnopyranoside (13) also isolated from U. maritima and 
U. altissima and 12p-hydroxyseilliroside (45) also isolated from U. maritima, U. sanguinea 
and Drimia robusta, seillarenin-3-0-|3-D-glueopyranoside (34) and seillieyanoside (27) also 
isolated from U. maritima, seilliphaeoside (38) also reported from U. maritima, U indica and 
U. hesperia. Also reported from U. aphylla are eompounds (8 8 ) and (89).^^
16
OH
Ri— O'
Table 2.7: Compounds 88 -  89 isolated from U. aphylla50
No. Name Ri Rz R] R4
88 (5a)-4,5-Dihydroscillirosidin-3-0-[p- 
D-glucopyranosyl-(l—>4)- p-D- 
glucopyranosyl-(l—»4)- a-L- 
thevatopyranoside
p-D-glucopyranosyl-(1^4)- p- 
D-glucopyranosyl-(1^4)- a-L- 
thevatose
OAc H H
89 16p-Acetylgamabufotalin 3-O-a-L- 
rhamnopyranoside
a-L-rhamnose H OH OAc
2.3.3.1.11 Urginea hesperia Webb and Berthel (syn. Drimia hesperia Webb and Berthel)
There are no reports on the ethnomedicinal usage of Urginea hesperia. Bufadienolides that 
have been reported from Urginea hespera include lla-hydroxyscillaglaucosidin-3-O-a-L- 
rhamnoside (26) isolated from U maritima, proscillaridin A (31) also isolated from U indica 
and U. maritima, scilliphaeoside (38) isolated from U maritima, U indica and U aphylla 
and glucoscillaren A (33) isolated from U. maritima. Other compounds isolated are 
scillarenin (71), scilliphaeosidin (87) scillarenin-3-O-a-L-rhamnoside (72), scilliphaeosidin- 
3-0-a-L-rhamnoside (79), gamabufotalin-3-O-a-L-rhamnoside (18), 11a-
hydroxyscilliglaucosidin-3-O-a-L-rhamnoside (90) and compounds (91-101)/^
OH
RO'
90: R = a-L-rhamnose
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Table 2.8: Compounds 91 -  101 isolated from U. hesperia51
No. Name Ri R2
91 Scilliphaeosidin H P-OH
92 Scillarenin-3-0-a-L-2',3'-diacetylrhamnopyranosyl-4'-P-
D-glucoside
ot-L-2',3'-
diacetylrhamnopyranosyl-4'-
p-D-glucose
93 Scillarenin-3-(9-a-L-rhamnopyranosyl-4'-P-D- 
glucopyranosyl-3 "-P-D-glucoside
a-L-rhamnopyranosyl-4'-P- 
D-glucosyl-3 "-p-D-glucose
H
94 Scillarenin-3-0-a-L-rhamnopyranosyl-4'-P-D-
glucopyranosyl-4"-p-D-glucoside
a-L-rhamnopyranosyl-4'-p-
D-glucosyl-4"-P-D-glucose
H
95 Scillarenin-3-0-a-L-2',3'-diacetylrhamnopyranosyl-4'-P-
D-glucopyranosyl-3"-p-D-glucoside
a-L-2',3'-
diacetylrhamnopyranosyl-4- 
P-D-glucosyl-3 "-P-D-glucose
H
96 Scillarenin-3-O-a-L-2',3'-diacetylrhamnopyranosyl-4'-P- 
D-glucosido-4"-P-D-glucoside
cc-L-2',3'-
diacetylrhamnopyranosyl-4'-
p-D-glucosyl-4"-p-D-glucose
H
97 Scilliphaeosidin-3-0-a-L-rhamnopyranosyl-4'-P-D- 
glucopyranosyl-3 "-P-D-glucoside
a-L-rhamnopyranosyl-4'-P- 
D-glucosyl-3 "-P-D-glucose
OH
98 Scilliphaeosidin-3-0-a-L-rhamnopyranosyl-4'-P-D-
glucopyranosyl-4"-p-D-glucoside
a-L-rhamnosyl-4'-P-D-
glucosyl-4"-P-D-glucose
OH
99 Scillarenin 3-0-[ P-D-glucopyranosyl-(1^3)- P-D- 
glucopyranosyl-(l—>4)- a-L-(2,3- 
diacetylrhamnopyrano side)
p-D-glucopyranosyl-(l ^ 3 ) -  
P-D-glucopyranosyl-( 1^4 )- 
a-L-(2,3 -diacetylrhamnose)
H
100 Scilliphaeosidin 3-0-[ p-D-glucopyranosyl-(l-^3)- P-D- 
glucopyranosyl-( 1 —>4)-a-L-rhamnopyranoside
P-D-glucopyranosyl-(l —>3)- 
p-D-glucopyranosyl-(1^4) -  
a-L -rhamnose
OH
101 Scillaren 3-0-p-[D-glucopyranosyl-(l -^4)-(2,3- 
diacetylrhamnopyranoside]
P-[D-glucopyranosyl-(1^4)- 
(2,3-diacetylrhamnose)
H
2.3.3.1.12 Urginea pancration Steinh.
U. pancration Steinh yielded lla-hydroxyscillaglaucosidin-3-O-a-L-rhanmoside (26), 
scillaglaucoside (30) and scilliroside (42) which have been reported previously from U. 
maritima, scillirubroside (102), arenobufagin-3-0-[P-D-glucopyranosyl-(14)-a-L-
18
rhamnopyranosyl (103) and (5a)-4,5-dihydroscillirosidin 3-0-p-D-glucopyranosyl-(14)-a-L- 
thevetopyranoside (104)/^'^^
RO'
102: R = p-D-glucose
HO...
OH
RO'
H
OH
OH
RO'
103: R = a-L-rhamnopyranosyl 104: R = a-L-thevetopyranoside
2.33,2 The Bowiea genus
Taxonomical and phytoehemieal analysis of the Bowiea genus has eentered on Bowiea 
volubilis. The genus Bowiea is endemie to the eentral and eastern regions of South Afriea 
and it forms an important and popular eomponent of traditional medieine.^"^
2.3.3.2.1 Bowiea volubilis Harv. ex Hook. f.
B. volubilis Harv. ex Hook. f. is a frequently traded medieinal plant in South Afriea. It grows 
in forests and valley thiekets in the Kwazulu Natal provinee.^^ It is used to treat oedema 
(dropsy), infertility in women and headaehes. It is also used as a purgative, a lotion for sore 
eyes and a remedy for aseites, sterility and bladder eomplaints."^  ^ A phytoehemieal 
investigation led to the identifieation of eleven bufadienolide glyeosides and out of these, five 
struetures have been determined. Bufadienolides isolated inelude bovoside A (105), 
bovoruboside (106), bovoeryptoside (107) and glueobovoside A (108)^^, bovogenin A 
(109).^^ The struetures of bovoside bovoside bovoside bovogenin E, 
kilimandseharogenin A,^  ^ and bowieasubstanz have not been determined. Also isolated 
from Bowiea volubilis inelude nabogenin (seilliglaueosidin) (16),^  ^ reported from Urginea 
altissima.
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OH
HO
HO.OHC OHC
OHOH OH
HO HO- HO'
OH
109
108
105:R = a-H,Ri = H 
106: R= p-OH, Ri = =0  
107:R=B-OH. Ri = OH
2.3.3.3 Drimia genera
Plants of the genus Drimia are typically geophytes with scaly bulbs and are closely related to 
the genus Urginea. The two genera are sometimes used interchangeably and there is debate 
on whether they should form one genus. The genus Drimia, however, is well defined by the 
apomorphic short lived flowers with the tepals mostly more or less fused below and the 
perianth caducous, abscising at the base and withering as a cap on the developing fruit. 
Drimia species are used to treat stabbing chest pains, stomach ailments, high blood pressure 
and feverish colds.
2.3.3.3.1 Drimia altissima (L. f.) Gawl. (syn. Urginea altissima (L. f.) Baker)
D. altissima is sometimes known as the sea onion. It was used by ancient Greeks to plant on 
graves and to hang over their doors to keep away evil. It was also used in the 18* century in 
the European courts and in Africa as a diuretic. Gamabufatalin-3-O-a-L-rhamnopyranoside 
(13), also isolated from U. maritima and U. aphylla, and arenobufagin-3 -0-a-L- 
rhamnopyranoside (110) were isolated from Drimia altissima.
HO.
OH
110
OH OH
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2 3 3 3 .2  Drimia depressa Baker. Jessop (syn. Urginea depressa Baker)
D. depressa is a widespread bulb of open upland grassveld in the summer-rainfall region of 
southern Africa. It is used in tradional medicine by the Sotho people as a good luck and 
protective charm and as a means of inflicting harm to foes.^^ The methanol extract of the 
bulbs of D. depressa yielded two bufadienolides: 3p,5p,16p-dihydroxybufa-20,22-dienolide 
(111) and 16p-hydroxy-5p-bufa-20,22-dienolide-3P-O-P-D-galactoside (112).^^
OH
RO'
H
111:R = H
112: R = p-D-galactose
2.3.S.3.3 Drimia robusta Baker
D. robusta Baker is a widely used medicinal plant among the Zulus in South Africa. Its 
preparations are used as diuretics, emitics, expectorants, for treatment of febrile complaints, 
diseases of the uterus and to promote the healing of broken bones."^  ^ Phytoehemieal studies 
of D. robusta led to the isolation of 12p-hydroxyseillirosidin (44),^^ also isolated from U. 
sanguinea and U. maritima, proscillaridin A (31), also isolated from U. indica and U. 
maritima and scilliroside (42), also isolated from U. maritima and U. pancration. Other 
compounds reported from D. robusta are 16p-hydroxyhellebrigenin-3-(9-P-D- 
glucopyranoside (113), 5p,16p-hydroxybufalin-3-0- P-D-glueopyranoside (114).
OH
,0H
OH
HO
OH 
113: R = CHO 
114: R = CH3
HO OH
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2.3.3.3.4 Drimia macrocentra (Baker) Jessop
D. macrocentra (Baker) Jessop is used as an anthelmintic'^^ and a bufadienolide, rubellin (74), 
isolated previously from U. rubella, has been isolated from this plant.'^^
2.3.4 Cardenolides isolated from members of the Urgineeae tribe
U. fugax (Moris) Steinh. is the most widespread species of the Urginea genus. 
Phytoehemieal studies of U. fugax led to isolation of 12a,14p-dihydroxy-2a,Sp-(tetra-hydro- 
3',5'-dihydroxy-4-methoxy-6'-methyl-2H-pyran-2',4'-diylbisoxy)-card-4,20-dienolide, 
commonly called fiigaxin (115).^^ This is the only report of the presence of cardenolides 
from a member of the Urgineeae tribe. Cardenolides are regularly reported from members of 
the Omithogaleae tribe.^^
OH
0 C H 3HO.
»"0H OH
115
O
2.3.5 Sesquiterpenoids from members of the Urgineeae tribe
Koorbanally et ah, reported two sesquiterpenoids, (+)-ip,6a-dihydroxy-4(15)-eudesmane 
(116) and 6a-hydroxy-4( 15)-eudesmen-1 -one (117), from U. epigea?^ This was the first 
report of the presence of sesquiterpenoids from a member of the Urgineeae tribe.
OH
OH
116
OH
117
2.3.6 Homoisoflavanones from members of the Urgineeae tribe
Koorbanally et al., reported the first isolation of a homoisoflavanone, (i?)-5,7-dihydroxy-(4- 
hydroxy-3-methoxybenzyl)chroman-4-one (118), from D. delagoensis?^ Six
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homoisoflavonoids, urgineanins A-F (119-124), have also been reported from Urginea 
depressa?^ The investigation of Urgineanins A-F for antiproliferative activity against the 
A2780 ovarian cancer cell line showed that the highly oxygenated urgineanins A-E had 
strong antiproliferative activity with IC50 values of 0.32, 3.4, 1.35, 0.35 and 1.44 pM 
respectively. The less oxygenated urgineanin F (124) showed a much lower activity with an 
IC50 value of 23
OH
0 CH3
OH o H
MeO
MeO
118
119:Ri=OH, R2=CH3 
120:Ri=OH, R2=H 
121:Ri=H, R2=CH3
MeO
MeO
MeO O
122
MeO O
123
OH 0
OMe
2.3.1 Alkaloids isolated from members of the Urgineeae tribe
Lycorine (125) and acetylcaranine (126) isolated from Urginea altissima Baker are known to 
possess antimicrobial activity against Phytophthora capsici?^ However, these two alkaloids 
are typical constituents of bulbs of the Amaryllidaceae family^® and these reported alkaloids 
are likely to have resulted from misidentification of an Amaryllidaceous species.
OH
AcO'
OH
125 126
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2.3.2 Flavonoids isolated from members of the Urgineeae tribe
5,6-Dimethoxy-3',4"-dioxymethylene-7-(9-(6"-P-D-glucopyranosyl-P-D-glucopyranosyl)- 
flavanone (127), 5,4'-dihydroxy-3-0-a-L-rhamnopyranosyl-6-C-glucopyranosyl-7-(9-(6"- 
j!7fl[ra-coumaroyl-p-D-glucopyranosyl)-flavone (128) and 5,4'-dihydroxy-3-0-(2'""-P- 
glucopyranosyl-a-L-rhamnopyranosyl)-6-C-glucopyranosyl-7-0-(6"-pârra-coumaroyl-P-D- 
glucopyranosyl)-flavone (129) have been isolated from the n-butanol soluble fraction of the 
bulbs of Urginea indica (Roxb.) Kunth (Indian Squill). "^^
.OH
OHHO
.0
HO-
HO
HO-
OH
OH
OH
OR
127 128: R = H
129: R = p-D-glucose
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CHAPTER THREE: THE CHEMISTRY OF URGINAVIA ALTISSIMA
3.1 Introduction
Urginavia altissima (L. f.) Speta (syn. Urginea altissima (L. f) Baker, Drimia altissima (L.f.) 
Ker Gawl) is an African species belonging to the Urgineeae tribe of the Scilloideae family. 
The genus Urginavia, was recently split from the well-known genus, Urginea}^ Urginavia 
altissima grows from a large bulb, often half above ground, with fleshy scales, and tough 
leaves [Picture 1].
Picture 1: A photograph of Urginavia altissima (Photograph by Linda Langat)
There are no reports on the chemistry and the ethnomedicinal uses of the concept Urginavia 
altissima, however two of its synonyms, Urginea altissima and Drimia altissima that are both 
widespread in sub-Saharan Africa are widely studied.^^’^  ^ Urginea altissima (syn. Drimia 
altissima) is reported to cause serious loss of stock in South and East Africa and in northern 
Z i m b a b w e . T h e  toxicity of this plant is attributed to the presence of bufadienolide 
glycosides which are known to exhibit digitalis-like action.^^ In South Africa, preparations 
from the bulbs are used in the treatment of gout, rheumatism, respiratory complaints, 
influenza and b r o n c h i t i s .Urginea altissima and Drimia altissima have been reported to 
yield eight (14-19)^ ’^^  ^and two (13 and 110)^  ^bufadienolides respectively.
The plant material of Urginavia altissima that is currently being studied was obtained from a 
green house in Graz, Austria. The plant material was initially collected from South Africa 
and propagated in Graz, Austria. Urginea altissima, previously analysed, was purchased
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from the Warwick Triangle Herbal Market in Durban^^, whereas Drimia altissima was 
collected from Negele, Sidamo province in Ethiopia.^^ In the present study, ten novel 
bufadienolides (Compounds UA.l, UA.2, UA.3, UA.5 UA.6, UA.7, UA.8, UA.9, UA.IO and 
UA.12), two known sesquiterpenoids (UA.13 and UA.l4) previously reported only from 
Urginea epigea (Page 22), one known homoisoflavonoid (UA.15), the polyhydroxylated 
compound, polybotrin (UA.16), a purine nucleoside, adenosine (UA.l7) and a new di­
unsaturated hydroxylated fatty acid ethyl ether (UA.18) were isolated from Urginavia 
altissima. Compounds UA.4, UA.5 and UA.10 were purified as acetylated derivatives and 
their precursors are novel. Compound UA.11 was also purified as an acetylated derivative 
and its precursor was isolated previously from Urginea maritima and Urginea 
pancration.^^’^  ^ Compounds UA.2 and UA.8 are likely to be artefacts as ethanol was used as 
extraction solvent. The observed differences in the chemical constituents of Urginavia 
altissima to the previously investigated Urginea altissima and Drimia altissima could be 
attributed to geographical and ecological variations. The structural elucidation of the 
compounds isolated from Urginavia altissima is described below. The extraction and 
isolation of compounds from Urginavia altissima is described on experimental section 8.4.
HO,HO.HO,
OH
OHOHOH
HO'
HO'""
OHHO'
UA.1 UA.2 UA.3
HO,
OAc OAc
OH OH
AcO AcO
OAcAcO' OAcAcO"
UA.4 UA.5
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3.2 RESULTS
3.2.1 Structural elucidation of compound UA.l: 3a,llp,14p-Trihydroxybufa-4,20,22- 
trienolide
Compound UA.l was isolated as a colourless oil from the ethanol extract of the bulbs of 
Urginavia altissima. Compound UA.1 was identified as the novel 3a,lip,14p- 
trihydroxybufa-4,20,22-trienolide.
HO,
OH
HO'
UA.1
Figure 3.2.1: Structure for compound UA.1: 3a,lip,14p-Trihydroxybufa-4,20,22-
trienolide
The HRMS spectrum [Spectrum 3.2.1.1] of compound UA.1 gave a [M + Na]  ^ ion at m/z 
423.2135 which indicated a molecular formula of C24H32O5. The IR spectrum [Spectrum
3.2.1.2] for compound UA.l showed absorption bands at 3418 and 1715 cm'^ assigned to OH 
and C=0 stretches respectively.^^ The carbonyl group stretch at 1715 cm'^ was attributed to 
the a,p-unsaturated carbonyl group of an a-pyrone ring.^  ^ Goel and Ram in their review of 
natural and synthetic 2H-pyran-2-ones showed that the characteristic peak in the IR spectrum 
for the C=0 stretching frequency for pyran-2-ones appears at 1730-1704 cm"\ and is 
sometimes accompanied by less intense peaks at higher frequency of 1770-1740 cm"\^^ The 
lowering of the frequency of the carbonyl stretch occurs due to the presence of the C=C 
bonds adjacent to the carbonyl group which results in the delocalization of the n electrons in 
the C=0 and C=C bonds, causing an increase in the single-bond character of the C=0 and 
C=C bonds, thus lowering their force constants, resulting in a lower f r e q u e n c y . T h e  
NMR spectrum of UA.l [Spectrum 3.2.1.3] showed characteristic proton resonances of 
protons of an a-pyrone ring at 5 7.78 (dd, J= 9.8, 2.6 Hz), ô 7.22 (d, J= 2.6 Hz), and 5 6.27 
(d, J= 9.8 Hz), an alkene proton resonance at 8  5.29 (hr s, W 1/2 = 4.7 Hz), two oxymethine 
proton resonances at 4.16 (m) and 4.23 (m) and two methyl group proton singlets at 0.98 and 
1.32.
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The NMR [Spectrum 3.2.1.4], DEPT [Spectrum 3.1.5] and HSQCDEPT [Spectrum
3.2.1.6] spectra displayed twenty-four carbon resonances for compound UA.1, which 
included a lactone carbonyl carbon resonance at 5 162.5, six double bond carbon resonances 
at 5 148.8, 5 147.9, ô 146.8, 5 122.5, 5 122.3 and 5 115.6 and three resonances for carbons 
attached to oxygen at ô 86.5, ô 67.7 and 5 67.5. The NMR spectrum of compound UA.1 
showed two methyls, seven methylenes, nine methines and six fully substituted carbon 
resonances (Table 3.1). This information suggested that compound UA.l was a 
bufadienolide. The proton resonances at ô 7.22, ô 7.78 and ô 6.27 which corresponded with 
carbon resonances at ô 148.8, 5 146.8 and 8 115.5 in the HSQCDEPT spectrum were 
assigned to H-21, H-22 and H-23 of the a-pyrone ring respectively. These three resonances 
showed correlations in the HMBC spectrum [Spectrum 3.2.1.7] with a carbonyl carbon 
resonance at 8 162.5 assigned to C-24. In addition, the H-21 and H-23 resonances showed 
correlations in the HMBC spectrum with a fully substituted double bond carbon resonance at 
8 122.5 assigned to C-20. The allylic proton resonance at 8 2.46 (dd, J= 6.3, 9.8 Hz) which 
corresponded to a carbon resonance at 8 52.0 in HSQCDEPT spectrum was assigned to H-17 
due to a correlation observed in the HMBC spectrum with C-20.
The H-17 resonance showed coupling in the COSY spectrum [Spectrum 3.2.1.8] with two 
proton resonances at 8 2.15 and 8 1.71 assigned to the two H-16 protons, which, in turn, 
showed coupling with proton resonances at 8 1.89 and 8 1.71 assigned to the two H-15 
protons. The carbon resonances for C-16 and C-15 occurred at 8 28.7 and 8 32.8 
respectively. The C-17 carbon resonance showed a correlation in the HMBC spectrum with a 
methyl proton resonance at 8 0.98, assigned to 3H-18 (8c 19.9). This methyl resonance 
showed a correlation in the HMBC spectrum with carbon resonances at 8 49.0 (CHi), 8 48.0 
(C) and 8 86.5 (C) which were assigned to C-12, C-13 and C-14 respectively. The two H-12 
proton resonances occurred at 8 1.70 and 8 1.50. These two resonances were coupled to an 
oxymethine proton resonance at 8 4.23 (8c 67.7) ascribed to H-11. This resonance was seen 
to be coupled in the COSY spectrum to a methine proton resonance at 8 1.08, corresponding 
to H-9 whose carbon resonance occurred at 8 52.6. The C-9 carbon resonance showed a 
correlation in the HMBC spectrum with a methyl proton resonance at 8 1.32 (3H, s) assigned 
to 3H-19, which, in turn, showed further correlations in the HMBC spectrum with carbon 
resonances at 8 35.4 and 8 147.9 ascribed to C-1 and C-5 respectively. The HSQCDEPT 
spectrum showed that the two H-1 proton resonances occurred at 8 1.87 and 8 1.42, and the 
corresponding carbon resonance occurred at 8 35.4.
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The two H-1 proton resonances showed coupling in the COSY spectrum with two proton 
resonances at 5 1.94 and 5 1.48 for the two H-2 protons, which, in turn, showed coupling in 
the COSY spectrum with an oxymethine proton resonance at 5 4.16 ascribed to H-3. The H-3 
proton resonance showed coupling with an alkene proton resonance at 6 5.29 indicating the 
presence of a double bond at C-4. The C-2, C-3 and C-4 resonances occurred at 5 29.3, 5 
67.5 and 5 122.3 respectively. The previously assigned H-9 proton resonance was seen to be 
coupled to a methine proton resonance at 5 2.08 (H-8), which, in turn, was coupled to the two 
H-7 methylene proton resonances at 5 2.20 and 5 2.07. The two H-7 proton resonances was 
also seen to be coupled to overlapped methylene proton resonances at 5 2.15 assigned to the 
two H-6 protons.
The relative configuration of compound UA.l was assigned using the NOESY experiment, a 
Spartan08 generated model (Figure 3.2) using MMFF basis set and biosynthetic principles. 
Biosynthetically, bufadienolides would have H-8, 3H-18, 3H-19 and the a-pyrone ring in the 
P-orientation, and H-9 and H-17 in the a-orientation of the molecule. The a-eonfigured H-9 
proton resonance showed a correlation in the NOESY spectrum [Spectrum 3.2.1.9] with the 
H-11 resonance, therefore allowing for the determination of the configuration of 11-OH as p. 
Using the P configured 3H-19 proton resonance as a starting point, and the correlations 
observed in the NOESY spectrum for 3H-19 with H-ip, H-2P and H-6P proton resonances 
these resonances could be assigned. The p-configured H-2 and H-6 proton resonances 
showed correlations in the NOESY spectrum with the H-3 resonance therefore allowing for 
the placement of 3-OH on the a face of the molecule. Selected NOESY correlations for the 
compound are shown in Figure 3.2.1 Compound UA.1 was therefore determined to be a 
novel 3a,lip,14p-trihydroxybufa-4,20,22-trienolide. A specific rotation value of + 53.4 for 
compound UA.l was measured.
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Figure 3.2.2: A 3D model for compound UA.l showing selected NOESY correlations
Table 3.2.1: Correlation table for compound UA.l: 3a,lip,14p-Trihydroxybufa-4,20,22- 
trienolide
No NMR (125 
MHz) CDCI3
H NMR (500 MHz) 
CDCI3
HMBC
(H ^C )
COSY (H ^H ) NOESY (H-^H)
la 35.4 1.87 m IP, 2a, 2P IP, 9,11
IP 1.42 m la, 2a, 2p la, 19
2a 29.3 1.48 m 1, 19 la, 1P,2P,3 2P
2P 1.94 m la, ip, 2a, 3 2a, 3, 19
3 67.5 4.16 (br m W 1/2 = 22.2 Hz) 2 ,4 2P, 4, 6P
4 122.3 5.27 (br s Wi/2 = 4.7 Hz) 3 3,6
5 147.9 - - - -
6a 31.6 2.20 m 6P, 7a, 7P 4, 6p
6p 2.07 m 6a, 7a, 7p 3, 4, 6a, 19
7a 28.9 2.15 m 6a, 6P, 7p, 8 7P,9
7(3 2.15 m 6a, 6p, 7a, 8 7a
8 37.8 2.08 m 7a, 7P, 9 18
9 52.6 1.08 (dd, 2.4, 11.8 Hz) 8 8,11 la, 7a, 11
10 38.2 - - - -
11 67.7 4.23 (br s Wi/2= 9.2 Hz) 9, 12a, 12P la, 9, 12a, 12p
12a 49.0 1.50 m 18 11,12P 11, 17
12P 1.70 m 13, 18 11, 12a 11
13 48.0 - - - -
14 86.5 - - - -
15a 32.8 1.89 m 16a, 16p 153
15P 1.71 m 14 16a, 16p 15a, 18
16a 28.7 2.15 m 15a, 15P, 16p, 17 16P, 17
16(3 1.71 m 14, 17 15a, 15p, 16a, 17 16a, 17, 18
17 52.0 2.46 (dd, J= 6.3, 9.8 Hz) 15, 16, 20 16a, 16p 16a, 16p,21
18 19.9 0.98 s 12, 13, 14, 17 - 8, 15P, 16P
19 23.2 1.32 s 1 ,5 ,9 - 1P,2P, 6P,8
20 122.5 - - - -
21 148.8 7.22 (d, 2.6) 20, 22, 24 22 17, 22
22 146.8 7.78 (dd, 9.8, 2.6 Hz) 21,24 21,23 12, 18, 23
23 115.6 6.27 (d, 9.8) 20,24 22 22
24 162.5 - - - -
31
3.2.2 Structural elucidation of compound UA.2: 3a-Ethoxy-lip,14p-dihydroxybufa-
4,20,22-trienolide
Compound UA.2 was isolated as a colourless oil from the ethanol extract of the bulbs of 
Urginavia altissima. Compound UA.2 was found to be an ethoxy derivative of compound 
UA.1 and identified as 3a-ethoxy-lip,14p-dihydroxybufa-4,20,22-trienolide.
'20
HO.
OH
UA.2
Figure 3.2.3: Structure for compound UA.2: 3a-Ethoxy-lip,14p-dihydroxybufa-4,20,22-
trienolide
The HRMS spectrum [Spectrum 3.2.2.1] of compound UA.2 gave a [M + Na]  ^ ion at m!z 
451.2453 which indicated a molecular formula of C26H36O5. The IR spectrum [Spectrum 
3.2.2.2J for compound UA.2 showed absorption bands at 3448, 1714 and 1660 cm'^assigned 
to OH, C=0 and C=C stretches respectively.^^ The ^H NMR spectrum [Spectrum 3.2.2.3J 
showed characteristic proton resonances of an a- pyrone ring at 8  7.78 (dd, J= 9.8, 2.6 Hz), 8  
7.22 (d, J=2.6 Hz) and 8  6.27 (d, J=9.7 Hz), a double bond proton resonance at 8  5.31 (br s 
Wi/2= 4.5 Hz), four proton resonances at 8  4.23 (m), 8  3.82 (m) and 8  3.53 (m) and 3.57 (m) 
for hydrogens attached to oxygenated carbons, two methyl group proton singlets at 8  1.32 and 
8  0.98 and a triplet methyl proton resonance at 1.22 (J= 7.0 Hz).
The ^^ C NMR [Spectrum 3.2.2.4], DEPT [Spectrum 3.2.2.S] and HSQCDEPT [Spectrum
3.2.2.6] spectra displayed twenty-six carbon resonances for compound UA.2, which included 
a lactone carbonyl carbon resonance at 8  162.5, six double bond carbon resonances and four 
resonances for carbons attached to oxygen at 8  86.2, 8  74.7, 8  67.5 and 63.5. Overall, the 
NMR spectrum of compound UA.2 showed three methyls, eight methylenes, nine methines 
and six fully substituted carbon resonances (Table 3.2). The NMR chemical shifts for 
compound UA.2 were identical to those of compound UA.l except at C-1 ( 8  35.7), C-2 ( 8  
25.7), C-3 ( 8  74.7) and C-4 ( 8  120.4) positions. Those for compound UA.l occurred at 8
35.4 (C-1), 8 29.3 (C-2), 8 67.5 (C-3) and 8 122.3 (C-4). In addition, the H^ NMR and COSY
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[Spectrum 3.2.2.S] spectra showed an ethyl group eoupling system of a triplet methyl proton 
resonance at 6 1.22 (t, J= 7.0 Hz) and oxymethylene group proton resonances at 5 3.53 (m) 
and 3.57 (m). Compound UA.2 was likely to be an ethoxy derivative of compound UA.l.
The HMBC spectrum of compound UA.2 [Spectrum 3.2.2.7] was used to confirm the 
placement of the ethoxy group at the C-3 position. A correlation in the HMBC spectrum was 
seen between the 3H-19 proton resonance singlet at § 1.31 and an alkene carbon resonance at 
5 147.6 ascribed to C-5, as was observed for compound UA.l. It was also seen that the H-4 
alkene proton resonance at 5 5.31 coupled with an oxymethine proton resonance at 5 3.82 
assigned to H-3. This proton resonance showed correlation in the HMBC spectrum with an 
oxygenated earbon resonance at Ô 63.5 ascribed to C-T of the ethoxy group.
The NOESY experiment [Spectrum 3.2.2.9J confirmed that the eonfiguration at the C-3 
position was the same as that of eompound UA.l Correlations in the NOESY spectrum were 
observed between the H-3 and H-lp and H-2p proton resonances. The H-2p proton 
resonance, in turn, showed a correlation with the p-configured 3H-19 methyl group proton 
resonance. Compound UA.2 was therefore identified to be 3a-ethoxy-lip,14p- 
dihydroxybufa-4,20,22-trienolide and a derivative of compound UA.l. The specific rotation 
for this compound was + 60.7°. Since the extraction of the bulbs of Urginavia altissima was 
done using ethanol, compound UA.2, the 3a-ethoxy derivative of UA.l was likely to be an 
extraction artefact.
7 /
Figure 3.2.4: A 3D Spartan model of compound UA.2 showing selected NOESY
correlations
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Table 3.2.2. Correlation table for UA.2: 3a-Etboxy-lip,14p-dibydroxybufa-4,20,22-
trienolide
No. " c  NMR (125 
MHz) CDCI3
NMR (500 MHz) 
CDCI3
HMBC (H ^H ) COSY (H-^H) NOESY (H ^H )
la 35.7 1.91 m 10 IP, 2a, 2P 11
IP 1.43 m 19 la, 2a, 2p 2P,3
2a 25.7 1.58 m 1P,2P,3P 2P
2P 1.96 m 10 la, 2a, 3p 20,3
3 74.7 3.82 brmWi/2= 19.0 Hz) 2 ,4 IP, 2P,4
4 120.4 5.31 (br s Wi/2= 4.6 Hz) 2, 6, 10 3 8
5 147.8 - - - -
6a 31.6 2.28 m 7 6P, 7a, 7p, 8 6P
6P 2.11 m 5 6a, la,  7P, 8 6a
7a 28.9 2.20 m 5 6a, 6p, 7P, 8 7P
7P 2.23 m 5 6a, 6p, la,  8 70,8
8 37.8 2.06 m 14, 15 7a, 7P, 9 4, 7P, 18
9 52.9 1.06 (dd, J=2.6, 12.3 Hz) 8, 12 8,11 11, 15a
10 38.4 - - - -
11 67.5 4.23 (t, J= 3.0) 8, 12, 13 12a, 12P, 9 la  ,9, 12a, 12p
12a 48.9 1.48 m 13,18 11, 12P 11, 12P, 17
12P 1.70 (d d ,/-2 .7 , 14.9 Hz) 9,11,13 11, 12a 11, 12a
13 48.0 - - - -
14 86.2 - - - -
15a 32.6 1.73 m 13, 14,17 15P, 16a, 16P 15P, 16a
15P 1.90 m 14 15a, 16a, 16p 15a, 16P
16a 28.5 1.75 m 13, 14,17 15a,15P, 16P, 17 17, 16P
16p 2.14 m 14 15a, 15P, 16a, 17 15P, 16a
17 52.0 2.46 (dd, 7= 5.7, 9.7 Hz) 13, 14, 20, 22 16a, 16P, 17 12a, 16a
18 19.9 0.98 s 12, 13, 14, 17 - 8, 12P, 22
19 23.1 1.31s 1,5, 9, 10 - 2P,8
20 122.9 - - - -
21 148.8 7.21 (d, J= 2.6 Hz) 17, 20, 22, 24 22 17,23
22 146.8 7.77 (dd, 7= 2.6, 9.7 Hz) 21,24 23,21 12P, 18, 23
23 115.6 6.27 (d, 7= 9.7 Hz) 20, 24 22 21,22
24 162.4 - - - -
r 63.5 3.53 m 2% 3 2’ 2’
3.57 m 2% 3 2’ 2’
2’ 15.9 1.22 (t, 7= 7.0 Hz) V r 1’
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3.2.3 Structural elucidation of compound UA.3: 3a-(0-p-D-GIucopyranoside)-lip,14p- 
dihydroxybufa-4,20,22-trienolide
Compound UA.3 was isolated as a colourless oil from the ethanol extract of the bulbs of 
Urginavia altissima. Compound UA.3 was found to be a glucose derivative of compound 
UA.l and was identified as the novel 3a-(0-P-D-glucopyranoside)-lip,14p-dihydroxybufa-
4,20,22-trienolide.
OH
HO' 4
HO 3
HO,
OH
O'
UA.3
Figure 3.2.5: Structure for compound UA.3: 3a-(0-p-D-GIucopyranoside)-llp,I4p-
dihydroxybufa-4,20,22-trienolide
The HRMS spectrum [Spectrum 3.2.3.1] of compound UA.3 gave a [M + Na] ion at mtz 
585.2672 which indicated a molecular formula of C30H42O10. The IR spectrum [Spectrum
3.2.3.2] for compound UA.3 showed absorption band at 3396, 1715 and 1629 cm'^ assigned 
to OH, C=0 and C=C stretches respectively.^^ The NMR spectrum [Spectrum 3.2.3.3] 
showed characteristic proton resonance of an a-pyrone ring at 8  7.98 (dd, J= 9.5, 2.5 Hz), 8  
7.44 (dd, J=2.5, 0.7 Hz), and 8  6.31 (dd, J=9.5, 0.7 Hz), a double bond proton resonance at 8  
5.41 (br s Wi/2 =4.5 Hz) and nine proton resonances at 8  4.44 (d, J= 7.8 Hz), 4.28 (m), 4.17 
(m), 3.89 (dd, 1.99, 12.1 Hz), 8 3.69 (dd, 5.5, 12.1 Hz), 8 3.38 (m), 8 3.31 (m), 8 3.30 
(m) and 8  3.18 (dd, /=  7.8, 9.1 Hz) for hydrogens attached to oxygenated carbons and two 
methyl group proton singlets at 1.34 and 1.01.
The ^^ C NMR [Spectrum 3.2.3.4J, DEPT [Spectrum 3.2.3.5] and HSQCDEPT [Spectrum
3.2.3.6] spectra showed thirty carbon resonances for eompound UA.3, which included a 
lactone carbonyl earbon resonance at 8  165.0, six double bond carbon resonances, an 
anomeric carbon resonance at 8  103.5, eight oxygenated carbon resonances at 8  86.9, 8  78.3, 
8  78.1, 8  76.9, 8  75.3, 8  71.9, 8  67.7 and 8  63.0. The NMR spectrum of Compound UA.3
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showed two methyls, eight methylenes, fourteen methines and six fully substituted carbon 
resonances (Table 3.2.3). Twenty-four of these carbon resonances were attributed to the 
same bufadienolide aglycone as UA.l, leaving six carbons to be accounted for. The presence 
of a resonance at 8 103.5 in NMR spectrum which correlated to an anomeric proton 
resonance at 8 4.44 (d, J= 7.8 Hz) in the HSQCDEPT spectrum, suggested the presence of a 
sugar group. As was observed in compound UA.1, the alkene was placed at the C-4 position. 
The double bond proton resonance at 8 5.41 (br s, Wi/2= 4.5 Hz) which was attributed to H-4 
showed coupling in the COSY spectrum [Spectrum 3.2.3.S] with the oxymethine proton 
resonance at 8 4.28 (8c 76.9) assigned to H-3. The C-3 carbon resonance showed a 
correlation in the HMBC spectrum [Spectrum 3.2.3.7] with the anomeric proton resonance at 
8 4.44, hence allowing the placement of the sugar unit at the C-3 position. The sugar was 
identified as P-D-glueose using the NOESY experiment. Correlations were seen in the 
NOESY spectrum [Spectrum 3.2.3.9] between H-1’, H-3’ and H-5’ and correlation between 
H-2’ and H-4’ was also observed. In addition, a correlation was observed in the NOESY 
spectrum between H-1’ and H-3 confirming the position of the glucose unit. The glucose 
residue was determined to be a P-anomer according to a coupling constant of the anomeric 
proton (H-1’, J= 7.8 Hz).^  ^ The carbon resonances for the glucose of compound UA.3 were 
comparable to those reported by Ye et al., for cinobufagin-3-O-p-D-glucoside.^^ Acid 
hydrolysis was done to separate the aglycone and the sugar unit in order to confirm the type 
of the sugar. The proton NMR spectrum of the sugar unit was compared with the proton 
NMR spectrum of both glucose and galactose [Spectrum 3.2.3.10]. The sugar product was 
therefore confirmed to be P-D-glucose. On the basis of the above ID, 2D, MS and IR 
experiments, compound UA.3 was identified as the novel 3 a-(O-P-D-glucopyranoside)- 
llp,14p-dihydroxybufa-4,20,22-trienolide. The specific rotation for this compound was + 
31.5°.
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Table 3.2.3. Correlation table for UA.3: 3a-(0-p-D-Glucopyranoside)-lip,14p-
dihydroxybufa-4,20,22-trienolide
No. "CNMR (125 
MHz) CD3OD
^HNMR (500 MHz) 
CD3OD
HMBC (H->C) COSY (H ^H ) NOESY (H->H)
la 36.3 1.98 m 13, 2a, 23 9,11
IP 1.50 m la, 2a, 23 23,3
2a 28.2 1.72 m la, 13, 23,3 23
2P 2.01 m la, 13, 2a, 3 20,3
3 76.9 4.28 (brmWi/2= 19.1 Hz) 2a, 23, 4 13, 23, 4 ,1 ’
4 120.2 5.41(brsWi/2=4.5Hz) 2, 6, 10 3 23, 33, 1'
5 150.2 - - - -
6a 32.9 2.29 m 5 63, 7a, 73 63, la, 73
6P 2.08 m 5 63, la, 73 6a, la, 73
la 30.4 2.26 m 6a, 63, 73, 8 6a, 63
73 2.26 m 6a, 63, la, 8 6a, 63
8 38.3 2.22 m 9, la, 73 123, 19
9 54.2 1.10 (dd, 7=2.9, 12.1 Hz) 8, 11 la, 11, 12a
10 39.5 - - - -
11 67.7 4.17m 9, 12a, 123 la, 9, 12a
12a 50.0 1.51 m 11,123 11, 123, 17
12p 1.76 m 14 12a, 11 8, 12a, 18
13 49.2 - - - -
14 86.9 - - - -
15a 33.4 1.96 m 153, 6a, 163 153, 16a
153 1.70 m 14 15a, 16a, 163 15a, 163
16a 29.8 1.73 m 14 15a, 153, 17 15a, 17
16(3 2.17 m 15a, 153, 17 153, 17
17 53.0 2.55 (dd, 7= 6.0, 9.4 Hz) 20,22 16a, 163 12a, 16a, 163
18 20.6 1.01 s 12, 13, 14, 17 - 123,8
19 23.4 1.34 s 1,5, 9, 10 - 23,8
20 125.3 - - - -
21 150.6 7.44 (dd, 7= 2.5, 0.7 Hz) 20, 21, 24 22 17
22 149.6 7.98 (dd, 7= 2.5, 9.5 Hz) 21,24 21,23 123,16a, 183, 23
23 115.5 6.31 (dd, 7= 9.5, 0.7 Hz) 20,24 22 23
24 165.0 - - - -
V 103.5 4.44 (d, 7= 7.7 Hz) 3’ 3 T 2 ’, 3’, 3 ,4 , 5’
T 75.3 3.18 (dd, 7= 7.8, 9.1 Hz) l ’,5 ’ l ’, 3 ’ l ’,4 ’, 5 ’
y 78.1 3.38 m 4’ 2% 4' 1’
4’ 71.9 3.31 m 5’ 3% 5' 4 ’ 6’
5’ 78.1 3.30 m 4’ 6'a, 6'b l ’,2 ’
6'a 63.0 3.89 (dd, 7= 2.0,12.1 Hz) 4’ 6’b, 5’ 4 ’
6’b 3.69 (dd, 7= 5.5,12.2 Hz) 4’ 6’a ,5 ’ 4’
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3.2.4 Structural elucidation of compound UA.4: 3a-[2’,3’,4’,6’-Tetra-0-acetyl-0-p-D- 
glucopyranoside]-lip,14p-dihydroxybufa-4,20,22-trienolide
A fraction isolated from the ethanol extract of Urginavia altissima that was difficult to purify 
was acetylated. After purification of the acetylated mixture several compounds were 
identified including compound UA.4. Compound UA.4 was obtained as a colourless oil and 
was found to be the tetracetylated derivative of compound UA.3. As will be described below, 
acétylation occurred on the hydroxyl groups of the glucose unit, but not on the hydroxyl 
group at C-11. Compound UA.4 was identified as 3a-[2’,3’4’,6’-tetra-0-acetyl-(9-P-D- 
glucopyranoside] -11 p, 14p-dihydroxybufa-4,20,22-trienolide.
HO,
OH
AcO 4 *
1
2 UA.4OAcAcO 3
Figure 3.2.6: Structure for compound UA.4: 3a-[2’,3’,4’,6’-Tetra-0-acetyI-0-p-D- 
glucopyranoside]-llp,14p-dihydroxybufa-4,20,22-trienolide
The HRMS spectrum [Spectrum 3.2.4.1] of compound UA.4 gave a [M + Na]  ^ ion at m!z 
753.3091 which indicated a molecular formula of C38H50O14. The IR spectrum [Spectrum 
3.2.4.2J for compound UA.4 showed absorption bands at 3501, 1748, 1714 and 1634 cm"^  
assigned to OH, C=0 of an acetate, C=0 of the a-pyrone ring and C=C stretches 
respectively.^^ As was observed in compound UA.3, the ^H NMR spectrum [Spectrum
3.2.4.3] showed characteristic proton resonances for the a-pyrone ring at 5 7.76 (dd, J= 9.7,
2.6 Hz, H-22), Ô 7.22 (d, 2.6 Hz, H-21) and Ô 6.27 (d, J= 9.7 Hz, H-23). An alkene proton
resonance at Ô 5.22, br s, Wi/2= 4.5 Hz (H-4), two oxymethine proton resonances at 5 4.21 
(H-11) and ô 4.15 (H-3) and two methyl group proton singlets at 5 0.98 and 5 1.29 were also 
observed. In addition, proton singlets for the methyl groups of the acetates at 5 2.08 (s), ô
2.04 (s), 5 2.02 (s) and 5 2.01 (s) were also seen. The proton resonances of the glucose unit 
of compound UA.4 were shifted downfield when compared to those of compound UA.3 as 
seen on Table 3.2.3.
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The ‘^ C NMR [Spectrum 3.2.4.4], DEPT [Spectrum 3.2.4.S] and HSQCDEPT [Spectrum
3.2.4.6] spectra showed that compound UA.4 contained five carbonyl carbon resonances 
(four for the acetate carbonyls and one for the a-pyrone ring), six double bond carbon 
resonances, one dioxygenated carbon resonance and eight oxygenated carbon resonances. 
The C-11 carbon resonance for compound UA.4 was similar to those of compounds UA.l, 
UA.2 and UA.3. The H-11 proton resonance for compound UA.4 was at 5 4.21 whereas 
those of compounds UA.l, UA.2 and UA.3 were at ô 4.23, ô 4.23 and ô 4.17 respectively. 
The H-11 proton resonance of compound UA.4 indicated that the hydroxyl group at C-11 was 
not acetylated. Compound UA. 4 was found to be 3a-[2’,3’,4’,6’-tetra-0-acetyl-0-P-D- 
glucopyranoside]-lip,14p-dihydroxybufa-4,20,22-trienolide whose unacetylated precursor 
was compound UA.3. The specific rotation for this compound was + 64.8°.
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Table 3.2.4. Correlation table for UA.4: 3a-[2’,3’,4’,6’-Tetra-0-acetyl-0-P-D-
glucopyranoside]- llp,14p-dihydroxybufa-4,20,22-trienolide
No. NMR 
(125 MHz) 
CDCls
NMR (500 MHz) 
CDCls
HMBC(H-»C) COSY (H->H) NOESY
(H->H)
la 34.9 1.87 m 13, 2a, 23 13,9
IP 1.41 m la, 2a, 23 la
2a 26.7 1.91 m la, 13, 23,3 la, 11
2P 1.68 m la, 13, 2a, 3 3
3 76.0 4.15 m 2a, 23 2a, 23,4
4 118.5 5.22 m 6, 2, 10 3 3, 6a
5 149.4 - - - -
6a 31.7 2.05 m 63, 7a, 73 4
6P 2.23 m 6a, 7a, 73 73
7a 28.9 2.19 m 6a, 63, 73, 8 73
7P 1.15m 6a, 63, 7a, 8 7a
8 37.7 2.10 m 7,9 63,18
9 52.4 1.05 (dt, J=12.1,2.6 Hz) 8 8, 11 la, 11, 12a
10 38.3 - - - -
11 67.4 4.21 m 12a, 123 la, 9, 12a
12a 49.0 1.48 m 9, 13, 14 11, 123 11,17
12P 1.70 m 18 11, 12a 12a, 18
13 48.0 - - - -
14 86.2 - - - -
15a 32.8 1.71 m 14, 17 153, 16a, 163
15P 1.85 m 15a, 16a, 163
16a 28.7 2.14 m 14 15a, 153, 163, 17 163, 17
163 1.72 m 13, 15 15a, 153, 16a, 17 16a
17 52.0 2.45 (dd, 9.8, 5.8 Hz) 15, 16, 20, 22 16a, 163 12a, 16a
18 19.9 0.98 s 12, 13, 14, 17 - 8, 123, 153
19 23.2 1.29 s 1, 5, 9, 10 - 13, 23,6
20 122.4 - - - -
21 148.9 7.22 (d, J=2.6Hz) 20,22,24 22 163, 17, 18
22 146.7 7.76 (d, J=9.7,2.6H z) 17,21,24 21,23 18, 123, 17,23
23 115.6 6.27 (d, ^  9.7 Hz) 20, 24 21,22 21,22
24 162.4 - - -
r 100.0 4.64 (d, 8.0 Hz) 3 ,3 ’ 2’ 2’, 3, 3’, 5’
2’ 71.8 4.97 (dd, J=8.9 , 8.0 Hz) 1’, 2’ Ac-C l ’,3 ’ 1%3’,4 ’
3’ 73.1 5.21 (t, J =  9.8 Hz) 2’,4 ’,5 ’,3’Ac-C 2’ l ’, 2 ’, 5 ’, 6’
4’ 68.8 5.08(t, J=9.8H z) 2 ’, 5’, 6’, 4’ Ac-C 3’, 5’ 5’, 6’
5’ 72.0 3.68 m 4 ’, 6’a, 6’b l ’,3 ’, 6’a, 6’b
6’a 62.4 4.24 m 5’, 6’ Ac-C 5’, 6’b l ’,3 ’,4 ’,5’, 6’b
6’b 4.14 m 5’, 6’ Ac-C 5’, 6’a 4 ’, 5’, 6’a
2’Ac- CHs 20.6 2.04 s 2’ Ac-C - -
2' Ac-C 169.5 - - - -
3 ’Ac-CH3 20.7 2.01 s 3’ Ac-C - -
3’Ac-C 170.6 - - - -
4’Ac- CHs 20.6 2.02 s 4’ Ac-C - -
4’Ac- C 169.6 - - - -
6’Ac- CHs 20.8 2.08 s 6’ Ac-C - -
6’Ac- C 170.9 - - - -
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3.2.5 Structural elucidation of compound UA.5: 3a-[2’,3’,4’,6’-Tetra-0-acetyl-0-P-D- 
glucopyranoside]-14p-hydroxy-ll-oxobufa-4,20,22-trienolide
AcO 3
OH
O"
UA.5
Figure 3.2.7: Structure for compound UA.5: 3a-[2’,3’,4’,6’-Tetra-0-acetyI-0-p-D- 
glucopyranoside]-14p-hydroxy-ll-oxobufa-4,20,22-trienolide
Compound UA.5 was isolated from an acetylated fraction from the ethanol extract of the 
bulbs of Urginavia altissima. It was obtained as a colourless oil and its unacetylated form 3 a 
-(O-p-D-glucopyranoside)-14P-hydroxy-ll-oxobufa-4,20,22-trienolide has not been reported 
previously. Compound UA 5 was determined to be the 11-keto derivative, 3a-[2’,3’4’,6’- 
tetra-O-acetyl-O-P-D-glucopyranoside] -14p-hydroxy-11 -oxobufa-4,20,22-trienolide, of
compound UA 4.
The HRMS spectrum [Spectrum 3.2.5.1] of compound UA.5 gave a [M + Na]  ^ ion at m!z 
751.2938 which indicated a molecular formula of CgglUgOM. The IR spectrum [Spectrum
3.2.5.2] showed absorption bands at 3481,1745,1732, 1715 and 1649 cm'^ indicating OH, 
C=0 of the acetate, C=0 of the keto group, C=0 of the a-pyrone ring and C=C stretches 
respectively.^^
As was observed for compounds UA 1, UA 2, UA 3 and UA 4 the proton resonances for the 
a- pyrone ring occured at 5 7.61, dd, J= 2.5, 9.7 Hz (H-22), 5 7.21, d, J= 2.5 Hz (H-21) and ô
6.29, d, J= 9.7 Hz, (H-23) [Spectrum 3.2.5.3J. The H-22 proton resonance was shifted 
upfreld in comparison to H-22 proton resonances of compound UA 1, UA 2, UA 3 and UA 4. 
Also observed in compound UA 5 were an alkene proton resonance at ô 5.32 (br s Wi/2= 5.1 
Hz) ascribed to H-4, an oxymethine proton resonance at 5 4.13 (m) ascribed to H-3 and two 
methyl group singlets at 6  0.74 and 5 1.23 ascribed to 3H-18 and 3H-19 respectively. The 
oxymethine proton resonance observed for H-11 in compound UA 4 was missing in the ^H
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NMR spectrum of compound UA 5. Also observed in the NMR [Spectrum 3.5.4] 
spectrum of UA 5 was a keto carbonyl carbon resonance at 6  209.0.
Correlations observed in the HMBC spectrum [Spectrum 3.2.5.7] between the keto carbonyl 
carbon resonance with H-9 ( 8  1.86) and the two H-12 ( 8  2.3 and 8  2.21) proton resonances 
indicated that the keto group was at the C-11 position. The downfield chemical shifts of the 
two H-12 proton resonances are attributed to the electronegative effect of the carbonyl group 
at C-11. Detailed 2D NMR analysis particularly HMBC, COSY [Spectrum 3.2.5.S] and 
NOESY [Spectrum 3.2.5.9] (Table 3.2.5) supported the identification of compound UA.5 as 
3a-[2’,3’,4’,6’-tetra-O-acetyl-O-P-D-glucopyranoside]-14p-hydroxy-ll-oxobufa-4,20,22- 
trienolide. The specific rotation for this compound was + 38°.
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Table 3.2.5. Correlation table for compound UA.5: 3a-[2’,3’,4’,6’-Tetra-0-acetyl-0-p-D-
glucopyranoside]-14p-hydroxy-ll-oxobufa-4,20,22-trienolide
^^CNMR 
(125 MHz) CDCI3
NMR (500 MHz) 
CDCI,
HMBC (H->C) COSY(H->H) NOESY(H->H)
34.7 IP
la
26.8 P,3 2P
a, 3 2a
76.7 2p, 4P, 19
122.7 1%3, 6,19
146.2
29.1
71. 6a, 19
27.7 P,8 7P
a, 8 7a, 8
44.1 7P, 19
59.8 la
37.9
209.0
55.0 12P
12a, 18
51.8
83.4
32.1 16P 15P
16P 15a
33.6 16p 16P, 17
16a 16a
50.2 ip 16a
18.2 8, 12a, 12P,15P
19.5 2P, 3, 4, 8
120.4
149.5 17
145.5 18.23
116.1 22
162.2
100.3 2%3, 3%4,5
71.8 1%3=
73.4 1%2% 4% 5 :
68.9 3 \5 '6 '
72.0 5’b r,3% 4% 6’a, 6’b
62.6
20.7 
169.4
20.7 
170.6
20.7 
169.9
20.8 
171.0
2.08 s
) 5’, 6’b 
l ’,5 ’
6’-Ac-C
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3.2.6 Structural elucidation of compound UA.6 : 3a-(0-p-D-Glucopyranoside)- 
llp,14p,19-trihydroxybufa-4,20,22-trienolide
Compound UA . 6  was isolated as a colourless oil from the ethanol extract of the bulbs of 
Urginavia altissima and was found to be the 19-hydroxy derivative of compound UA.3. It 
was identified as the novel 3a-(0-p-D-glucopyranoside)-lip, 14P, 19-trihydroxybufa-4,20,22- 
trienolide.
HO 3
OH
O'"
UA.6
Figure 3.2.8: Structure for compound UA.6 : 3a-(0-p-D-gIucopyranoside)-llp,14p,19-
trihydroxybufa-4,20,22-trienolide
The HRMS spectrum [Spectrum 3.2.6.1] of compound UA . 6  gave a [M + Na]  ^ ion at m!z 
601.2621 which indicated a molecular formula of C30H42O11. The IR spectrum [Spectrum 
3.2.6.2J for compound UA . 6  showed an absorption band at 3390 and a broad band at 1732 
cm'^ assigned to OH and 0 = 0  stretches respectively.^^ The ^H NMR spectrum [Spectrum
3.2.6.3] showed characteristic proton resonances of an a-pyrone ring at 5 7.98 (dd, J= 9.5, 2.5 
Hz), 5 7.44 (dd, J=2.5, 0.7 Hz), and ô 6.31 (dd, J=9.5, 0.7 Hz), an alkene proton resonance at 
5 5.57 (hr s W1/2 = 4.6 Hz) and eleven proton resonances at ô 4.45 (d, J= 7.8 Hz), 4.32 (m), 
4.11(m), 5 4.06 (d, J=11.7), 3.89 (dd, J= 1.99, 12.1 Hz), 5 3.69 (dd, J= 5.5, 12.1 Hz), 5 3.49 
(d, /=11.70 Hz) Ô 3.38 (m), 5 3.31 (m), Ô 3.30 (m) and Ô 3.19 (dd, J= 7.8, 9.1 Hz) for 
hydrogens attached to oxygenated carbons. Also present was only one methyl group proton 
singlet at 5 1 .0 1 .
Comparison between the ^H and NMR chemical shifts of this compound and those of 
compound UA 3 showed that one of the methyl groups typical of a bufadienolide had been 
oxidised. The NMR spectrum [Spectrum 3.2.6.4] of compound UA 6  showed an 
additional oxymethylene carbon resonance at 5 64.1. This carbon resonance corresponded to 
oxymethylene proton resonances at Ô 4.06 (d, J=11.7) and ô 3.49 (d, J=11.70 Hz) in the 
HSQCDEPT spectrum [Spectrum 3.2.6.6]. Correlations in the HMBC spectrum [Spectrum
3.2.6.7] between the two proton resonances and the C-10 (44.1) and C-5 (147.2) resonances
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suggested that the CHg-19 group had been oxidised. Correlations were seen in the NOESY 
spectrum [Spectrum 3.2.6.9J between the H-ip, H-3 and H-4 resonances and between the H- 
9 and H-11 resonances. In addition, correlation was observed between the two H-19 and the 
H- 8  proton resonances. The specific rotation for compound UA 6  was [a]o^  ^+42.9 and it was 
identified as the novel 3a-(O-P-D-glucopyranoside)-lip,14p,19-trihydroxybufa-4,20,22- 
trienolide.
Table 3.2.6. Correlation table for UA.6 : 3a-(0-p-D-GIucopyranoside)-llp,14p,19- 
trihydroxybufa-4,20,22-trienolide
No. NMR (125 
MHz) CD3OD
NMR (500 MHz) 
CD3OD
HMBC
(H-^C)
COSY (H ^H ) NOESY (H ^H )
la 29.2 2.39 m 5, 19 IP, 2a, 23 1M 3, 2a, 23
P 1.29 m 5, 10, 19 la, 2a, 23 la, 23, 19
2a 27.6 1.70 m 1, 10 23, la, 13 23
P 1.98 m 1,3 2a, la, 13 13, 2a, 19
3 76.3 4.32 (t, y =  7.20 Hz) 5 4 ,2 1M 3,23
4 122.5 5.57 (br s, Wi/2= 4.6 Hz) 2, 6, 10 1%3,4 r ,3 ,6
5 147.2 - - - -
6a 30.2 1.31 m 7, 8,10 63 63
P 2.29 m 5 6a 6a, 73
7a 33.3 2.12 m 5, 6, 8 8 la, 73
P 2.12 m 5, 6 ,8 8 7a, 19
8 38.0 2.29 m 7,9 7a, 73, 9 18, 19
9 54.3 1.31 m 10, 19 8, 11a 11
10 44.1 - - - -
11 66.7 4.11 m 9a, 12a, 123 la, 12a, 9
12a 48.1 1.56 (dd, J=2.45, 14.9 Hz) 9,11 ,14 ,18 11 123
P 1.84 (dd, 2.45, 14.91 Hz) 17, 18 11 12a, 19
13 49.2 - - - -
14 86.8 - - - -
15a 33.2 1.71 m 14, 17 153, 16a, 163 153, 16a
P 1.98 m 14, 17 15a, 16a, 163 15a, 163
16a 29.8 2.18 m 14, 17,20 15a, 153, 17 15a, 163, 17
P 1.74 m 20 15a, 153, 17 16a
17 53.0 2.58 m 14, 16, 20,22 16a, 163 12a, 16a
18 20.8 1.01 s 12, 13, 14, 17 - 8,123
19 64.1 a 4.06 (d, J=11.7Hz) 1,9,10 b la, 13, 23, 63, 73,8
b 3.49 (d, J=11.7Hz) 5 a la, 13, 23, 63, 73,8
20 125.0 - - - -
21 150.6 7.44 (dd, J= 0.7,2.35 Hz) 17, 20, 22, 24 22,23 16a, 163, 17, 19, 23
22 149.5 7.97 (dd, J= 2.35, 9.77 Hz) 17,21,24 21,23 16a, 163, 19, 23
23 115.5 6.31(dd, J=0.7, 9.77 Hz) 20, 24 22,21 21,22
24 164.9 - - - -
1’ 103.5 4.45 (d, 7.8 Hz) 3,3%5' 2 ’ 2 ’, 3’, 3 ,4 , 5’
2’ 75.3 3.19 ( d ,^  7.8 Hz) l ’,3 ’ l ’,3 ’ l ’,3 ’
3’ 78.3 3.38 m 4’ 2’, 4 ’ l ’, 2 ’
4 ’ 71.9 3.31 m 3% 5% 6' 3’, 5’ l ’,6 ’
5’ 78.1 3.30 m 3’ 4’, 6’ l ’,6 ’
6’ 63.0 a 3.89 m 6’ b 5’ 5’
b 3.69 m 6’ a 5’ 5’
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3.2.7 Structural elucidation of compound UA.7: 3p,lip,14p-Trihydroxybufa-4,20,22-
trienolide
Compound UA.7 was isolated as a colourless oil firom the ethanol extract of the bulbs of 
Urginavia altissima. It was found to be the 3-epimer of compound UA.l and identified as the 
novel Sp,l ip,14p-trihydroxybufa-4,20,22-trienolide.
HO.
OH
UA.7
Figure 3.2.9: Structure for compound UA.7: 3p,llp,14p-Trihydroxybufa-4,20,22-
trienolide
The HRMS spectrum [Spectrum 3.2.7.1] of eompound UA.7 gave a [M + Na]  ^ ion at m!z 
423.2130 which indicated a molecular formula of C24H32O5. The IR spectrum [Spectrum
3.2.7.2] for eompound UA.7 showed absorption bands at 3427 and 1711 em"^  assigned to OH 
and C=0 stretches respectively.^^ The ^H NMR spectrum [Spectrum 3.2.7.3] of compound 
UA.7 showed characteristic proton resonances of an a-pyrone ring at 5 7.77 (dd, J= 9.8, 2.6 
Hz), 5 7.22 (d, J= 2.6 Hz) and 6  6.27 (d, J= 9.8 Hz), an alkene proton resonance at Ô 5.41 (d, 
J= 4.3 Hz), two oxymethine proton resonances at 4.13 (m) and 4.29 (br s, Wi/2= 8.7 Hz) and 
two methyl group proton singlets at 0.98 and 1.25.
The NMR [Spectrum 3.2.7.4J, DEPT [Spectrum 3.2.7.5J and HSQCDEPT [Spectrum
3.2.7.6] spectra for eompound UA.7 displayed twenty-four earbon resonances which included 
a lactone carbonyl carbon resonance at ô 162.5, six double bond carbon resonances, three 
oxygenated carbon resonances at 5 86.2, ô 67.9 and ô 64.6. Overall, eompound UA.7 
contained two methyls, seven methylenes, nine methines and six fully substituted earbon 
resonances.
The ^^ C NMR chemical shifts for compound UA7 were found to be similar to those of 
eompound UA.1 except for the carbon resonances of ring A. In particular, upfield chemical 
shifts were seen on the earbon resonances at C-1, 5 32.2 (5 35.4 for UA 1), C-2, 6  27.9 ( 8
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29.3 for UA 1), C-3, 6  64.6 (Ô 67.5 for UA 1), C-4, 6  119.9 (Ô 122.3 for UA 1) and C-5, Ô
150.3 (Ô 147.9 for UA 1) positions. The relative eonfiguration of H-3 of eompound UA.7 
was deduced from the NOESY spectrum [Spectrum 3.2.7.9]. Correlations between the H-3 
and H-2a resonances for compound UA 7 (which occurred between H-3 and H-2p for UA 1) 
in the NOESY spectrum confirmed that the 3-OH of compound UA.7 was in the P-position, 
making it a C-3 epimer of eompound UA.l. The half-peak width of H-3 for eompound UA.7 
was 9.9 Hz, which differed to those of eompound UA.1 (W1/2 = 22.2 Hz), UA.2 (Wi/2 = 19.0 
Hz) and UA.3 (W1/2 =19.1 Hz). From these observations it can be deduced that when H-3 is 
in the a-orientation the half-peak width is about 10 Hz and when the H-3 is in p-orientation 
the half-peak width is about 20 Hz. Compound UA.7 was therefore identified as a novel 
3 p, 11 p, 14p-trihydroxybufa-4,20,22-trienolide. The specific rotation for this eompound UA.7 
was found to be [a]D^  ^+51.1°.
Table 3.2.7. Correlation table for UA.7: 3p,lip,14p-Trihydroxybufa-4,20,22-trienoIide
). NMR (125 MHz) 
CDCI3
NMR (500 MHz) 
CDCI3
HMBC (H ^C ) COSY (H ^H ) NOESY (H->H)
1 32.2 2.26 m 1(3,2a, 2(3
3 1.71 m 2, 3, 5, 10, 19 la, 2a, 2p 19
X 27.9 1.71 m 10,3 2P,3 2P,3
3 1.71 10,3 20,3 2a, 3, 19
64.6 4.13 (brm Wi/2 = 9.9 Hz) 4 2a, 4
119.9 5.41 (d, J= 5.2 Hz) 2, 3, 6, 10 3 3a, 8
150.3 - - - -
X 31.7 1.71 m 4,5 6P 9
3 2.26 m 4,5 6a 7(3, 8, 19
X 28.7 2.17 m 5,8 7(3 9
3 2.12 m 14 7a 6(3
37.7 2.09 m 7, 9, 10, 14, 15, 9 6(3,18
52.3 1.18 (dd,J= 2.8, 12.4 Hz) 7, 8,19 11,8 6a, 7a, 11
) 38.4 - - - -
I 67.9 4.29 (Wi/2= 8.7 Hz) 12 9, 12a, 12(3 9, 12a
a 49.0 1.50 (dd, J=2.5, 15.0 Hz) 13, 18 12(3 11, 17
P 1.70 m 9,11 11, 12a 18
5 48.0 - - - -
I 86.2 - - -
a 32.9 1.90 m 16 15(3, 16a, 16P 153, 16a
P 1.71 m 8, 13, 14, 17 15a, 16a, 16(3 15a, 163
a 28.7 2.12 m 14 15a, 15(3, 16(3, 17 15a, 163, 17
P 1.71 m 12, 13, 14, 17, 18, 20 15a, 15(3, 16a, 17 153, 16a
52.0 2.46 (dd, J= 5.8, 9.6 Hz) 13, 14, 16, 20,21,22 16a, 16(3 12a, 16a
20.0 0.98 s 13, 14,17 - 8, 123, 19
22.6 1.25 s 1,2, 5 ,9 - 13, 23,8
122.5 - - - -
148.9 7.21 (d, J=2.6 Hz) 20,22,24 22 163, 17
146.8 7.78 (d, J=2.6, 9.7 Hz) 21,24 21,23 123, 18, 23
115.6 6.27 (d, J= 9.7 Hz) 20,24 22 22
162.5 - - - -
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3.2.8. Structural elucidation of compound UA.8 : 3p-Ethoxy-llp,14p-dihydroxybufa-
4,20,22-trienoIide
Compound UA . 8  was isolated as a colourless oil from the ethanol extract of the bulbs of 
Urginavia altissima. Compound UA . 8  was found to be an ethoxy derivative of compound 
UA.7 and a C-3 epimer of compound UA.2. It was identified as 3P-ethoxy-llp,14p- 
dihydroxybufa-4,20,22-trienolide.
HO.
OH
UA . 8
Figure 3.2.10: Structure for compound UA.8 : 3p-Ethoxy-lip,14p-dihydroxybufa-
4,20,22-trienolide
The HRMS spectrum [Spectrum 3.8.1] of compound UA . 8  gave a [M + Na] ion at m!z 
451.2450 which indicated a molecular formula of C26H36O5. The IR spectrum [Spectrum
3.8.2] for compound UA . 8  showed an absorption band at 3445 and a broad band at 1738 cm'^ 
assigned to OH and C=0 stretches respectively.^^ The ^H NMR spectrum [Spectrum 3.8.3] 
showed characteristic proton resonances of an a-pyrone ring at ô 7.78 (dd, J= 9.8, 2.7 Hz), 6
7.21 (dd, J= 2.6, 0.7 Hz), and Ô 6.27 (dd, J= 9.7, 0.7 Hz), an alkene proton resonance at 8  
5.41 (br s Wi/2 =4 . 5  H z) ,  two oxymethine proton resonances at 8  4.27 (quin, J  = 3.0 Hz) and 
8  3.72 (Wi/2= 9.7 Hz), an oxymethylene proton resonances at 3.57 (m) and 8  3.49 (m), two 
methyl proton singlets at 8  1.24 and 8  0.97 and a triplet methyl group proton resonances at 8
1.22 (J= 7.0 Hz).
The ^^ C NMR [Spectrum 3.2.8.4], DEPT [Spectrum 3.2.8.S] and HSQCDEPT [Spectrum
3.2.8.6] spectra displayed twenty-six carbon resonances for compound UA.8 , which included 
a lactone carbonyl carbon resonance at 8  162.5, six double bond carbon resonances and four 
oxygenated carbon resonances at 8  86.2, 8  74.7, 8  67.5 and 8  63.5. Compound UA . 8  
contained three methyls, eight methylenes, nine methines and six fully substituted carbon 
resonances (Table 3.2.8). The ^^ C NMR chemical shifts for this compound were identical to
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those of compound UA.7 except at C-1 (8 32.5), C-2 (8 24.2), C-3 (8 72.0) C-4 (8 118.9) and 
C-5 (8 149.8) positions. Those for compound UA.7 were at 8 32.2 (C-1), 8 27.9 (C-2), 8 64.6 
(C-3), 8 119.8 (C-4) and 8 150.3 (C-5). In addition the NMR and the COSY [Spectrum 
3.2.S.8] spectra showed an ethyl group coupling system proton resonance at 1.22 (t, J= 7.0 
Hz) and an oxymethylene group proton resonances at 3.57 (m) and 3.47 (m).
The NOESY experiment [Spectrum 3.2.8.9J confirmed that the relative configuration at C-3 
was the same as that of compound UA.7. Correlations were observed between the H-3 
proton resonance with the H-2a and the H-4 proton resonances. The H-2a proton resonance 
also showed a correlation with the H-11 proton resonance, which, in turn, showed correlation 
with the H-9 proton resonance, bio synthetically known to be in an a-position of a 
bufadienolide. The half-peak width of H-3 for compound UA . 8  was 9.7 Hz which was very 
close to that of compound UA.7 (W1/2 = 9.9 Hz) and lower than those of compound UA.1 
(Wi/2 = 22.2 Hz) and UA.2 (W1/2 = 19.0 Hz). Compound UA . 8  was therefore identified to be 
a novel 3 g-ethoxy-11P, 14P-dihydroxybufa-4,20,22-trienolide. The specific rotation for this 
compound was [a]o^  ^ +34.8°. Since extraction of the bulbs of Urginavia altissima was 
carried out using ethanol, compound UA . 8  would be an artefact of compound UA.7.
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Table 3.2.8.CorreIation table for compound UA.8 3B-Ethoxy-llB,14B-dihydroxybufa-
4,20,22-trienolide
No " c  NMR (125 
MHz) CDCI3
NMR (500 MHz) 
CDCI3
HMBC (H ^H ) COSY (H ^H ) NOESY (H-^H)
r 63.9 3.57 m 2’ 2’ 2’
3.49 m 2’ 2’ 2’
T 16.0 1.22 s r 1’ 1’
la 32.5 1.70 m 3, 19 1(3, 2a, 2P 19
B 1.63 m 3, 19 la, 2a, 2p 2P, 19
2a 24.2 1.68 m 10 la, ip, 2P 11
B 1.76 m 10 la, ip, 2a IP, 19
3 72.0 3.72 (Wi/2= 9.7 Hz) 1 2a, 2p, 4 r ,2 a ,4
4 118.5 5.41 (d, J=4.5 Hz) 2, 6, 10 3 3, 6a, 6p
5 149.8 - - - -
6a 31.7 2.09 m 7,8 6P 6P
B 2.26 m 4 6a 6a, 8, 19
7a 28.7 2.14 m 8 7P,8
B 2.14m 8 7a, 8 19
8 37.7 2.08 m 7, 9, 14 7a, 7P, 9 6P, 18, 19
9 51.6 1.24 m 19 8, 11 11, 12a
10 38.4 - - - -
11 67.9 4.27 (quin, J= 3.0 Hz) 8, 10 9, 12a, 12P la, 2a, 9, 12a
12a 48.9 1.49 m 18 12P, 11 11, 12P, 17
B 1.69 m 9, 11, 13, 14 12a, 11 12a, 18
13 48.0 - - - -
14 86.3 - - - -
15a 32.9 1.67 m 14 15p, 16a, 16p 15P, 16a
B 1.88 m 15a, 16a, 16P 15a, 16P
16a 28.5 1.73 m 13 15a, 15P, 16P, 17 15a, 16P, 17
B 2.14 m 13, 14 15a, 15p, 16a, 17 15P, 16a, 17
17 52.0 2.45 m 13, 14, 18, 20,21,22 16a, 16p 12a, 16a, 16p
18 19.9 0.97 s 12, 13, 14 - 8, 12P, 19
19 22.8 1.24 s 1,5, 9, 10 - la, ip, 2P, 6P, 7P, 8, 18
20 122.5 - - - -
21 148.8 7.21 (dd, 0.7, 2.7 
Hz)
20, 22, 24 22 17, 23
22 146.8 7.77 (dd, 2.7, 9.8
Hz)
17,21,24 21,23 12P, 18,23
23 115.6 6.27 (dd, 0.7,9.8
Hz)
20, 24 22 21,22
24 162.5 - - - -
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3.2.9 Structural elucidation of compound UA.9: 3a,14p-Dihydroxy-5p-19-oxobufa-
20,22-dienolide ((3-J^/-19-oxobufalin)
Compound UA.9 was isolated as a colourless oil from the ethanol extract of the bulbs of 
Urginavia altissima. Compound UA.9 was found to be the 3-epimer of 19-oxobufalin (130) 
previously isolated from the chansu drug, a product of toad secretion/"^ Compound UA.9 was 
identified as a novel 3a,14p-dihydroxy-5p-19-oxobufa-20,22-dienolide {?>-epi-l9- 
oxobufalin).
OH
HO'
U A .9
Figure 3.2.11: Structure for compound UA.9: 3a,14p-dibydroxy-5p-19-oxobufa-20,22-
dienolide (3-£p/-19-oxobufalin)
The HRMS spectrum [Spectrum 3.2.9.1] of compound UA.9 gave a [M + Na]  ^ ion at m!z 
423.2128 which indicated a molecular formula of C24H32O5. The IR spectrum [Spectrum
3.2.9.2] for compound UA.9 showed absorption bands at 3418, 1730 and 1715 cm'^ assigned 
to OH, C=0 of an aldehyde and a C=0 for the a-pyrone ring stretches respectively.^^ The ^H 
NMR spectrum [spectrum 3.2.9.3] showed characteristic proton resonance of an a-pyrone 
ring at Ô 7.78 (dd, J= 9.7, 2.6 Hz), 5 7.21 (dd, J=2.5, 0.8 Hz) and Ô 6.26 (dd, J= 9.7, 0.8 Hz), 
an aldehyde group proton singlet at 8  9.98, an oxymethine proton resonance at 8  3.64 and a 
methyl group proton singlet at 8  0.65.
The ^^ C NMR spectrum [spectrum 3.2.9.4] together with the DEPT spectrum [spectrum 
3.2.9.5] displayed twenty-four carbon resonances including a characteristic carbon resonance 
of a lactone carbonyl at 8  162.5, an aldehyde carbonyl carbon resonance at 8  208.4, two 
oxygenated carbon resonances at 8  70.6 and 8  85.1, four quaternary carbons at 8  48.3, 8  51.5, 
8  85.1, 8122.4, a methyl carbon resonance at 8  16.5, nine methylenes and eight methines. 
The above information suggested that compound UA.9 was a monohydroxylated 
bufadienolide where one of the methyl groups had been oxidized to an aldehyde. The 
presence of one methyl and an aldehyde on this compound indicated that one of the methyls, 
typical of a bufadienolide, had been oxidised. The aldehyde proton resonance showed
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correlations in the HMBC spectrum [spectrum 3.2.9.7J with carbon resonances at 5 51.5, ô 
43.3, Ô 31.5, ascribed to C-10, C-5 and C-1 respectively. The methyl proton resonances at Ô 
0.65 showed correlations in the HMBC spectrum with two quaternary carbon resonances at 5
85.1 and 5 48.3 ascribed to C-13 and C-14 and a methine carbon resonance at 51.3 ascribed 
to C-17. The above information allowed the placement of the aldehyde at the C-19 position. 
The H-5 proton resonance showed coupling in the COSY spectrum [spectrum 3.2.9.S] with 
the two H-4 proton resonances (5 1.31 and 5 1.83), which, in turn, showed coupling with an 
oxymethine proton resonance at ô 3.64 assigned to H-3. A search in the literature for a 
bufadienolide possessing a hydroxyl group at C-3 and an aldehyde at C-19 gave a compound 
known as 19-oxobufalin (3 g, 14|3-dihydroxy-19-oxobufadienolide), previously isolated from 
the Chinese traditional drug Ch’an Su, a product of skin secretions of the local toads known 
as Bufo gargarizans Cantor or Bufo melanostrictus The ^^ C NMR chemical shifts for 19- 
oxobufalin significantly differed from those of compound UA.9 with major differences 
observed for carbon resonances C-1, C-3 and C-10 positions.
OH
KG'
130
The correlations observed in the NOESY spectrum showed that compound UA.9 was a C-3 
epimer of the reported 19-oxobufalin. The NOESY spectrum of UA.9 showed correlations 
between the H-3 and H-5, H-3 and H-2(3, H-2P and H-19, H-19 and 3H-18, H-19 and H-8 and 
3H-18. The half-peak width of H-3 for compound UA.9 was 22.7 Hz indicating an a- 
orientation. This compound was therefore confirmed as a novel 3a,14p-dihydroxy-5p-19- 
oxobufa-20,22-dienolide (3 -^ z -19-oxobufalin). The specific rotation for UA.9 was found to 
be [a]D^  ^ +87.0 whereas the reported specific rotation for 19-oxobufalin was found to be 
+ 7.0.^ ^
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Table 3.2.9: Correlation table for UA.9: 3a,14p-dihydroxy-5p-19-oxobufa-20,22-
dienolide (3-^f-19-oxobufalm)
"C NMR 
(125 MHz) 
CDCI3
"C NMR 
(125 MHz) 
CDCI374
^H NMR (500 MHz) 
CDCI3
HMBC
(H->C)
COSY
(H ^H )
NOESY
(H-^H)
31.5 21.9 IP, 2a
la,2P ,3P ,5
32.7 26.38 2P
20,3
70.6 65.56 2P,1P,4P,5
39.5 32.33 46
3P, 4a, 6p
43.3 28.80 1P,3P, 4P, 6P
28.5 28.07 6p, 7a
6a
27.6 21.37 6a, 7P
70,8
43.8 42.50 19
48.9 34.90 6a, 11a
51.5 51.06
22.3 21.00 lip
11a, 18
40.6 40.86 12P
12a, 18P
48.3 48.46
85.1 85.04
32.2 31.87 15P, 17
15a, 16P
28.7 28.56 ,17 22
17 22
51.3 51.11 21
16.5 16.42 8, lip , 12P
208.4 205.97 5, 8P, 18P
122.4 122.59
148.8 148.63 7.21 (dd, 0.8, 2.6 Hz) 17, 20 22 17
146.7 146.72 7.78 (dd, J= 2.6, 9.7 Hz) 17,21,24 21,23 16a, 18,23
115.7
162.6
115.37
162.36
6.26 (dd, J= 0.8, 9.7Hz ) 20,24 22,21 22
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3.2.10 Structural elucidation of compound UA.10: 3a-[2’,3’,4’,6’-Tetra-0-acetyl-0-p-D- 
glucopyranoside]-14p-hydroxy-5p-19-oxobufa-20,22-dienolide
Compound UA.10 was identified as a colourless oil from an acetylated fraction from the 
ethanol extract of the bulbs of Urginavia altissima. The unacetylated precursor of compound 
UA.10 was found to be a glucose derivative of compound UA.9. The unacetylated precursor 
of compound 10, 3a-[2’,3’,4’,6’-tetra-0-acetyl-(9-p-D-glucopyranoside]-14p-hydroxy-5p-19- 
oxobufa-20,22-dienolide, was determined to be a novel 3a-O-p-D-glucopyranoside-14p- 
hydroxy-5 P-19-oxobufa-20,22-dienolide.
AcO 4
AcO 3
Hfh
OH
O'"
UA.10
Figure 3.2.13: Structure for compound UA.10: 3a-[2’,3’,4’,6’-Tetra-0-acetyl-0-p-D- 
glucopyranoside]-14p-hydroxy-5p-19-oxobufa-20,22-dienolide
The IR spectrum [Spectrum 3.2.10.2] for compound UA.10, C3 8 H5 0 O1 4 , showed an 
absorption band at 3445 cm'^for an OH stretch and a broad band at 1747 cm'^assigned to 
C=0 stretches for the acetates, aldehyde and C=0 stretch for a-pyrone ring.^^ The NMR 
spectrum [spectrum 3.2.10.3] showed characteristic proton resonances of an a-pyrone ring at 
Ô 7.78 (dd, J -  9.7, 2.6 Hz), Ô 7.23 (dd, 2.6, 0.8 Hz), and 5 6.26 (dd, J= 9.7, 0.8 Hz), an 
aldehyde proton singlet at 6 9.93, eight proton resonance at 6 3.64, Ô 3.68, 5 4.14, Ô 4.23, ô 
4.60, Ô 4.93, 5 5.07 and ô 5.19 for hydrogens attached to oxygenated carbons and a methyl 
group proton singlet at ô 0.65.
The NMR [spectrum 3.2.10.4], DEPT [spectrum 3.2.10.5] displayed thirty-eight carbon 
resonances including a lactone carbonyl carbon resonance at 5 162.4, four acetate carbonyl 
carbon resonances at ô 169.4, 5 169.6, 5 170.6, Ô 170.9, an aldehyde carbonyl carbon 
resonance at Ô 208.2, four double bond carbon resonances for the a-pyrone ring at 6 148.9, 5 
146.7, Ô 122.7 and 5 115.8, eight oxygenated carbon resonances at 5 62.3, ô 68.7, ô 71.7, ô 
73.1, ô 71.9, ô 78.1, ô 85.2 and a dioxygenated carbon resonance at ô 99.3. Overall the 
NMR of compound UA.10 showed ten methylenes, thirteen methines, four quaternary
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carbons and five methyls, four for the acetate methyls and one for the bufadienolide 
aglycone.
The above information suggested that this compound was a bufadienolide glycoside 
possessing an aldehyde. The C-22 (6c 146.7) resonances of the a-pyrone ring showed a 
correlation in the HMBC spectrum [spectrum 3.2.10.7] with the H-17 (6 h 2.43) resonance. 
The H-17 proton resonance corresponded to a carbon resonance at 6 51.3 in the HSQCDEPT 
spectrum [spectrum 3.2.10.6]. The C-17 carbon resonance showed a correlation in the 
HMBC spectrum with a methyl proton resonance at 5 0.65 ascribed to 3H-18, which, in turn, 
showed correlation to two quaternary carbon resonances at 6 48.5 and 5 85.2 ascribed to C-13 
and C-14 respectively. The aldehyde showed a correlation in the HMBC spectrum with a 
quaternary carbon at 5 51.6 ascribed to C-10. This allowed the placement of the aldehyde 
group at C-19 position. The carbon resonances for compound UA.9 and UA.10 were 
compared and it showed that there were significant changes in the chemical shifts of their 
ring A, in particular the carbon resonances at C-2, C-3 and C-4 positions of compound UA.10 
showed downfield chemical shifts. The HMBC spectrum ftrrther showed a correlation 
between the anomeric proton H-1’ (5 4.60) and a carbon resonance at 6  78.1 ( 6 h  3.64) 
ascribed to C-3. The COSY spectrum [spectrum 3.2.10.8] showed coupling between the H-3 
proton resonance and two methylene proton resonances at 6 1.28 and 6 2.00 ascribed to the 
two H-2 proton resonances. This information suggested that the glucose unit was attached to 
C-3 position. The specific rotation for this compound was [a]o^^ +32.0°. Compound UA.10 
was found to be 3 a-[2’ ,3 ’ ,4’ ,6 ’ -tetra-0-acetyl-0-|3-D-glucopyranoside]-14|3-hydroxy-5p 19- 
oxobufa-20,22-dienolide.
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Table 3.2.10. Correlation table for UA.10: 3a-[2’,3’,4’,6’-Tetra-0-acetyI-0-p-D-
glueopyranoside]-14p-hydroxy-5p-19-oxobufa“20,22-dienolide
NMR (125 
MHz) CDCI3
NMR (500 MHz) 
CDCI3
HMBC
(H -.C )
COSY
(H ^H )
NOESY
(H -.H )
31.6 0.98 m 2 IP, 2a, 2P 13, 2a
2.44 m 2 la, 2a, 2p la
30.4 1.28 m la, 13, 23,3 la
2.00 m la, 13, 2a, 3 3
78.1 3.64 brm 2a, 23, 3 23, 43,5
35.8 1.27 m 3, 43,5 43
1.79 m 3, 4a, 5 4a
43.0 1.28 m 4a, 43, 6a, 63 43,19
28.5 1.99 m 5, 63 63
1.26 m 5, 6a 6a
27.6 2.18 m 6a, 63, 73 73,9
1.26 m 6a, 63, 7a 7a
43.8 1.51 m 7 a, 7 3, 9 18
49.0 1.18m 8, 11 a, 113 7a, 11a
51.6 - - - -
22.2 1.68 m 9, 113, 12a, 123 113
1.21 m 9, 11a, 12a, 123 11a
40.6 1.31 m 123 123, 17, 18
1.53 m 12a 12a, 18
48.4 - - -
- - -
32.3 1.93 m 153, 16a, 163 153, 17
1.65 m 15a, 16a, 163 15a
28.7 2.15 m 15a, 153, 163, 17 163
1.76 m 15a, 153, 16a, 17 16a
51.3 2.43 m 13,22 16a, 163 15a, 16a
16.5 0.65 s 12, 13, 14, 17 - 8, 113, 12a, 123
208.2 9.93 s 1,5,10 - 13, 23, 5 ,8
122.7 - - - -
148.9 7.23 (dd, 0.8, 2.5 Hz) 20,22,24 22 17
146.7 7.78 (d, J=2.5, 9.8 Hz) 24 21,23 163, 18,23
115.8 6.25 (dd, J= 0.8, 9.8 Hz) 20, 24 22 22
162.4 - - - -
99.3 4.60 (d, J= 8.0 Hz) 3 2’ 5’
71.7 4.93 (dd, J= 8.0, 9.5 Hz) 3%2'-Ac-C l ’,3 ’ 1’
73.1 5.19 (t,J= 9.5 Hz) 2% 4% 3'-Ac-C 2’, 4’ 5’
68.7 5.07 (t, J= 9.5 Hz) 2% 6% 4'-Ac-C 3’, 5’ 5’
71.9 3.68 m - 4’, 6’ a, 6’ b l ’,3 ’
62.3 4.23 m 6’-Ac-C 5’, 6’b 4’
4.14 m 6’-Ac-C 5’, 6’a 4’
C —CH3 21.0 2.08 s 2’-Ac-C - -
c-C 170.9 - - - -
C-CH3 20.8 2.02 s 3’-Ac-C - -
c-C 169.6 - - - -
C-CH3 20.8 2.02 s 4’-Ac-C - -
c-C 169.4 - - - -
C-CH3 20.9 2.00 s 6’-Ac-C - -
c-C 170.6 - - - -
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3.2.11 Structural elucidation of compound U A .ll: 5p-[2’,3’,4’,6’-Tetra-0-acetyI-0-p-D- 
glucopyranoside]-14p-hydroxy-19-oxobufa-4,20,22-trienolide -4,20,22-trienoIide
Compound UA.11 was identified as a colourless oil firom an acetylated fraction from the 
ethanol extract of the bulbs of Urginavia altissima. Compound UA.11 was found to be a 
bufadienolide glycoside with a double bond at C-3 and an aldehyde at the C-19 position. It 
was identified as an acetylated derivative of the known 5p-(O-P-D-glucopyranoside)-14- 
hydroxy-19-oxo-bufa-3,20,22-trienolide (scilliglycoside/scillaren F) previously isolated fi'om 
U. maritima and U. pancration?^’^ ’^^  ^ Compound U A .ll was identified as 5p-[2’,3’,4’,6’- 
tetra-0-acetyl-0-p-D-glucopyranoside]-14p-hydroxy-19-oxobufa-4,20,22-trienolide-4,20,22- 
trienolide
AcO. OH
AcO 4
OAcAcO 3
UA.11
Figure 3.2.14: Structure for compound UA.11: Sp-[2’,3’,4’,6’-Tetra-0-acetyI-0-p-D- 
glucopyranoside]-14p-hydroxy-19-oxobufa-4,20,22-trienolide-4,20,22-trienolide
The HRMS spectrum [Spectrum 3.2.11.1] of compound UA.11 gave a [M + Na] ion at m/z 
751.2946 which indicated a molecular formula of CgglUgOM. The IR spectrum [Spectrum
3.2.11.2] for compound UA.11 showed an absorption band at 3415 cm'^ for an OH stretch 
and absorption bands at 1743, 1732 and 1715 cm"^  assigned to C=0 for the acetates, C=0 for 
an aldehyde and C=0 for the a-pyrone ring stretches respectively.^^ The ^H NMR spectrum 
[spectrum 3.2.11.3] showed characteristic proton resonances of an a-pyrone ring at Ô 7.76 
(dd, J= 9.8, 2.6 Hz), 5 7.23 (dd, 2.6, 0.6 Hz) and ô 6.26 (dd, J= 9.8, 0.6 Hz), an aldehyde 
proton singlet at 5 9.69, five oxymethine proton resonances at 8 3.61, 8 4.72, 8 4.88, 8 4.90 
and 8 5.17, oxymethylene proton resonances at 8 4.12, 8 4.14, two alkene proton resonances 
at 8 5.41 and 8 5.99 and one methyl group proton singlet at 8 0.67.
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The NMR [spectrum 3.2.11.4], DEPT [spectrum 3.2.11.5] displayed thirty-eight carbon 
resonances including a characteristic lactone carbonyl carbon resonance at Ô 162.4, acetate 
carbonyl carbon resonances at Ô 169.4, 5 169.7, 5 170.6 and 8 170.9, an aldehyde carbonyl 
carbon resonance at 5 207.2, six double bond resonances, of which four are for the a-pyrone 
ring, eight oxygenated carbon resonances at 8 62.6, 8 69.1, 8 71.5, 8 71.8, 8 71.5, 8 78.6 8
85.1 and 8 95.1. Overall, the NMR spectrum of compound UA.11 showed nine 
methylenes, thirteen methines, five quaternary carbons, six carbonyls and five methyls, four 
for the acetates and one for the bufadienolide aglycone.
The above information suggested that this compound was a bufadienolide glycoside with an 
aldehyde group and an alkene. The alkene proton resonance at 8 5.99 showed coupling in the 
COSY spectrum [spectrum 3.2.11.8] with methylene group proton resonances at 8  2.23 and 
8 2.01, the other alkene proton resonance at 8 5.41 showed only coupling with the proton 
resonance at 8 5.99, implying that the double bond was near a quaternary carbon. The above 
information allowed the placement of the double bond on ring A at C-3, as this was the only 
position on the molecule where the observed coupling pattern could occur. The anomeric 
proton resonance at 8  4.72 showed a correlation in the HMBC spectrum [spectrum 3.2.11.7] 
to an oxygenated quaternary carbon resonance at 8 78.6. Therefore, the glucose unit was 
placed at the C-5 position. The C-22 resonance of the a-pyrone ring showed a correlation in 
the HMBC spectrum with an allylic proton resonance at 8 2.43, which corresponded to a 
carbon resonance at 8  51.1 in the HSQCDEPT spectrum [spectrum 3.2.11.6]. The carbon 
resonance at 8 51.1 was ascribed to C-17. The C-17 carbon resonance showed correlation 
with a methyl group proton resonance at 8 0.67 in the HMBC spectrum, which, in turn, 
showed correlations with two quaternary carbon resonances at 8 48.5 and 8 85.1 ascribed to 
C-13 and C-14 respectively. The methyl group carbon resonance was assigned to C-18 and 
the aldehyde was placed at the C-19 position. A search on the literature for a bufadienolide 
with an aldehyde, glucose at C-5 and an alkene at C-3 position gave scilliglaucoside, also 
known as scillaren F, isolated previously from U. maritima and U. pancration?^’^ ’^^  ^
Compound U A .ll was therefore identified as the acetylated derivative of scillaglaucoside. 
The specific rotation of UA.11 was found to be [a]o^^ +47.8°.
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Table 3.2.11:Correlation table for compound UA.ll:5p-[2’,3’,4’,6’-Tetra-0-acetyI-0-p- 
D-glucopyranoside]- 14p-hydroxy-19-oxobufa-4,20,22-trienolide -4,20,22-trienoIide
No. NMR (125 
MHz) CDCI3
NMR (500 MHz) 
CDCI3
HMBC
(H->C)
COSY
(H-^H)
NOESY
(H -.H )
la 20.5 2.27 m IP, 2a, 2P 13, 8,9
IP 1.90 m la, 2a, 23 la.
2a 21.7 2.23 m la, IP, 23,3 3
2P 2.01 m la, Ip, 2a, 3 2a
3 133.1 6.00 (bd,J= 10.1 Hz) 2a, 23, 4 13, 2a, 4
4 129.4 5.41 (d, 7-10.1 Hz) 3 13,3
5 78.6 - - - -
6a 31.7 1.58 m 63, 7a, 73
6P 1.85 m 6a, 7a, 73
7a 23.8 2.09 m 73,8 73
73 1.09 m 70,8 7a
8 42.3 1.86 m 9, 7a, 73 73,18
9 39.4 1.36 m 8, l ia , 113 la
10 52.2 - - -
l ia 22.8 1.45 m 113, 12a, 123 113
IIP 1.17 m lia , 12a, 123 l ia
12a 40.9 1.49 m lia , 113, 123 123, 17
12P 1.29 m lia , 113, 12a 12a
13 48.5 - - -
14 85.1 - - -
15a 33.3 1.90 m 153, 16a, 163
15P 2.03 m 15a, 16a, 16p
16a 28.7 2.15 m 17, 15a, 153 163, 17
16P 1.73 m 17, 15a, 153 16a, 17
17 51.1 2.43 (dd, J= 6.8, 8.3 Hz) 22 16a, 163 12a, 16a
18 16.6 0.67 s 12, 13, 14, 17 - 123, 153,22
19 207.2 9.69 s 10 - la, 13, 23, 63,8
20 122.5 - - - -
21 148.9 7.20 (d, 7=2.6 Hz) 20,22,24 22,23 17,23
22 146.6 7.76 (dd, 7= 2.6, 9.8 Hz) 21,24 21,23 16, 18, 23
23 115.7 6.27 (d, 7= 9.8 Hz) 20,24 21,22 22
24 162.4 - - - -
1’ 95.1 4.72 (d, 7= 7.9 Hz) 2% 5' 5 2’ 3% 4% 5'
2’ 71.5 4.88 (dd, 7= 7.9, 9.5 Hz) l ’ 3’,5 ’,2 ’-Ac-C 1’ 3’
3’ 73.0 5.17(1,7=9.5 Hz) 2%3',3'-Ac-C 2 \4 ' 5’
4 ’ 69.1 4.99 (t, 7= 9.5 Hz) 2’, 5’, 4’-Ac-C 3% 5' 5’
5’ 71.8 3.6 m 4% 6'a, 6'b 3' 1% 6'a, 6'b
6'a 62.6 4.14 (dd, 7= 5.4, 11.6 Hz) 5% 6'-Ac-C 5% 6b 4', 5'
6’b 4.12 (dd, 7= 5.4, 11.6 Hz) - 5% 6a 4% 5'
2 ’-Ac-CH3 20.9 2.03 s 2’-Ac-C - -
2’-Ac-C 169.4 - - - -
3 ’-Ac-CH3 21.0 2.08 s 3’-Ac-C - -
3’-Ac-C 170.9 - - - -
4 -AC-CH3 20.8 2.01 s 4’-Ac-C - -
4’-Ac-C 169.7 - - - r
6’-Ac-CH3 20.8 1.99 s 6’-Ac-C - -
6’-Ac-C 170.6 - - -
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3.2.12 Structural elucidation of compound UA.12: 3a-(0-P-D-gIucopyranoside)-14p- 
hydroxy-19-oxobufa-4,20,22-trienolide
Compound UA.12 was isolated as a colourless oil from the ethanol bulb extract of Urginavia 
altissima. It was identified as the 3-epimer of scilliglaucosidin-Sp-O-p-D-glueopyranoside 
(altoside) isolated previously from Urginea altissima^^ and Urginea depressa^^ and was 
determined to be the novel 3a-(O-P-D-glueopyranoside)-14p-hydroxy-19-oxobufa-4,20,22- 
trienolide.
OHQ
,1
2 OHHO 3 UA.12
Figure 3.15: Structure for compound UA.12: 3a-(0-p-D-gIucopyranoside)-14p-hydroxy-
19-oxobufa-4,20,22-trienolide
The HRMS spectrum [Spectrum 3.2.12.1] of compound UA.12 gave a [M + Na] ion at miz
583.3 which indicated a molecular formula of C30H40O10. The IR spectrum [Spectrum
3.2.12.2] for compound UA.11 showed an absorption bands at 3433 and 1710 cm'^ for the 
OH stretch and C=0 for the a-pyrone ring respectively.^^ The NMR spectrum [spectrum
3.2.12.3] showed eharacteristie proton resonances of an a-pyrone ring at 5 8.01 (dd, J= 9.7,
2.6 Hz), Ô 7.45 (dd, 2.6, 0.8 Hz) and 5 6.30 (dd, J= 9.7, 0.8 Hz), an aldehyde proton 
singlet at 8  9.85, eight oxymethine proton resonances at 5 3.17, 8  3.28, 8  3.29, 8  3.37 and 8
4.30, an oxymethylene proton resonances at 8  3.68 and 8  3.88, an anomeric proton resonance 
at 8  4.44 (d, J= 7.9 Hz), an alkene proton resonances at 8  5.87 and one methyl group proton 
singlet at 8  0.74.
The NMR [Spectrum 3.2.12.4] and DEPT [Spectrum 3.2.12.5] displayed 30 carbon 
resonances including a lactone carbon resonance at 8  164.9, an aldehyde carbonyl at 8  205.6, 
six double bond carbon resonances at 8  115.6, 8  125.0, 8  127.9 8  140.2, 8  150.7 and 8  149.4, 
four of which are for the a-pyrone ring. Using the correlations in the HMBC [Spectrum
3.2.12.7], COSY [Spectrum 3.2.12.8] and NOESY [Spectrum 3.2.12.9] spectra, the double 
bond was assigned to position C-4. The olefinic proton resonance at 8  5.87 (H-4) showed a
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correlation in the HMBC spectrum with the quaternary carbon at 5 55.1 for C-10, which in 
turn correlated with an aldehyde at 5 9.85 for H-19. The olefinic proton resonance at 6 5.87 
(H-4) also showed coupling in the COSY spectrum with one oxymethine proton resonance at 
Ô 4.30 for H-3. The sugar unit was identified as P-D-glueose by using correlations in the 
NOESY spectrum and was assigned to C-3 position of the aglycon based on a correlation in 
the HMBC spectrum between the anomeric proton and the oxygenated carbon at 5 75.3 for C- 
3. Correlation in the NOESY spectrum was also observed between the anomeric proton and 
the oxymethine proton resonance for H-3.
The above information suggested that compound UA.12 is a A^^-derivative of the unacetylated 
derivative of compound UA.IO. A search in the literature for a bufadienolide possessing a 
glucose at C-3 and an aldehyde at C-19 gave a compound known as 3P-(0-P-D- 
glueopyranoside)-14p-hydroxy-19-oxobufa-4,20,22-trienolide (altoside) isolated previously 
from Urginea depressa. The ^^ C NMR chemical shifts for compound UA.12 significantly 
differed from those of compound UA.IO with compound UA.12 showing higher carbon 
resonances values compared to those of 3 P-(O-p-D-glucopyranoside)-14p-hydroxy-19- 
oxobufa-4,20,22-trienolide. The NOESY spectrum of UA.12 showed correlations between 
the H-3 and H-4, H-3 and H-2p, H-2P and H-ip, H-ip and H-19, H-19 and 3H-18, H-19 and 
H-8 and 3H-18. The half-peak width of H-3 for compound UA.12 was 20.0 Hz. This 
compound was therefore confirmed as the novel 3 epimer of 3P-(O-P-D-glucopyranoside)- 
14p-hydroxy-19-oxobufa-4,20,22-trienolide. The specific rotation for compound UA.12 was 
found to be [a]o^^ +27.5 whereas the reported specific rotation for 3p-(0-P-D- 
glucopyranoside)-14p-hydroxy-19-oxobufa-4,20,22-trienolide was found to be [a]ü^  ^+23.^^ 
3p-(O-P-D-glucopyranoside)-14p-hydroxy-19-oxobufa-4,20,22-trienolide has been tested for 
its antiproliferative activities against the A2780 for ovarian cancer, the A2058 for melanoma 
and the H522-T1 for human non-small lung cancer cell lines. It was found to show strong 
antiproliferative activity with IC5 0  values of 24, 48 and 34 nm for the A2780, A2058 and 
H522-T1 respectively.^^
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Table 3.2.12: Structural elucidation of compound UA.12: 3a-(0-p-D-glucopyranosidc)- 
14p-hydroxy-19-oxobufa-4,20,22-tricnolidc
No. NMR (125 
MHz) MeOD
"C NMR (150 
MHz) MeOD^°
^H NMR (500 MHz) 
MeOD
HMBC
(H-^H)
COSY
(H ^H )
NOESY
(H->H)
la 23.2 28.1 1.72 m IP, 2a, 2P IP, 2a
IP 1.42 m la, 2a, 2p la, 2P, 3, 19
2a 28.8 27.6 1.45 m la, ip, 2P,3 la ,2p
2P 2.10 m la. Ip, 2a, 3 Ip, 2a, 3
3 75.8 74.2 4.30 m 2a, 2P,4 1P,2P, 4 ,1 ’
4 127.9 126.2 5.87 s 6, 10 3 l ’,3 ,6 a , 6P
5 140.2 138.2 - - -
6a 34.4 32.9 2.46 m 6P, 7a, 7P 6P, 7a, 9
P 2.36 m 6a, 7a, 7p 6a
7a 29.9 28.4 2.20 m 6a, 6p, 7p, 8, 7P
7P 1.18 m 6a, 6P, 7p, 8, 7a
8 44.6 43.0 1.91 m 7,9 18
9 51.2 49.4 1.34 m 8, 11a, lip 6a
10 55.1 53.6 - - -
11 29.6 21.5 2.26 m 9, lip , 12a, 12P lip
P 1.76 m 9, 11a, 12a, 12p 11a
12a 41.7 40.2 1.54 m 12P, 11a, lip 12P, 18
P 1.40 m 12a, 11a, lip 12a, 18
13 49.5 47.7 - - -
14 85.6 84.0 - - -
15a 32.7 31.4 1.64 m 15P, 16a, 16P 15P
isp 2.01 m 15a, 16a, 16p 15a
16a 29.7 28.2 1.75 m 15a, 15P,16P,17 16P
16P 2.20 m 15a, 15p,16a,17 16a
17 52.1 50.6 2.57 m 16a, 16p 12a, 16a
18 17.3 15.7 0.74 s 12, 13,
14, 17
- 8, 12a, 12P
19 205.6 204.1 9.85 s 10 - IP, 6P, 8, 12P
20 125.0 123.7 - - - -
21 150.7 149.1 7.45 (dd, J -  2.6, 0.8 Hz) 20, 24 22 17
22 149.4 147.8 8.01 (dd, J=2.6, 9.7 Hz) 24 21,23 16a, 18,23
23 115.6 114.0 6.30 (dd, J= 0.8, 9.8 Hz) 22,21 22
24 164.9 163.5 - - - -
r 103.6 102.0 4.44 (d, J= 7.9 Hz) 2% 3 2’ 3 , 4 , 5 ’
2’ 75.3 73.6 3.17(dd, J= 1.3, 7.9 Hz) 5’ l ’, 3 ’ 1’
3’ 78.3 76.6 3.37 m 4’ 2', 4 ’ 1’
4’ 71.8 70.2 3.29 m 3% 5’ 3’, 5’ 6’
5’ 78.2 76.7 3.28 m 3’ 4’, 6’ 6’
6'a 63.0 61.5 3.88(d, 11.7 Hz) 4’ 5% 6b 4’, 5’, 6’b
6’b 3.68 m 5% 6a 4 ’, 5’, 6’b
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3.2.13 Structural elucidation of compound UA.13: ip,6a-Dihydroxy-4(15)-eudesmene
Compound UA.13 was isolated as a colourless oil from the ethanol extract of the bulbs of 
Urginavia altissima and was found to be the known sesquiterpenoid, ip,6a-dihydroxy-4(15)- 
eudesmene, previously isolated from Urginea epigea?^
OH
U A .13
Figure 3.16: Structure for compound UA.13: ip,6a-Dihydroxy-4(15)-eudesmene
The LREIMS spectrum [Spectrum 3.2.13.1] of compound UA.13 showed a molecular ion 
peak at m/z 238 which indicated a molecular formula of C15H26O2. The LREIMS spectrum 
showed fragment ions at m/z 220, [M-18]^ for a loss of a unit of H2O, m/z 202, [M-36]^ for 
losses of two units of H2O and m/z 177, [M-18-43]^ for a loss of unit of water and a further 
loss of an isopropyl group fragment.^^ The FTIR spectrum [Spectrum 3.2.13.2] gave an 
absorption band at 3428 cm'^ that was attributed to an OH stretch and absorption bands at 
1639 cm‘^  and 873 cm’^  that were attributed to the terminal double bond stretches.^^ The 
NMR [Spectrum 3.2.13.4], DEPT [Spectrum 3.2.13.5] and HSQCDEPT [Spectrum
3.2.13.6] spectra showed that compound UA.13 contained three methyl groups, five 
methylene groups, five methine groups and two fully substituted carbon resonances. The ^H 
NMR spectrum [Spectrum 3.2.13.3] gave one methyl group proton singlet at ô 0.71, and two 
methyl group doublet proton resonances at 0.87 (d, J  = 7.05 Hz) and 0.95 (d, J  = 7.05 Hz), 
that were attributed to an isopropyl group. Terminal alkene proton resonances at 6  4.75 (s) 
and 5.02 (s), two oxymethine proton resonances at 6 3.42 (m) and 5 3.72 (dt, J  = 9.8, 2.0 Hz) 
and a methine proton resonance at 5 2.24 (m) were also observed in the ^H NMR spectrum of 
compound UA.13. The above spectral information showed that this compound contained 
fifteen carbons with an isopropyl group which was consistent with an eudesmane 
sesquiterpenoid.
The two doublet methyl group proton resonances at 5 0.87 (d, J  = 7.05 Hz) and 0.95 (d, J  =
7.05 Hz) of an isopropyl group were assigned as 3H-12 and 3H-13. The 3H-12 and the 3H- 
13 proton resonances showed a correlation in the HMBC spectrum [Spectrum 3.2.13.7] with
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carbon resonances at Ô 49.3 (Ôh 1.29) and 26.2 (Ôr 2.24) ascribed to C-7 and C-11 
respectively. The COSY speetrum showed eoupling between the H-7 proton resonance and 
the oxymethine proton resonance at ô 3.72 (t, J  = 9.8 Hz) assigned as H-6 whieh, in turn, 
showed coupling with a methine proton resonance at ô 1.75 (d, J=  9.80 Hz) assigned as H-5. 
The H-6 and H-5 proton resonances corresponded to the carbon resonances at 6 62.7 and ô
56.1 respectively in the HSQCDEPT spectrum. The H-5 proton resonance showed 
correlations with the earbon resonances at 5 42.0 and 5 11.8 in the HMBC spectrum ascribed 
to C-10 and C-14 positions respectively. The H-14 (5 0.71, s) proton resonance showed a 
correlation in the HMBC speetrum with a carbon resonance at 8 79.2 assigned to C-1. The 
H-1 (8 3.42) proton resonance showed coupling with proton resonances at 8 1.85 and 8 1.53 
in the COSY spectrum [Spectrum 3.2.13.8] which were assigned to the two H-2 protons, 
which, in turn showed coupling with proton resonances at 8 2.05 and 8 2.34 assigned to the 
two H-3 protons. The two H-3 proton resonances corresponded to a carbon resonance at 8
35.3 in the HSQCDEPT speetrum. The C-3 carbon resonance correlated in the HMBC 
spectrum to the exocyclic double bond proton resonances at 8 4.75 and 8 5.02 ascribed to the 
two H-15 protons.
The NOESY experiment was used to assign the relative configuration of compound UA.13. 
The correlations in the NOESY spectrum [Spectrum 3.2.13.9] between the H-1 (8 3.42, dd J  
= 11.6, 4.7 Hz), the H-5 (8 1.75, d J  = 9.80 Hz), and the H-7 (8 1.29, m) proton resonances 
were observed. These correlations indicated that the H-1, H-5 and H-7 proton resonances 
were on the same face of the molecule. The orientations of the hydroxyl groups in the C-1 
and C-6 positions were on the opposite sides of the molecule as no correlation between H-1 
and H-6 protons resonances were observed in the NOESY experiment. The specific rotation 
for compound UA.13 was found to be + 44°, which is within the experimental error of the 
reported value of + 45°.^  ^ Compound UA.13 was identified to be the known eudesmane 
sesquiterpenoid, ip,6a-dihydroxy-4(15)-eudesmene isolated previously from Urginea 
epigea^^ Litsea verticillata and Caragana intermediaJ^’^  ^ The presence of a sesquiterpenoid 
in Urginavia altissima is the second report from a member of the Scilloideae subfamily.
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Table 3.2.13: Correlation table for compound UA.13: ip,6a-Dihydroxy-4(15)-
eudesmene
"C NMR 
(125 MHz) 
CDCI3
"C NMR 
(125 MHz) 
CDCI3
H NMR (500 MHz) 
CDCI3
H NMR’" HMBC
(H-^C)
COSY
(H^H)
NOESY
(H^H)
79.2 79.1 3.42 (dd,J=11.6, 4.7 Hz) 3.42 (dd,J=11.7, 4.8 Hz) - 2a, 2(3 2a, 3a, 5, 7
32.1 32.0 1.85 m 1.85 m 5, 10 1,2(3, 3a 1,23
1.53 m 1.53 (dd,J= 11.7, 5.0 Hz) 1 1, 2a, 3(3 2a, 13
35.3 35.2 2.05 m 2.09 m - la, 2a, 33 1,33
2.34 m 2.53 m 5 23,3a 3a
146.5 146.3 - - - - -
56.1 55.9 1.75 (d,J=9.80Hz) 1.75 (d ,J=9.8 Hz) 6, 10, 14 6 1
67.2 67.1 3.72 (dtJ=9.8, 2.0 Hz) 3.71 (td, J = 9 .8 ,1.7 Hz) - 5,7 12, 14, 15a
49.5 49.4 1.29 m 1.30 m - 6 1
18.4 18.2 1.25 m 1.25 m 83 83
1.60 m 1.53 m - 8a 8a
36.5 36.4 1.19m 1.20 m - 93 93
1.90 m 1.90 m - 9a 9a
42.0 41.8 - - - - -
26.2 26.1 2.24 m 2.25 (sept, à,J= 7.0, 2.4 Hz) 13 12,13 12,13
16.4 16.2 0.87 (d, J -  7.05 Hz) 0.87 (d, J = 7.0Hz) 7,11,13 11 6, 11
21.3 21.2 0.95 (d, J= 7.05 Hz) 0.95 (d,J = 7.0 Hz) 7,11,12 11 23,11
11.8 11.7 0.71 s 0.70 s 1,5,9,10 - 6
108.0 107.9 4.75 s 4.74 (d ,y = l.lH z) 3,5 15a 6, 15a
5.02 s 5.02 (d ,J = l.l  Hz) 3,5 15b 15b
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3.2.14 Structural elucidation of compound UA.14: 6a-Hydroxy-4(15)-eudesmen-l-one 
Compound UA.14 was isolated as a pale green oil from the bulbs of Urginavia altissima and 
was identified as the 1-keto derivative of compound UA 13. It was identified as the known 
6a-bydroxy-4(15)-eudesmen-l-one isolated previously from the bulbs of Urginea epigea?^
UA.14
Figure 3.2.17: Structure for compound UA.14: 6a-Hydroxy-4(15)-eudesmen-l-one
The HRMS spectrum [Spectrum 3.2.12.1] of compound UA.14 gave a [M + Na]  ^ion at m!z 
259.1674. The IR spectrum [Spectrum 3.2.14.2] of compound UA.14 showed absorption 
bands at 3445 and 1645 cm‘  ^assigned to OH and C=0 stretches respectively.^^ The ^H NMR 
spectrum [spectrum 3.2.14.3] showed a methyl group proton singlet at 5 1.00 ascribed to H- 
14 and two doublet methyl group proton resonances at 0.88 (d, J= 7.1 Hz) and 0.96 (d, J=7.1 
Hz) assigned to H-12 and H-13 respectively. The two doublet methyl proton resonances are 
the typical peaks of an isopropyl group of a eudesmane sesquiterpenoid. The ^H NMR 
spectrum also displayed an oxymethine proton resonance at ô 3.83 (dt,J= 9.8, 2.8 Hz) and 
exocyclic double bond proton resonances at ô 5.26 (s) and 6 5.00 (s). The NMR 
[spectrum 3.2.14.4], DEPT [spectrum 3.2.14.5] and HSQCDEPT [spectrum 3.2.14.6] 
spectra of compound UA.14 showed fourteen carbon resonances. Using correlations in the 
HMBC spectrum [Spectrum 3.2.14.7], it was observed that the 3H-14 proton resonance 
correlated with a keto carbonyl carbon resonance at 5 213.4 suggesting that compound UA.14 
bad fifteen carbons. The ^^ C NMR spectrum data of compound UA.14 differed from those of 
compound UA.13 by displaying one oxygenated carbon resonance at Ô 67.3 whereas 
compound UA.13 displayed two oxygenated carbon resonances at 6 79.1 and ô 67.1 ascribed 
to C-1 and C-6 positions respectively. Compound UA.14 was therefore determined to be a 
C-1 keto derivative of compound UA.13. It was also observed that the 3H-14 methyl group 
proton resonances of compound UA.14 was shifted downfield as compared to that of 
compound UA.13. The downfield chemical shift could be attributed to the anisotropic effect
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of the keto carbonyl group at C-1 position. Compound UA.14 was therefore identified as the 
known 6a-bydroxy-4(15)-eudesmen-l-one previously isolated from Urginea epigea?^
Table 3.2.14: Correlation table for compound UA.14: 6a-Hydroxy-4(15)-eudesmen-l-
one
No NMR (125 
MHz) CDCI3
NMR (500 MHz) 
CDCI3
HMBC (H-^C) COSY
(H ^H )
NOESY
(H->H)
1 213.4 - - -
2a 38.5 2.39 m - 2a, 3a, 3(3 2a, 3a, 3g
P 2.67 m - 2P, 3a, 3(3 2 3 , 3a, 3(3
3a 35.6 2.59 m - 3(3,2a,2p 3 3
P 2.30 m - 3a, 2a, 2(3 3a
4 144.4 - - - -
5 55.7 2.10 m - 6
6 67.3 3.83 (dt, 7=9.8, 2.8 Hz) - 5 12,15b
7 49.3 1.32 m - 5,9a, 9 3 , 12, 13
8a 18.1 1.12m - 12
P 1.51 m - 9, 13
9a 31.7 1.56 m - 9P 7, 93,13
P 1.81 m - 9a 7, 9a, 13
10 50.3 - - - -
11 26.2 2.24 m 12, 13 12, 13
12 16.4 0.88 (d, 7= 7.1Hz) 7,11,13 11 11, 13
13 21.2 0.96 (d, 7= 7.1Hz 7,11, 13 11 11, 12
14 18.1 1.00 s 1, 5, 9, 10
15a 110.3 5.26 s - 15b 3a, 15b
15b 5.00 s - 15a 6, 15a
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3.2.15 Structural elucidation of compound UA.15: 3-(4’-MethoxybenzyI)-5,6,7-
trimethoxyehroman-4-one
Compound UA.15 was isolated as a clear oil from the ethanol bulb extract of Urginavia 
altissima and was identified as 3-(4-metboxybenzyl)-5,6,7-trimetboxycbroman-4-one. This 
compound was isolated in a small quanity (2 mg), making it difficult to purify it. From the 
NMR spectrum, the major compound was deduced to be the previously reported, 3-(4- 
metboxybenzyl)-5,6,7-trimetboxycbroman-4-one isolated from the inter-bulb surfaces of 
Scilla nervosa and Urginea depressa from the Scilloideae subfamily.^®’^  ^ The minor 
compound whose peaks have been crossed in the spectrum [speetrum 3.2.15.3] could not be 
identified.
CHgCL 7 ^  ^4>0CH
C H 3 0   ^ ,
OCH3 o
UA.15
Figure 3.2.18: Structure for compound UA.15: 3-(4’-Methoxybenzyl)-5,6,7-
trimethoxychroman-4-one
The MS spectrum [spectrum 3.2.15.1] of compound UA.15 did not show an [M]^ however 
^^ C NMR [speetrum 3.2.15.4] and HSQC [spectrum 3.2.15.5] spectra suggested a molecular 
formula of C20H22O6 for UA.15. From the formula a double bond equivalence of ten was 
calculated. The FTIR spectrum [spectrum 3.2.15.2] showed absorption bands at 2917 cm'^ 
and 2850 cm'^ for CH and 1731 cm'^ for C=0 stretches.
The NMR spectrum [spectrum 3.2.15.3] showed the characteristic splitting pattern of the 
3 -benzyl-4-cbomanone type bomoisofiavonoid for the 2H-2, H-3 and 2H-9. The 2H-2 proton 
resonances of compound UA.15 occurred at 6 4.28 (m) and ô 4.10 (m), H-3 occurred at 5 
2.73 (m) and 2H-9 occurred at ô 3.19 (dt, 13.7, 4.15 Hz) and 5 2.64 (m). The ^H NMR 
spectrum displayed four singlet proton resonances at 5 3.80, 6 3.82, ô 3.88 and 5 3.93, which 
corresponded in the HSQC spectrum [speetrum 3.2.15.5] to four carbon resonances at ô 
55.5, Ô 61.5, Ô 56.3 and ô 61.8 respectively indicating the presence of four metboxy groups. 
The ^H NMR spectrum of compound UA.15 also displayed a pair of doublet proton 
resonances in the aromatic region, ô 6.85 and 5 7.15, each integrating to two protons and with
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a coupling constant of 8 .6  Hz which indicated a />ûtra-disubstituted aromatic system for ring 
B. A singlet proton resonance in the aromatic region at ô 6.26 integrating to one proton was 
assigned to H- 8  of the ring A based on the correlations in the HMBC spectrum [spectrum 
3.2.15.6] between H- 8  and C-8 a and C-4a. The methoxy groups at ô 3.88 and 5 3.80 were 
assigned to C-7 and C-4’ respectively based on correlations in the NOESY spectrum 
[spectrum 3.2.15.8] with H- 8  and H-3’/5’ proton resonances respectively. The ^^ C NMR 
chemical shifts for C-5, C- 6  and their corresponding methoxy carbons were assigned on the 
basis of data available in the literature.^^ The sample was not pure, therefore specific rotation 
and ECD studies were not done. Compound UA.15 was identified as 3-(4-methoxybenzyl)- 
5,6,7-trimethoxychroman-4-one.
Table 3.2.15: Correlation table for compound UA.15: 3-(4-Methoxybenzyl)-5,6,7- 
trimethoxyehroman-4-one
No "C NMR (125 
MHz) CDCI3
NMR (150 
MHz) CDCI3’*
^H NMR (500 MHz) 
CDCI3
HMBC
(H ^C )
COSY
(H -.H )
NOESY
(H-^H)
2a 69.3 69.0 4.28 m 4, 10 2b, 3 2b, 3
2b 4.10 m 4, 10 2a, 3 2a, 3
3 48.7 48.5 2.73 m - - -
4 191.6 191.4 - - - -
4a 108.8 108.7 - - - -
5 154.7 154.4 - - - -
6 137.8 137.4 - - - -
7 159.6 159.7 - - - -
8 96.2 95.9 6.26 s 4a, 7-C, 8a - 7-OCH3
8a 159.8 159.3 - - - -
9a 32.2 31.9 3.19 (dt, 7 =  13.7, 4.15 Hz) 2’ 3,9b 3,9b
9b 2.64 m 2’ 3, 9a 9a
r 122.3 120.6 - - - -
T 130.3 130.4 7.15 (d, 7 =  8.6 Hz) 9,4' 3'/5' 3'/5', 9b
y 114.5 114.0 6.85 (d, 7 =  8.6 Hz) 2'/6', 4' 2 '/6' 2’/6’, 4 ’-0CH3
4’ 158.4 158.2 - - - -
5’ 114.5 114.0 6.85 (d, 7 =  8.6 Hz) 2'/6', 4' 2 '/6' 2 ’/6’, 4 ’-0CH3
6’ 130.3 130.4 7.15 (d, 7 =  8.6 Hz) 9 ,4 ’ 3'/5' 3'/5', 9b
4’-0CH3 55.5 55.2 3.80 s 4’-C - 3'/5'
5-OCH3 61.8 61.6 3.93 s 5-C - -
6-OCH3 61.5 61.3 3.82 s 6-C - -
7-OCH3 56.3 56.1 3.88 s 7-C - 8
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3.2.16 Structural elucidation of compound UA.16:
Triliydroxy-5-liydroxymetliyl-2,3,4,5-tetrahydro-5H-[2,3]bifuranyl-2-one (polybotrin)
Compound UA.16 was isolated from the bulbs of Urginavia altissima as a colourless oil and 
was identified as the known polyhydroxylated furan, \TR,yS,A"R,5S,5'S\-?>\A\6"- 
trihydroxy-5-hydroxy-2,3,4,5-tetrahydro-5H-[2,3]bifuranyl-2-one (polybotrin), previously 
isolated from Hedysarum polyhotris^^ and Ledoburia ovativoliaF'
Ï  ....OH
HO 4 ^ ^
OH
UA.16
Figure 3.2.19: Structure for compound UA.16: [2’i?,3’A,4’i?,5*S',5’*S]"3’,4’,6’-Trihydroxy“ 
5-hydroxymethyl-2,3,4,5-tetrahydro-5H-[2,3]bifuranyl-2-one
The LREIMS spectrum [Spectrum 3.2.16.1] of compound UA.16 showed a molecular ion 
peak at m/z 254.8 indicating a molecular formula of C9H12O7. The LREIMS also showed a 
fragment ion at 226 [M-28]^ for the loss of CO. The IR spectrum [Spectrum 3.2.16.2] gave 
absorption bands at 3444 and 1682 cm'^ for the OH and C=0 stretches respectively.^^ The 
NMR spectrum [Spectrum 3.2.16.3] showed an alkene proton resonance at 8.02 (d, /=  8.1 
Hz) and seven proton resonance at 5 5.92, 5 5.72, ô 4.20, 5 4.17, 5 4.03, ô 3.86 and 5 3.76 for 
hydrogens attached to oxygenated carbons.
The ^^ C NMR [Spectrum 3.2.16.4], DEPT [Spectrum 3.2.16.5] and HSQCDEPT 
[Spectrum 3.2.16.6] spectra showed nine carbon resonances which included a lactone 
carbonyl carbon resonance at 5 166.5, two double bond carbon resonances at 152.7 and 
142.9, a dioxygenated carbon resonance at 5 102.8 and five oxygenated carbon resonances at 
5 90.9, 5 86.5,0 75.9, 71.5 and 5 62.4. Overall, this compound contained a methylene, six 
methines and two fully substituted carbons. The presence of an anomeric proton resonance at 
Ô 5.92 (d, /=  4.7Hz) in the ^H NMR suggested the presence of a sugar unit on compound 
UA.16.
The anomeric proton resonance at 5 5.92, showed coupling in the COSY spectrum 
[Spectrum 3.2.16.8] with an oxymethine proton resonance at 5 4.20 (t, J= 4.7 Hz) assigned 
to H-3’, which, in turn, showed coupling with a proton resonance at 5 4.17 (t, J= 4.6 Hz) 
ascribed to H-4’. The proton resonance at 5 4.16 also showed coupling with a proton
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resonance at 4.03 (m) which was assigned to H-5’, which, in turn, showed coupling with 
methylene proton resonances at 6 3.86 (dd, J= 10.8, 2.8 Hz) and 5 3.76 (m) ascribed to the 
two H-6’ protons. The above information suggested that the sugar unit was a pentose. The 
H-2’ anomeric proton resonance (5 5.92) showed correlations in the HMBC spectrum 
[Spectrum 3.2.16.7] with a double bond carbon resonance at 6 142.9 and a quaternary double 
bond carbon resonance at ô 152.9. This confirmed that the sugar unit was attached to the C-3 
position. The double bond carbon resonance was then assigned to C-4 (5 142.9). The C-4 
carbon resonance showed a correlation in the HSQCDEPT spectrum with a double bond 
proton resonance at 6 8.02. The H-4 proton resonance showed coupling in the COSY 
spectrum with a proton resonance at 5 5.72 ascribed to H-5 (5c 102.8). The H-4 and H-5 
proton resonances further showed correlation in the HMBC spectrum to a lactone carbonyl 
carbon resonance at 5 166.5 ascribed to C-2. The above information suggested that 
compound UA.16 contained a polyhydroxyl furanosyl structure unit attached to a five- 
membered a,p unsaturated lactone.
The NOESY experiment showed that the H-5’ and H-2’ proton resonances were on the same 
face of the molecule. Further correlations were observed in the NOESY spectrum [Spectrum 
3.2.16.9] between the H-5 and H-4, H-4 and H-2’ and H-4 and H-3’proton resonances. A 
search in the literature showed that this compound was the known polybotrin previously 
isolated from Hedysarum polyhotris^^ and Ledoburia ovatifoliaF' Polybotrin is common in 
the Scilloideae subfamily of the Asparagaceae family. The absolute configuration at C-3’ 
was determined by Zou et ah, 2007 using the Mosher m e t h o d . I t  was found to be 3*5 and 
the sugar unit a ribose. The specific rotation of compound UA.16 was found to be -41.1 
which was comparable with the literature value (Mo^^-43.3).^^ Compound UA.16 was 
therefore identified as the known [2’i?,3’*S',4’i?,5*S',5’*S]-3’,4’,6’-trihydroxy-5-hydroxymethyl- 
2,3,4,5-tetrahydro-5H-[2,3]bifuranyl-2-one).
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Table 3.2.16: Correlation table for compound UA.16: [2’i?,3’*S',4’i?,5*S',5’*S]-3’,4’,6’-
Trihydroxy-5-hydroxymethyl-2,3,4,5-tetrahydro-5H-[2,3]bifuranyl-2-one (polybotrin)
0. NMR 
(125 MHz) 
CD3OD
^^CNMR 
(125 MHz) 
DMSO-d6*^
"C NMR (125 
MHz) 
DMSO-d6*^
^H NMR (500 MHz) 
CD3OD
HMBC
(H->C)
COSY
(H -.H )
NOESY
(H ^H )
90.9 87.7 87.8 5.92 (d, J=4.7H z) 3% 4, 3 3’ 4, 5', 3'
75.9 73.5 73.6 4.20(1,7= 4.7 Hz) T T 2’, 4
71.5 69.9 69.9 4.17(1,7= 4.7 Hz) 2% 6'a, 6'b 5', 6'a,6'b 5’, 6’a,6’b
86.5 84.8 84.9 4.03 m 4’ 4 ’ 2', 4', 6'a,6'b
a 62.4 60.3 60.9 3.86 (dd, 7 =  10.8,2.8 Hz) 4% 5' 4’ 4', 5'
b 62.4 60.3 60.9 3.76 m - 4 ’ 4', 5'
166.5 163.4 163.1 - - - -
152.7 150.7 150.7 - - - -
142.9 140.8 140.7 8.02 (d, 7 =  8.1 Hz) 2, 5,2' 5 3% 5,2'
102.8 101.8 101.9 5.72 (dd, 7 =  8.1, Hz) 2,4 4 4
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3.2.17 Structural elucidation of compound UA.17: ( l ’7?,2’7?,3’*S',4’i?)-l’-(6-Amino-9H- 
purin-9-yl)-5-(hydroxymethyl)oxolane-2,3-diol (adenosine)
Compound UA.17 was isolated as a white solid from the bulbs of Urginavia altissima and 
was identified as the known purine nucleoside (ri? ,2 ’i?,3’‘S',4’i?)-r-(6-amino-9H-purin-9-yl)- 
5-(hydroxymethyl)oxolane-2,3-diol, commonly known as adenosine.
HO'
HO
UA.17
Figure 3.2.20: Structure for compound UA.17: ( l ’i?,2’i?,3’*S',4’7?)-l’-(6-Amino-9H-purin- 
9-yl)-5-(hydroxymethyl)oxolane-2,3-diol (adenosine)
The HRMS spectrum [Speetrum 3.2.17.1] of compound UA.17 gave a [M + Na]  ^ion at m!z 
290.0856 which indicated a molecular formula of C10H13N5O4 for UA.17. The IR spectrum 
[Spectrum 3.2.17.2] for compound UA.17 showed an absorption band at 3419 cm"^  assigned 
to OH stretches.^^ The ^H NMR spectrum [spectrum 3.2.17.3] showed two double bond 
proton resonances at 8  8.34 (s) and 8  8.21 (s). The ^H NMR spectrum also showed proton 
resonances at 8  5.99 (d, 6.4 Hz), 8  4.20 (q, /=  2.5 Hz), 8  4.77 (dd, J= 5.3, 6.4 Hz), 8  4.35
(dd, J= 2.6, 5.3 Hz), 8  3.91 (dd, J= 2.6, 12.5 Hz) and 8  3.77 (dd, J= 2.6, 12.5 Hz) for protons 
attached to oxygenated carbons. The proton resonance at 8  5.99 corresponded to a carbon 
resonance at 8  91.4 in the HSQCDEPT spectrum [spectrum 3.2.17.6]. The COSY spectrum 
[spectrum 3.2.17.8] showed coupling between the proton resonance at 8  5.99 (H-H) and a 
proton resonance at 8  4.77 assigned to H-2’, which, in turn, coupled with a proton resonance 
at 8  4.35 assigned to H-3’. The H-3’ proton resonance also showed coupling with a proton 
resonance at 8  4.20 assigned to H-4’, which, in turn coupled with the two oxymethylene 
proton resonances at 8  3.77 and 8  3.91 ascribed to the two H-5’ protons. The above 
information suggested the presence of a pentose. The ^^ C NMR [spectrum 3.2.17.4], DEPT 
[spectrum 3.2.17.5] and HSQCDEPT [spectrum 3.2.17.6] spectra showed a total of seven 
carbon resonances including two double bond resonances at 8  153.8 and 8  142.5, five 
oxygenated carbon resonances at 8  91.5, 8  88.5, 8  75.7, 8  72.9 and 8  63.6. The double bond 
proton resonance at 8  8.34 showed correlations in the HMBC spectrum [spectrum 3.2.17.7] 
with two double bond carbon resonances at 8  150.5 and 8  121.0 The other double bond
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proton resonance at ô 8 .2 1  showed correlation with carbon resonances at ô 157.8 and 5  150.5. 
This suggested the presence of three more quaternary double bond carbon resonances that 
were not observed on the NMR spectrum. The H-1’ proton resonance of the pentose 
showed correlations in the HMBC spectrum to the quaternary double bond carbon resonances 
at Ô 150.5 (C-4) and 5 142.5 (C-8 ). This information suggested that the pentose was attached 
to a second unit. A search using the molecular weight in CHEMDRAW for possible 
molecular formulae having ten carbons suggested C10H13N5O4 . From the Dictionary of 
Natural Products database, a fragment containing a pentose and ten carbons suggested that 
compound UA.17 was likely to be a purine glycoside, adenosine. Comparison of the 
published ^^ C NMR chemical shifts of adenosine and those of compound UA.17 matched. 
The coupling constant of H-1’, J v,t = 6.4 Hz, suggested a P-anomer of the pentose,^^ 
determined as a ribose using the NOESY spectrum [spectrum 3.2.17.9]. Compound UA.17 
was confirmed to be adenosine. Adenosine is a degradation product of adenine nucleotides. 
It is re-utilised in plants for the synthesis of adeny la te .Pur ine  nucleotides are building 
blocks for nucleic acid synthesis, source of energy, precursors for the synthesis of primary 
products such as sucrose, polysaccharides, phospholipids as well as secondary product. They 
are therefore frmdamental in the growth and development of plants.^^
Table 3.2.17: Correlation table for compound UA.17: ( l ’i?,2’l?,3’*S',4’i?)-l’-(6-Amino- 
9H-purin-9-yI)-5-(hydroxymethyI)oxoIane-2,3-dioI (adenosine)
No NMR (125 
MHz) CD3 OD
NMR (500 MHz) 
CD3 OD
HMBC
(H ^H )
COSY
(H-^H)
NOESY
(H->H)
1 - - -
2 153.6 8.21 (s, Wi/2 = 1 .4 Hz) 4 ,6 - -
3 - - - - -
4 150.2 - - - -
5 121.4 - - - -
6 157.7 - - - -
7 - - - - -
8 142.2 8.33 (s, Wi/2 = 1.6 Hz) 4 ,5 - -
9 - - - - -
1 ’ 91.4 5.99 (d, J= 6.4 Hz) 2’, 3% 4 ,8 2 ’ 2 % 3' 8
2 ’ 75.7 4.77 (dd, J= 5.3,6.4 Hz) 1 ’ r , 3 ’ l ’, 3 ’
3’ 72.9 4.35 (dd, J= 2.6,5.3 Hz) V 2% 4' 2% 5'a, 5'b
4’ 88.5 4.20 (dd, 2.6,5.1 Hz) l ’,3 ’ 3% 5'a, 5'b 3',5 'a ,5 'b
5'a 63.6 3.91 (dd,J= 2.6,12.5 Hz) 3% 4' 4% 5'b 3', 4', 5'b
5’b 3.77 (dd, J= 2.6,12.5 Hz) 3% 4' 4% 5'a 3', 4', 5'a
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3.2.18 Structural elucidation of compound UA.18: 9i?-Hydroxy-(10jE',12Z)-
octadecadienoic acid ethyl ester
Compound UA.18 was isolated as a light yellow oil from the ethanol extract of the bulbs of 
Urginavia altissima and was identified as a di-unsaturated hydroxylated fatty acid ethyl ester, 
9i^-hydroxy-(10E,12Z)-octadecadienoic acid ethyl ester.
UA.18
Figure 3.2.21: Structure for compound UA.18: 9i?-Hydroxy-(10£',12Z)-octadecadienoic
acid ethyl ester
The MS spectrum [Spectrum 3.2.18.1] of compound UA.18 did not show an [M]^ ion 
however ^^ C NMR [Spectrum 3.2.18.4] and DEPT [Spectrum 3.2.18.5] spectra suggested a 
molecular formula of C20H40O3 . The IR spectrum [Spectrum 3.2.18.2] for compound UA.18 
showed absorption bands at 3445 cm"^  and 1733 cm'^ assigned to OH and C=0 stretches 
respectively.^^ The ^H NMR spectrum [spectrum 3.2.18.3] showed four double bond proton 
resonances at 5 6.49 (dd, 15.7, 10.9 Hz), ô 5.98 (dd, J=  10.9, 10.9 Hz), 8  5.67 (dd, J  = 
15.7, 6.7 Hz), and 8  5.42 (dt, J  = 10.9, 7.8 Hz). The ^H NMR spectrum also showed two 
oxygenated proton resonances, a methine proton resonance at 8  4.19 (dd, J= 4.15, 6.4 Hz) and 
a methylene proton resonance at 8  4.12 (q, 7.15 Hz), two methyl group proton resonances
at 8  1.25 (t, J  = 7.15 Hz), and 8  0.89 (s) and several additional methylene group proton 
resonances. The NMR spectrum showed a carbonyl carbon resonance at 8  173.9, four 
double bond resonances at 8  135.9, 8  132.8, 8  127.8 and 8  125.8, oxygenated carbon 
resonances at 8  72.9 and 8  60.2. From the ^H NMR, NMR, DEPT and HSQCDEPT 
spectra 20 carbon resonances were accounted for compound UA.18.
The COSY experiment [spectrum 3.2.18.8] showed that the two double bonds and the 
oxygenated methine group formed a CH2-CH=CH-CH=CH-CH0 H splitting pattern due to 
the observed couplings in the COSY spectrum between H-9 and H-10, H-10 and H-11, H-11 
and H-12, H-12 and H-13, H-13 and 2H-14 resonances. On the other hand a triplet methyl 
proton resonance at 8  0.89 (3H-18, t, J =  6.85 Hz), typical of a terminal methyl group of an 
aliphatic compound was seen to be coupled to an overlapped methylene proton resonance at 8
1.30 for 2H-17 as observed in the COSY spectrum. This proton resonance at 8  1.30
75
corresponded to a carbon resonance at ô 22.6 in the HSQCDEPT spectrum assigned to C-17. 
Correlations in the HMBC spectrum were observed between the 3H-18 (5 0.89) and carbon 
resonances at 5 22.6 for C-17 and ô 31.8, assigned to C-16. The C-16 carbon resonance 
corresponed to the overlapped proton resonance at 6 1.30 in the HSQCDEPT spectrum. This 
proton resonance showed coupling in the COSY spectrum with a methylene proton resonance 
at 8 1.38 for 2H-15, which in turn, was coupled to 2H-14. The COSY and the HMBC 
[spectrum 3.2.18.7] experiments further showed the presence of an ethoxy group attached to 
a carboxylic acid via an oxygen group. The examination of the ^^ C NMR and DEPT 
experiments showed that compound UA.18 did not possess methine groups in the aliphatic 
region. This suggested that the compound was acyclic. A search in the literature showed that 
compound UA.18 was an ethoxylated artefact of the known 9-hydroxy-(l OE, 12Z)- 
octadecadienoic acid.^^ The specific rotation of UA.18 was found to be [a]o^^ +36.3°, which 
was similar to the reported specific rotation of 9i?-hydroxy-(10£,12Z)-octadecadienoic acid 
therefore compound UA.18 also had a 9R configuration.
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Table 3.2.18: Correlation table for compound UA.18:
octadecadienoic acid ethyl ester
9i?-Hydroxy-(10jE',12Z)-
No "C NMR (125 
MHz) CD3 OD
^H NMR (500 MHz) CD3 OD HMBC
(H ^H )
COSY
(H ^H )
NOESY
(H->H)
1 173.9 - -
2 34.4 2.28 (t, J =  7.45 Hz) 1,4 3 3 ,4
2.28 (t, J =  7.45 Hz) 1,4 3 2
3 24.9 1.61 m 4 2,4 2
1.61 m 4 2,4 2
4 29.1 1.31 m 3 3 2
1.31 m 3 3 2
5 29.5 1.37 m 6 4,6 -
1.37 m 6 4 ,6 -
6 29.0 1.37 m 7 5,7 -
1.37 m 7 5,7 -
7 29.1 1.31 m 6 6 , 8 -
1.31 m 6 6 , 8 -
8 37.3 1.53 (d, J=4.15H z) 9, 10 7 ,9 7 ,9
1.53(d, J=4.15H z) 9, 10 7 ,9 7,9
9 72.9 4.15 (dd, 7 =  6.54, 4.15 Hz) - 8 , 1 0 8 , 1 1
1 0 135.9 5.67 (dd, 15.7, 6.7 Hz) 9, 12 9,11 8 , 9 ,11,12
1 1 125.8 5 6.49 (dd,7= 15.7, 10.9 Hz), 9,12,13 1 0 , 1 2 9, 10, 12, 14
1 2 127.8 5 5.98 (dd, J =  10.9, 10.9 Hz) 1 0 , 1 1 11,13 1 0 , 1 1 , 1 2
13 132.8 5.42 (dt, 7=10.9, 7.8 Hz) 11,14 12, 14 12, 14, 15
14 27.7 2.17(dd,J= 14.63,7.3 Hz) 12, 13 13 11, 15
2.17 (dd, 7= 14.63,7.3 Hz) 12, 13 13 11, 15
15 25.1 1.38 m - 14, 16 14
1.38 m - 14, 16 14
16 31.8 1.30 m 17, 18 15, 17 18
1.30 m 17, 18 15, 17 18
17 2 2 . 6 1.30 m 16, 18 16, 18 18
1.30 m 16, 18 16,18 18
18 14.0 0.89 (t, 7= 6.85 Hz) 16, 17 17 17
1 ’ 60.2 4.12 (q, 7= 7.15 Hz) 1 , 2 ’ 2 ’ 2 ’
T 14.3 1.25(1,7=7.15 Hz) 1 ’ 1 ’ 1 ’
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3.3; CONCLUSION
The phytochemical investigation of Urginavia altissima yielded ten new bufadienolides 
(UA.1-UA.3, UA.5-UA.10 and UA.12) and a known bufadienolide (UA.ll). Compounds 
UA.2 and UA.8 are 3-ethoxy derivatives of compound UA.l and UA.7 respectively and are 
likely to be extraction artefacts. Four bufadienolides UA.4, UA.5, UA.IO and U A .ll were 
purified as acetylated derivatives. The precusor compound of compound UA.4 is compound 
UA.3 whereas the precursor of compound U A .ll is the known scillaglycoside/scillaren
p  39,52,53
HO. HO,
OH
OH
HO'OH OH
HO""" OHHO'
UA.1
UA.3
UA.2
HO.
OAc
OHOAc
AcOOH
AcO OAcAcO'
UA.5OAcAcO'
UA.4
HO.HO. HO.HO.
OH
OHOH OH
HO'
HO'
OHHO'
UA.6 UA.8UA.7
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UA.10
U A .9
UA.12
UA.11
The other compounds isolated from the bulbs of Urginavia altissima are the two known 
eudesmanes (UA.13 and UA.14), a known 3-benzyl-4-chromanone type homoisoflavonoid 
(UA.15), a known polyhydroxylated compound (UA.16), a purine nucleoside (UA.17) and a 
di-hydroxylated fatty acid ethyl ester (UA.18)
OH
OH
OHUA.13 UA.15
UA.14
HO'
HO'
HO'
NH2OH
UA.17
HO'
OH
UA.16 OH
UA.18
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The occurrence of bufadienolides in Urginavia altissima is in accordance to the reports of 
bufadienolides from the Urgineeae tribe, however the identification of sesquiterpenoids from 
Urginavia altissima is only for the second time from the Hyacinthaceae family, having been 
reported earlier from Urginea epigea?^
Another objective of this study was to compare the chemical constituents of Urginavia 
altissima and its synonyms, Urginea altissima and Drimia altissima. Bufadienolides isolated 
from Drimia. altissima contained a rhamnose sugar unit at C-3 position, 11-a hydroxyl and 
hydrogen at the C-5 position. The bufadienolides isolated from Urginea altissima included 
one with a trisaccharide unit containing two rhanmosyl units and a glucose unit at the C-3 
position and a double bond, two bufadienolides with hydroxyl group at the C-5 position 
and two with rhamnose unit at the C-3 position (Compounds 14-19^ ’^^  ^ section 2.3.3.1.1, 
page 6-7) and two (Compounds 13 and 114^ ,^ section 2.3.3.3.1, page 119). All the 
compounds identified from Urginavia altissima were not reported from either Urginea 
altissimc^^ or Drimia altissima.^^ The bufadienolide glycosides isolated from Urginavia 
altissima contained a glucose unit at the C-3 position and a P-hydroxyl group at the C-11 
position except those with an aldehyde group at C-19 position. These bufadienolides differed 
from those isolated from Drimia altissima and Urginea altissima in that they had the 
hydroxyl group at C-11 in an a- orientation. The differences of the compounds present in the 
three synonymous plants may be attributed to their differences in geographical distribution 
and the ecological variation or could be used to support their placement in three different 
genera.
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CHAPTER FOUR: THE ORNITHOGALEAE TRIBE, ITS BOTANICAL ASPECTS, 
CHEMICAL CONSTITUENTS 
4.1 Introduction
The Omithogaleae tribe consists of bulbous plants characterised by helicoidally disposed 
flowers, fused tepals and filament adnation. The Omithogaleae tribe is distributed through 
Europe, South-West Asia and Africa and includes approximately 280 species/ Following a 
number of morphological and phylogenetic studies in recent years, at least four different 
taxonomic arrangements at the generic level were proposed for the Omithogaleae tribe by 
Speta, 1998 and Manning, 2004, 2009. '^ '^^ The arrangements were all based exclusively on 
the plastid DNA region. The four proposed taxonomic arrangements of the Omithogaleae 
tribe all included, Albuca, Dipcadi, Ornithogalum and Pseudo gaitonia. However, the
latest comprehensive study of the Omithogaleae tribe by Martinez-Azorin et al., 2011, 
recognised 19 genera.^ This study was based on a combination of plastid and nuclear data 
which yielded a phylogenetic trees which is better resolved than those obtained with only the 
plastid regions or the combination of the plastid regions.^ The 19 genera recognised by 
Martinez-Azorin et al., 2011 include, Albuca, Avonsera, Battandiera, Cathissa, Coilonox, 
Dipcadi, Eliorkarmus, Elsiea, Ethesia, Galtonia, Honorius, Loncomelos, Melomphis, 
Neopaters onia, Nicipe, Ornithogalum, Pseudogaltonia, Stellar oides and Trimelopter)
4.1.1 The Chemistry of the Omithogaleae tribe
Phytochemical studies on the Omithogaleae tribe are mainly centred on the genus 
Ornithogalum due to the significant biological activities of compounds such as cardenolides 
and cholestanes isolated from the plants of the Ornithogalum genus. A few phytochemical 
studies have also been done on the Albuca, Eliokarmus, Galtonia, Honorius, Loncomelos and 
Stellaroides genera.^ The Ornithogalum genus is reported to contain mainly cardenolides, 
cholestanes and their glycosides, flavonoids and a limited number of homoisoflavonoids. 
The Albuca genus mainly contains homoisoflavonoids and steroidal saponins, Galtonia and 
Eliokarmus genera contains cholestanes, Honorius and Loncomelos contain cardenolides and 
Stellaroides are known to yield homoisoflavonoids and steroidal saponins.^
4.1.2 The ethnomedicinal properties of the Omithogaleae tribe
The plants from the Omithogaleae tribe are used in traditional medicine in South Africa and 
China for the treatment of food poisoning, wounds, diabetes, cancer, hepatitis and parotitis. 
They are also used as antimicrobial and anti-inflammatory agents.^’^
4.2 Chemical constituents from members of the Omithogaleae tribe and their biological 
activities
4.2.1 Ornithogalum genus
The Ornithogalum species are bulbous plants characterised by long linear leaves, sometimes 
with a white longitudinal band on the adaxial side.^ They are distributed in Europe, Asia and 
Arica. Ornithogalum is the genus with most number of species and is thought to consist of 
about 200 species.^ There are few reports on the ethnomedical uses of plants from the 
Ornithogalum genus. The Ornithogalum genus is known to contain mainly cardenolides, 
cholestanes and their glycosides, flavonoids and very rarely homoisoflavonoids.^ The 
Ornithogalum species whose chemistry has been studied will be discussed in this chapter.
4.2.1.1 Ornithogalum longibracteatum (Jacq.)
Ornithogalum longibracteatum is widely distributed in eastem and southem Africa and is 
widely used in traditional medicine, mostly by the Zulus, to reduce swelling.^ Phytochemical 
investigation of the bulbs of Ornithogalum longibracteatum yielded one homoisoflavanone, 
7-0-methyleucomin (131) of the 3-benzyl-3-hydroxy-4-chromanone type, which has been 
reported previously from Eucomis bicolor (Bak.).^ The reported use of Ornithogalum 
longibracteatum by the Zulus to reduce swelling may be substantiated by the presence of 
homoisoflavonoids, which are known for their anti-inflammatory properties.^
CH3CL ^OCHs
OH 
OH O
131
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4.2.1.2 Ornithogalum caudatum (Ait.)
Ornithogalum caudatum is used in northern China for the treatment of hepatitis, parotitis, 
some tumour types and it is also known in Chinese folk medicine to exhibit anticancer, 
antimicrobial and anti-inflammatory activities.^ Some of the compounds isolated from this 
species include spirosterols, caudaside A (132) and hecogenin (133) and homoisoflavanones 
(134-136).^
The homoisoflavonoids in this species were tested for their antitumor activity against a 
mouse leukemia cell line (P388) and human pulmonary adenocarcinoma (A549) cells and 
were found to show no significant antitumour activities.^
OH OHGRi
HO
RO
132: Ri = a-L- rhamnopyranosyI-(l- 
D-xylopyranosyl-(l—>3)-a-L- 
arabinopyranoside
.2)-IP- 133: R= [p-D-glucopyranosyl-(1^2)-]p-D- 
xyIopyranosyi-(l—>3)-p-D-glucopyranosyl- 
(1—>4)-p-D-galactopyranoside
OCR-
OH
HO OR,
HO
No Name Ri Rz
134 (-)-7-0-Methyleucomol 5-0-p-D-glucopyranoside H H
135 (-)-7-0-Methyleucomol 5-0-P-D-rutinoside H a-L-rhamnopyranoside
136 (-)-7-0-Methyleucomol 5-0-p-D-neohesperidoside a-L-rhamnopyranoside H
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4.2.1.3 Ornithogalum umbellatum (L.)
Ornithogalum umbellatum (L.) also known as the ‘common star of Bethlehem’, is a widely 
studied European Ornithogalum species. This species is characterised by the presence of 
cardenolides.^ The two cardenolides, convallotoxin (137) and convalloside (142) , were the 
first steroidal glycosides isolated and identified from Ornithogalum s p e c ie s .A p a rt  from 
several cardenolides isolated from Ornithogalum umhellatum, some flavonoids (154-157) 
have also been identified. The extracts of the bulbs of Ornithogalum umhellatum have 
been found to show digitalis-like activity on frog, rabbit and cat hearts. The active 
component of Ornithogalum umhellatum has been identified to be the cardenolide 
convallotoxin.^^ The cytotoxicity studies of convallotoxin against Eagles KB strain human 
carcinoma showed significant cytotoxic activity with an IC50 of 0.02 pg m l'\ Structure 
activity studies have shown that the glycosidic portion is essential for the activity and that the 
presence of P-hydroxyl groups at C-5 and C-14 and an aldehyde at C-19 significantly 
enhances the activity. From this species, seventeen cardenolides and six flavonoids have 
been isolated.
0
OH
RiC
No. Ri R2 R3 R4 Rs
137 a-L-rhamnopyranoside H C H O O H H
138 R= P-D-glucopyranosyl-(l-^4)- a-L-fucopyranoside H C H O O H H
139 a-L-rhamnopyranoside H C H 2 O H O H H
140 6 -deoxy-P-D-gulopyranoside H C H O O H H
141 a-L-rhamnopyranoside H C H 3 H O H
142 a-L-rhamnopyranosyl-P-D-glucopyranoside H C H 3 H O H
143 6 -deoxy-P-D-allopyranoside H C H O O H H
144 P-D-allopyranoside H C H O O H H
145 3-acetyl-p-digitopyranosyl-P-D-glucopyranosyl-a-L-
rhamnopyranoside
H C H O O H H
146 a-L-rhamnopyranoside H C H O O H O H
147 6 -deoxy-P-D-allopyranoside H C H 3 O H H
148 6 -deoxy-p-D-gulopyranoside H C H 3 H O H
149 6 -deoxy-P-D-allopyranoside H C H 3 H O H
150 P-D-allopyranoside H C H 3 H O H
151 6 -deoxy-a-L-glucopyranoside H C H 3 O H O H
152 a-L-rhamnopyrano side H C H 3 O H O H
153 P-D-ribose H C H 3 O H O H
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HO.
OH O
154
OH
HO.
OH 0
156: R= p-D-glucopyranoside
OH
HO.
OH
OH O
155
OH
RiO.
OH O
157: Ri = P-D-glucopyranoside, R] = P-D- 
glucopyranosyl-P-D-glucopyranoside
4.2.1.4 Ornithogalum algeriense (Boiss.)
The phytochemical investigation of the leaves of Ornithogalum algeriense yielded two C- 
glycoflavones known as isovitexin (156) and isovitexin-7-2” -di-0-glueoside (157), which 
have also been reported from Ornithogalum umbellatum and Ornithogalum kochiiP
4.2.1.5 Ornithogalum kochii (Pari.)
Ornithogalum kochii is commonly known as star of Bethlehem. A phytochemical study on 
the ethanol extract of the fresh leaves of Ornithogalum kochii yielded the two C- 
glycoflavones (156) and (157), which have also been reported from Ornithogalum algeriense 
and Ornithogalum umbellatumP
4.2.1.6 Ornithogalum magnum  (Krasch. & Schischk.)
Ornithogalum magnum is a synonym of Loncomelos magnum. Several cardenolides have 
been isolated from Ornithogalum magnum including (137) and (141) isolated from 
Ornithogalum umbellatum. Others isolated are compounds 158-162.^ '^^^
OH
RiQ....
o
158: Ri = a-L-rhamnopyranoside
159: Ri = p-D-rhamnopyranosyl)-p -D-glucopyranoside
160: Ri = a-L-arabinopyranoside
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OH
HO'
161
O
HO OH'I,HO'
H
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4.2.1.7 Ornithogalum nutans (L.) Gray
Ornithogalum nutans is a synonym of Honorius nutans. The compounds that have been 
reported from this species include compound (137) from Ornithogalum umbellatum and 
compounds (158) and (159) from Ornithogalum magnum. Other compounds isolated are 
compounds 163-189.^^’^ ^
OH
RiO'
No. Ri R2 Rs R4 Rs R6 R?
163 6  ’ -desoxy-P-D-allopyranosyl-4’ -p-D- 
xyllopyanosyl-3 ” -P-D-apiofuranoside
H C H O O H H H H
164 R -  a-L-rhamnopyranosyl-4’-P -D- 
apiofuranoside
H C H s H H H O H
165 P-D-digitoxopyranosyl-4 ’ -P-D- 
xylpyranosyl-3 ” -p-D-aplofliranoside
H C H s H H H OAc
166 2 ’ -desoy-P-Dallopyranosyl-4 ’ -p-D- 
xylopyranosyl-3 ” -p-D-aplofliranoside
H C H s H H H OAe
167 P-D-digitoxopyraosyl4’-p-D- 
xylopyranosyl-3 ’’-P-D-aplofuranoside
H C H s H H O H OAc
168 6 ’-desoxy-a-L-glucopyranoside H C H O O H H H H
169 a-L-rhamnosyl-P-D-glueopyranoside H C H O O H H H H
170 P-D-allopyranosyl-4 ’ -P-D-xyloside H C H O O H H H H
171 P"D-digitoxopyransyl-4’ - 
glucopyranoside
H H O H H H H
172 a-L-rhamnopyranoside H C H O O H O H H H
173 6 ’-desoxy-a-L-glucopyranoside H C H O O H O H H H
174 a-L-rhamnopyranosyl-4 ’ -P-D- 
apiofuranoside
H C H s H O H H H
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175 a-L-rhamnopyranosyl-a-L-
rhamnopyranoside
H C H s H O H H H
176 P-D-digitoxopyranosyl-p-D- 
xylopyranosyl- a-L-rhamnopyranoside
H C H s H O H H H
177 a-L-rhamnopyranoside H C H s O H O H H H
178 P-D-glucopyranoside H C H s O H O H H H
179 2-desoxy-p-D-allopyranoside O H C H s O H O H H H
OH
OH
RiO'
No. R i R 2
180 P-D-digitoxopyranosyl-p-D-xylopyranosyl-a-L-rhamnopyranoside O H
181 3’-(9-acetyl-P-D-digitoxopyranosyl-p-D-xylopyranosyl-a-L-rhamnopyranoside O H
182 p-D-digitoxopyranosyl-P-D-xylopyranosyl-P-D-apiofuranoside H
183 3’-0-acetyl-P-D-digitoxopyranosyl-p-D-xylopyranosyl-a-L-rhamnopyranoside H
184 P-D-digitoxopyranosyl-P-D-xylopyranosyl-a-L-rhamnopyranoside H
OH
RiO'
No. Ri R2 Rs R 4 Rs
185 P-D-digitoxopyranosyl-4 ’ -P-D-xylopyranosyl-4 ’ ’ -a-L- 
rhamnopyranoside
O H O H O H H
186 3’-0-acetyl-p-D-digitoxopyranosyl-4’-P-D- 
ylopyranosyl-4 ’ ’ -a-L-rhamnopyranoside
H H H O H
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RO'
H
O
No. Ri
187 3’-0-acetyl-p-D-digitoxopyranosyl-4’-P-D-xylopyranosyl-4” -a-L-rhamnopyranoside
188 P-D-digitoxopyranosyl-4’-P-D-xylopyranosyl-4” -a-L-rhamnopyranoside
189 P-D-digitoxopyranosyl-4’-P-D-xylopyranosyl-4” -a-L-rhamnopyranoside
4.2.1.8 Ornithogalum boucheanum (Kunth) Holub
Ornithogalum boucheanum is a synonym of Honorius boucheanum. Eight cardenolides have 
been isolated from this speeies.^^
^ 2 0 ....
RiO'
No. Ri R 2 R3 R4 Rs
190 6 ’-deoxy-p-D-allopyranosyl-P-D-xylopyranosyl-a-L-rhamnoside OH H H H
191 6 ’-deoxy-P-D-allopyranosyl-P-D-xylopyranosyl-P-D-apiofuranoside OH H H H
192 P-D-digitoxopyranosyl-P-D-xylopyranosyl-a-L-rhamnopyranside H H OH OH
193 P-D-digitoxopyranosyl-p-D-xylopyranosyl-a-L-apiofriranoside OH H H H
194 P-D-digitoxopyranosyl-P-D-xylopyranosyl-a-L-rhamnopyranside H OH H H
195 a-L-rhamnopyranosyl-P-D-apiofuranoside OH H H H
196 p-D-digitoxopyranosyl-p-D-xylopyranosyl-a-L-rhamnopyranside H H H H
197 6 ’-deoxy-p-D-allopyranosyl-p-D-xylopyranoside H H H H
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4.2.1.9 Ornithogalum gussonei (Ten.)
Several cardenolides have been isolated from the bulbs of Ornithogalum gussonei, including 
compounds (158) and (162) isolated from Ornithogalum magnum. Also isolated are 
compounds (198-202)?'^’^ ^
HO...
OH
HO' 198
4.2.1.10 Ornithogalum nanum (Sibth. & Sm.)
A study on the Bulgarian species of Ornithogalum nanum yielded five cardenolides (198- 
202), also isolated from Ornithogalum gussonei?^
OH
RiO'
OH
o
No. Ri R2 Rs
199 H H CHs
2 0 0 H O H C H O
2 0 1 H O H C H 2 O H
2 0 2 6 -deoxy-P-D-allopyranoside H C H s
4.2.2 Albuca (L.) genera
The Albuca species are bulbous plants characterised by nodded, patent or erect flowers, 
dimorphic tepals and flattened/ The Albuca genus comprises of approximately 60 species 
and is distributed mainly in southem and eastem Africa, with only a few species extending 
northwards to Nigeria, north of Chad, Ethiopia and Saudi Arabia/ The southem African 
species of Albuca genus are used in traditional medicine by the Zulus as protective charm and 
also for the treatment of malicious food poisoning. Some of the species are also used by 
traditional healers to treat wounds and diabetes.^^
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4.2.2.1 Albuca fastigiata (Diyand.)
Albuca fastigiata is a species found on the East coast of South Afiica and is used by the Zulu 
people to treat food poisoning and also used as a protective charm. The investigation of the 
bulbs 0 Î  Albuca fastigiata yielded only one homoisoflavonoid (203).^^
H 3 C 0
OH O
4.2.2.2 Albuca setosa (Jacq.)
Albuca setosa is a southem African species used by traditional healers to treat wounds and 
diabetes.^^ The anti-inflammatory activity study of this plant showed significant inhibitory 
activity in carrageenan-induced paw oedema on rats. There are no reports on the compounds 
isolated from this plant.^^
4.2.2.3 Albuca nelsonii (N.E.Br.)
Phytochemical study of Albuca nelsonii yielded the steroidal saponin (msogenin) (205).^^ 
This compound was identified by comparing the melting point, speeific rotation, infrared and
mass spectrum against an authentic sample.29
OH
HO'
205
4.2.3 Galtonia (Decne.) genera
Galtonia species are bulbous plants characterised by large leaves sheathing the stem, nodded 
flowers and irregularly compressed seeds. ^  The Galtonia genus is mainly found in summer- 
rainfall, high altitude regions of the Drakensburg, low Drakensburg, Southem Berg and Natal 
midlands in southem Africa. There are no report on the ethnomedieal uses of the Galtonia 
genus, however some of the species are cultivated for omamental purposes.^
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4.2.3.1 Galtonia candicans (Baker) Decne.
Galtonia candicans is a native South African species/ The bulb methanol extract has been 
found to be active against HL-60 leukemia cell lines with an IC50 value of 0.0056 pM. It 
contains cholestanes diglycosides, candicanoside (206), galtonioside (207), cholestanes 
bisdesmosides (208-213) and cholestanes glycosides (214-219). Candicanoside and 
galtonioside have been shown to posses potent anticancer activity against HL-60 leukemia 
cells with an IC50 values of 0.032 and 0.057 pM respectively.^®’^ ’^^ ’^^ ^
RO'
0 R2
HOOH
OH^
RiO'
206: R = a-L-rhamnopyranosyl- 
(1^2)-p-D-glucopyranoside
OH
24
OR:
RiO'
208: Ri = P-D-glucopyranoside, R2 =3-0- 
acetyl- a-L-rhamnopyranoside
209: Ri = p-D-glucopyranoside, R% =3-0- 
acetyl- a-L-rhamnopyranoside,
207: Ri = 3,4,5 trimethoxybenzoyl ester, R2 
a-L-arabinopyranosyl-(l—>4)-P-D- 
glucopyranoside
OH
24
OR] OR2
HO'
210: Ri = P-D-glucopyranoside, R% = P-D-
glucopyranoside
211: R I = P-D-glucopyranosyl-(l—>6 )- P-D-
gluopyranoside, R2 = P-D-glueopyranoside,
212: Ri = p-D-glucopyranosyl-(l—>6 )- P-D-
glucopyranoside, R2 = P-D-glucopyranoside
213: Ri = a-L-rhamnopyranoside, R 2 = p-D- 
glucopyranoside
214: Ri = P-D-glucopyranoside, R2 = p-D-
glucopyranoside
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ORz
215: Ri = P-D-glucopyranoside, R2 = (2-(9-(E)-cinnamoyl-P-D-xylopyranosyl-(1^3)-2-0-acetyl- 
a-L-arabinopyranoside
216: Ri = P-D-glucopyranoside, R2 = (2-0-3,4-dimethoxybenzoyl-P-D-xylopyranosyl-(l—>3)-2-0- 
acetyl- a-L-arabinopyranoside
217: Ri = P-D-glucopyranoside, R2 = P-D-xylopyanosyl)-(1^3)-2-0- acetyl- a-L- 
arabinopyranoside
218: Ri = P-D-glucopyranoside, R2 = a-L-arabinopyranoside
„.0H
RjO'
219: Ri = a-L-rhamnopyranosyl-(1^2)-p-D-glucopyranoside, R2  = CH2OH
4.2.3.2 Galtonia princeps (Baker) Decne.
Galtonia princeps is a South African species of the Galtonia genus.^ A phytochemical study 
on the methanol extract of the bulbs of this plant yielded one eholestane derivative (2 2 0 ).^ '^
...OH
RiO'
220: Ri = H, R2  = a-L-arabinopyranoside
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4.2.S.3 Galtonia saundersiae (Baker) Mart.-Azonn
Galtonia saundersiae is a synonym of Ornithogalum saundersiae. It is native to the east 
coast of South Africa.^ A study on Galtonia saundersiae led to the isolation of compounds 
221-248.^^’^  ^ Compounds (222), (223), (228) and (232) were tested for their inhibitory 
activity on cyclic AMP phosphodiesterase. Compound (222), (223), (228) and (232) showed 
good inhibitory activity with IC50 of 0.00025 pM, 0.00020 pM, 9.9 x 10'  ^pM, 10.9 x 10"^  pM 
respectively.^^ Compound 246-248 were also tested for their antitumour activity against 
leukemia HL-60 cells and MOLT-4 cells and all were found to show significant cytotoxic 
activity through the induction of apoptosis.^^'^^
RiO'
No. Ri R2
221 H P-D-xylopyranosyl-2-0-acetyl-(l—>3)-a-L-arabinopyranoside
222 H 2-0-4-methoxybenyl-p-D-xylopyranosyl-2-0-acetyl-(l—»3)-a-L- 
arabinopyranoside
223 H 2-0-3,4-dimethoxybenyl-P-D-xylopyranosyl-2-0-acetyl-(1^3)-a-L- 
arabinopyranoside
224 H 2-0-(E)-cinnamoyl-P-D-xylopyranosyl-2-0-acetyl-(1^3)-a-L-
arabinopyranoside
225 P-D-
glucopyranoside
2-0-4-methoxybenyl-p-D-xylopyranosyl-2-0-acetyl-(l —>3)-a-L- 
arabinopyranoside
226 H p-D-glucopyranosyl-2-0-3,4-dimethoxybenyl-p-D-xylopyranosyl-2-0- 
acetyl-( 1 -^3 )-a-L-arabinopyranoside
227 H P-D-glucopyranosyl-2-0-3,4,5-trimethoxybenyl-P-D-xylopyranosyl-2-0-
acetyl-(1^3)-a-L-arabinopyranoside
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No. Ri R2
228 H H, lla-O H
229 H Ac lip-OH
230 Ac H lip-OH
231 H H lla-O H,
232 H Ac llp-OH, A"
233 Ac Ac lla-O H
234 Ac 3, 4, 5-trimethoxybenzoyl, lla-O H
235 Ac /7-methoxybenzoyl, lla-O H
236 Ac Ac lla-OH, A^ ’
MeO
OH
RO'
237: R = a-L-rhamnopyranosyl-(l—>2)-P-D-glucopyranosyl-(l—>2)-P-D-glucopyranoside 
238: R = 4-0-4-methoxybenzoyl-a-L-rhamnopyranosyl-(1^2)-P-D-glucopyranoside 
239: R = a-L-rhamnopyranosyl-(l-^2)-P-D-glucopyranoside
HO OH
HO- OH
HO'
ORMe' RO'
HO
241: R = a-L-rhamnopyranosyl-(1^2)-P-D-OH
240: R = 3,4,5-trimethoxybenzoyl glucopyranosyl-(1^2)-P-D-glucopyranoside
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OR
HO'
242: R  = p-D-glucopyranosyl-(l—>6)-P-D-glucopyranoside
OH
No. Ri R2
243 CHO 4-0-4-hydroxybenzoyl-a-L-rhamnopyranosyl-(l—>2)-P-D-glucopyranoside
244 CHO a-L-rhamnopyranosyl-( 1 -^2)-P-D-glucopyranosyl-(l ^ 2)-P-D- 
glucopyranoside
245 CHO a-L-rhamnopyranosyl-( 1 —>2)-P-D-glucopyranoside
246 CHO 4-(9-4-methoxybenzoyl-a-L-rhanmopyranosyl-(l-^2)-P-D-glucopyranoside
247 CH2OH 4-0-4-hydroxybenzoyl-a-L-rhamnopyranosyl-(1^2)-P-D-glucopyranoside
248 CH2OH 4-0-4-methoxybenzoyl-a-L-rhanmopyranosyl-(l—>2)-p-D-glucopyranoside
4.2.4 Eliokarmos Raf. genera
Eliokarmos species are bulbous plants eharacterised by ciliate leaves and large eolourful 
flowers/ Only one Eliokarmos species is found in South Africa/ and even though there are 
no reports on its ethnomedical uses, Eliokarmus thyrsoides (Jacq.) have been linked to stock 
poisoning. Some species also from Eliokarmus genus are widely cultivated and are used for 
omamental purposes.^
4.2.5 Honorius Gray. Genera
Honorius species are bulbous plants characterised by lobed filaments.^ There are no reports 
on ethnomedical uses of Honorius species, however they are eultivated for omamental 
purposes.
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4.2.6 Loncomelos Raf. genera
Loncomelos species are bulbous plants charaeterised by concolourous leaves and white or 
rarely yellowish tepals/ They are reported to occur in Spain^ and there are no reports on the 
ethnomedical uses of the Loncomelos genus
4.2.6.1 Loncomelos narbonense (L.) Raf.
The study on the chemistry of the Bulgarian species, Loncomelos narbonense led to the 
isolation of compounds (200-203/^ also isolated from the bulbs of Ornithogalum nanum and 
Ornithogalum gussonei?'^^^
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CHAPTER FIVE: THE CHEMISTRY OF ORNITHOGALUMDUBIUM TIYBRID’ 
AND ORNITHOGALUMPONTICUM‘SOCYLV
The bulbs of Ornithogalum dubium ‘Hybrid’ and Ornithogalum ponticum ‘Sochi’ were 
purchased from http://www.dixexport.com. Due to difficulties in obtaining bulb material 
from Southem Africa, it was decided to investigate the potential of bulbs that could be bought 
in large quantities from a horticultural supplier in the Netherlands to see if they contained the 
expected classes of compounds. The purchase of the bulbs from horticultural suppliers can 
be a longterm sustainable source of bioactive compounds as they can be bought in bulk, no 
biodiversity or legislative issues, and they are cheap to acquire.
5.1 Chemistry of Ornithogalum Dubium Hybrid'
5.1.1 Introduction
Ornithogalum dubium ‘Hybrid’ is a horticultural hybrid belonging to the Omithogaleae tribe 
of the Scilloideae subfamily. There are no reports on the chemistry and ethnomedical uses of 
this species.
Picture 2: A photograph of Ornithogalum dubium ‘Hybrid’ (Photograph from
http://www.dixexport.com)
The bulbs of Ornithogalum dubium ‘Hybrid’ were purchased from 
http://www.dixexport.com. In this study three known homoisoflavonoids (ODH.l, ODH.2 
and ODH.3) and three new homoisoflavonoids (ODH.4, ODH.5 and ODH.6) were isolated 
from Ornithogalum dubium ‘Hybrid’. All the homoisoflavonoids isolated from this plant are 
of the 3 -benzyl-4-chomanone type. The structural elucidation of the compounds isolated 
from Ornithogalum dubium ‘Hybrid’ is described below: The extraction and isolation of 
compounds from Ornithogalum dubium ‘Hybrid’is described on experimental section 8.4
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105
5.1.2 RESULTS
5.1.2.1 Structural elucidation of compound ODH.l: (35)-5-Hydroxy-7-methoxy-3-(4-
methoxybenzyI)-4-chromanone.
Compound ODH.l was isolated as a clear oil from the ethanol bulb extract of Ornithogalum 
dubium ‘Hybrid’ and was identified as (35)-5-hydroxy-7-methoxy-3-(4-methoxybenzyl)-4- 
chromanone.
CHgCL 7 ^  A,0CH3
H
OH O
ODH.1
Figure 5.1.2.1: Structure for compound ODH.l: (3*S)-5-hydroxy-7-methoxy-3-(4-
methoxybenzyl)-4-chromanone.
The MS [Spectrum 5.1.2.1.1] gave a molecular ion [M-H]^ peak at m/z 313.1, which 
indicated a molecular formula of CigHigOs for ODH.l. From the formula, a double bond 
equivalence of ten was calculated. The FTIR spectrum [Spectrum 5.1.2.1.2] showed 
absorption bands at 3432 cm‘^  and 1634 cm'^ for OH and C=0 stretches respectively.'^^ The 
carbonyl group stretch at 1634 cm'^ was attributed to the carbonyl group of the 4-chromanone 
ring. The characteristic peak in the IR spectrum for the C=0 stretching frequency for 
chromanone ring without hydroxyl group at C-5 occurs at approximately 1685 cm'V^ The 
lowering of the frequency of the carbonyl stretch occurs due to conjugation and hydrogen 
bonding effects.'^  ^ Hydrogen bonding to the carbonyl group lowers the stretching force 
constant by lengthening the C=0 bond which results in lowering of the absorption 
freq u en cy .A lso  observed in the FTIR spectrum were the C-H aliphatic stretches at 2921 
cm"^and 2849 cm '\ C-0 stretches at 1156 cm"^and C=C at 1513 cm"V^
The ^H NMR spectrum [Spectrum 5.1.2.1.3] showed the characteristic splitting pattern of the 
3 -benzyl-4-chromanone type homoisoflavonoid for the 2H-2, H-3 and 2H-9. The 2H-2 proton 
resonances for compound ODH.l occurred at 5 4.28 (dd, J =  11.5, 4.15 Hz) and ô 4.12 (dd, J  
= 11.5, 7.0 Hz), H-3 occurred at Ô 2.81 (m) and 2H-9 occurred at 5 3.18 (dd, 13.8, 4.5 Hz) 
and 2.71 (dd, J=  13.8, 10.5 Hz). ^H NMR spectrum displayed two singlet methoxy groups at 
Ô 3.81 and 5 3.80 and a hydroxyl singlet proton resonance at ô 12.12. The hydroxyl group 
was placed at C-5 due to hydrogen bonding with the carbonyl of chromanone ring (ring C) of 
the chromanone type homoisoflavonoids.
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The NMR spectrum of compound ODH.l also displayed two pairs of doublet proton 
resonances in the aromatic region, 5 6.87 and 5 7.15 each integrating to two protons and with 
a coupling constant of 8.6 Hz which indicated a^ara-disubstituted aromatic system for ring 
B. The other pair of aromatic proton resonances occured at 5 5.97 and 5 6.06 each integrating 
to one proton and having a coupling constant of 2.3 Hz indicating a meto-coupled proton 
resonances of the aromatic system of ring A. The doublet proton resonance at 5 7.15 showed 
correlation in the NOESY spectrum [Spectrum 5.1.2.1.9] with the proton resonances for H-9 
and H-3. A correlation was also observed in the HMBC spectrum [Spectrum 5.1.2.1.7] with 
the proton resonance at 5 7.15 and carbon resonance at 32.2 for C-9. This indicated that the 
doublet proton resonance at 5 7.15 was due to the 2’ and 6’protons. The other proton 
resonance at ô 6.87 was assigned to the 3’/5’ protons. This was confirmed by the correlation 
in the COSY spectrum [Spectrum 5.1.2.1.8] which showed coupling of the 3’/5’ proton 
resonance with the 2’/6’ proton resonance. The aromatic proton resonances at Ô 5.97 and Ô
6.06 showed correlations in the HMBC spectrum with carbon resonance at 5 102.8 for 
position C-4a. A correlation was also observed in the HMBC spectrum between the hydroxyl 
proton resonance at 5 12.1 for H-5 and the carbon resonance at 6 95.2, which correlates in the 
HSQCDBPT spectrum [Spectrum 5.1.2.1.6] with proton resonance at ô 6.06. The proton 
resonance at 5 6.06 was therefore assigned to H-6. The other proton resonance was therefore 
assigned to H-8 based on the coupling constant of 2.3 Hz which arise due to weto-coupling 
on aromatic systems. The methoxy group at 5 3.80 showed a correlation in the NOESY 
spectrum [Spectrum 5.1.2.1.9] with the 3’/5’ proton resonance and the other methoxy group 
at 5 3.81 showed a correlation in the NOESY spectrum with the »î^/a-coupled proton 
resonances for H-6 and H-8, hence allowing the placements of the methoxy groups at C-4’ on 
ring B and C-7 on ring A respectively.
The coupling constants for a pair of doublet of doublets for the two proton resonances at C-2 
(5 69.2) were different. The J  11.5 Hz coupling constant was attributed to germinal coupling 
of the two H-2 proton resonances, whereas the 4.15 Hz and 7.0 Hz coupling constants were 
attributed to V  (vicinal coupling) with the H-3 proton resonances. The configuration at C-3 
was determined by comparing the electronic circular dichroism (ECD) spectrum with those of 
previously reported homoisofalvanoids. The ECD spectrum showed a positive Cotton effect 
(Ac = 0.80) at 290 nm and a negative Cotton effect (Ac = -1.1) at 308 nm indicating the S  
configuration, in agreement with urgineanin C isolated from Urginea depressa.^^ These 
results are in agreement with the results obtained by Adinolfi et al., on the study of the
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absolute configuration of homoisoflavonoids isolated from Muscari species, where they 
found out that a positive Cotton effect in the 287-295 nm region of the BCD curves of 
homoisoflavonoids is indicative 0Ï3R configuration for C-3 hydroxylated compounds and 3S 
configuration for compounds lacking a C-3 hydroxyl g r o u p A  specific rotation of +22.6 
was measured for compound ODH.l. Compound ODH.l was found to be (35)-5-hydroxy-7- 
methoxy-3-(4-methoxybenzyl)-4-ehromanone, a C-3 enantiomer of the reported 
homoisoflavonoid isolated from Eucomis bicolar (Scilloideae subfamily) whose specific 
rotation value is -36.“^^
190 350 390 430
A (nm)
Figure 5.1.2.2: ECD curve for compound ODH.l
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Table 5.1.2.1: Correlation table for ODH.l: (35)-5-hydroxy-7-methoxy-3-(4-
methoxybenzyl)-4-chromanone.
No. NMR (125 
MHz) CDCI3
"H NMR (500 MHz CDCI3 J  
in Hz)
HMBC
(H ^C )
COSY NOESY
2 a 69.2 4.28 (dd,/=4.2, 11.5 Hz) 4,9 2 b 3
2 b 4.12 (dd,/=  7.0, 11.5 Hz) 3,4 2 a 3
3 47.1 2.81 m - 2,9 2 ,2V6'
4 198.2 - - - -
4a 1 0 2 . 8 - - - -
5 168.0 - - - -
6 95.2 6.06 (d, J= 2.3 Hz) 4a, 5, 8 8 7 -OCH3
7 164.7 - - - -
8 94.1 5.97 (d,J=2.3H z) 4a, 5, 6 6 7 -OCH3
8a 163.1 - - - -
9a 32.2 3.18 (dd,J= 4.5,13.8 Hz) 2V6% 3, 4 3 2%/6% 3V5'
9b 2.71 (dd,J=10.5, 13.8 Hz) 2V6% 3,4 3 2%/6% 3V5'
r 129.8 - - - -
T 130.3 7.15 (d, .7= 8.6 Hz) 1% 4% 9 3V5' 9,3
3’ 114.4 6.87 ( d , ^  8.6 Hz) r,2V 6% 4' 2%/6' 4’-0CH3
4’ 158.7 - - - -
5’ 114.4 6.87 ( d , ^  8.6 Hz) r,2V 6% 4' 2%/6' 4’-0CH3
6’ 130.3 7.15(d, J=8.6H z) 1% 4% 9 3V5' 9,3
4’-0CH3 55.5 3.80 s 4’-C - 3V5'
5-OH - 12.12 s 4a, 5, 6, 8a - -
7 -OCH3 55.9 3.81 s 7-C - 6,8
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5.1.2.2 Structural elucidation of compound ODH.2: (3i?)-3,5-diliydroxy-7-metlioxy-3-(4-
methoxybenzyl)-4-chromanone.
Compound ODH.2 was isolated as a clear oil from the ethanol bulb extract of Ornithogalum 
dubium ‘Hybrid’ and was identified as (3i?)-3,5-dihydroxy-7-methoxy-3-(4-methoxybenzyl)- 
4-chromanone.
OH O
Figure 5.1.2.3: Structure for compound ODH.2: (3R)-3,5-dihydroxy-7-methoxy-3-(4-
methoxybenzyl)-4-chromanone.
The MS [Spectrum 5.1.2.2.1] gave a [M + Na]^ ion at miz 353.0, which corresponded to a 
molecular formula of CigHigOg for ODH.2. From the formula a double bond equivalence of 
ten was calculated. The FTIR spectrum [Spectrum S.2.2.2] showed absorption band at 3467 
cm'^ and 1638 cm"^  for OH and C=0 stretches respectively, C-H aromatic stretches at 3068 
cm'^ and 2996 cm"\ C-H aliphatic stretches at 2935 cm'^ and 2836 cm"\ C=C aromatic 
stretches at 1573 cm'^ and 1512 cm'^ and C-0 stretches at 1158 cm‘\'^ ^
The ^H NMR spectrum [Spectrum 5.1.2.2.3] for compound ODH.2 showed the 
characteristic proton resonances for a w^to-coupled ring A at 5 6.12 (d, 2.3 Hz) and 5
6.05 (d, J=  2.3 Hz) and proton resonances for aj^am-disubstituted ring B at 6 7.12 (d, J=  8.7 
Hz) and 6 6.85 (d, J  = 8.7 Hz) which were similar to the proton resonances of compound 
ODH.l. The proton resonances for the 2H-2 protons occurred at 8 4.21 (d, 11.2 Hz) and
8 4.06 (d, J  = 11.2 Hz) and the 2H-9 non-first order resonance occurred at 8 2.97 (d, J  =
14.02 Hz) and 2.93 (d, J  = 14.02 Hz). These proton resonances differed from those of 
compound ODH.l with respect to the chemical shifts and splitting pattern of 2H-2 and 2H-9. 
It was also observed that the multiplet proton resonance usually present for H-3, which 
occurs due to coupling with both the 2H-2 and 2H-9 proton resonances was missing. This 
indicated that the C-3 was substituted. The proton NMR spectrum also showed an extra 
singlet proton resonance at 8 3.35 for the proton of a hydroxyl group.
The NMR [Spectrum 5.1.2.2.4] and DEPT [Spectrum 5.1.2.2.5] spectra showed an extra 
oxygenated quartenary carbon resonance at 8 72.4, which, in turn, showed a correlation in the
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HMBC spectrum [Spectrum 5.1.2.2.7] with the singlet proton resonance at 5 3.35. This 
proton resonance showed correlations in the HMBC spectrum with oxygenated carbon 
resonance at 6 72.2 for the C-2 and the carbonyl carbon resonance at 5 198.2 for C-4. This 
information indieated that the C-3 position of compound ODH.2 was substituted with a 
hydroxyl group. The placement of the hydroxyl group was also confirmed by the correlation 
in the NOESY spectrum [Spectrum 5.1.2.2.9] with the proton resonances for H-2|3, 2V6’and 
2H-9.
The configuration at the C-3 position was determined using the calculated ECD spectrum and 
the specific rotation. From the ECD specrum, a positive Cotton effeet (Ac = 5.3) at 289 nm 
and a negative Cotton effect (Ac — 1.2) at 310 nm was observed. A specific rotation of 
+14.62 was measured. This indicated that the configuration at C-3 of compound ODH.2 was 
R. This compound was found to be (3i?)-3,5-dihydroxy-7-methoxy-3-(4-methoxybenzyl)-4- 
chromanone. A similar homoisoflavonoid was reported from Ornithogalum 
longibracteatumj but its C-3 eonfiguration was not defined and its specific rotation is not 
given.
290 340 390
-10
-15
-20
Figure 5.1.2.4: ECD curve of compound ODH.2
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Table 5.1.2.2: Correlation table for ODH.2: (5i?)-5,5-dihydroxy-7-methoxy-3-(4’-
methoxybenzyI)-4-chromanone.
NO. ^^ C NMR (125 
MHz) CDCI3
^H NMR (500 MHz 
CDCIs/inH z)
HMBC (H->C) COSY NOESY
2a 72.0 4.21 (d,J=11.2H z) 3, 4, 8 a, 9 2b 2b, 9
2b 4.06 (d,J= 11.2 Hz) 3,4, 8 a, 9 2a 2a, 9
3 72.4 - - - -
4 198.2 - - - -
4a 100.7 - - - -
5 164.2 - - - -
6 95.6 6.12(d, J=2.3H z) 4a, 5, 7, 8 8 7 -OCH3
7 168.9 - - - -
8 94.7 6.05 (d, J= 2.3 Hz) 4, 4a, 6,7, 8a 6 7 -OCH3
8a 162.9 - - - -
?a 40.9 2.97 (d, J= 14 .0H z) r,2V6% 2, 3 ,4 9b, 2%/6' 2 , 2 %/6 '
?h 2.93 (d ,J=  14.0 Hz) r,2V6% 2, 3 ,4 9a, 2V6' 2 , 2 %/6 '
r 126.3 - - - -
Z’ 131.8 7.12(d, J=8.7H z) r,3V5%4%9 3V5% 9 9, 3V5'
r 114.0 6.85 (d, J=8.7H z) r,2V6%4' 2 %/6 ' 2V6%4'-0CH3
r 159.1 - - - -
114.0 6.85 (d ,/= 8 .7H z) r ,  2V6%4' 2 %/6 ' 2V6% 4'-0CH3
5’ 131.8 7.12 (d,J= 8.7 Hz) r,3V5%4%9 3V5% 9 9, 3V5'
5-OH - 3.35 2,3 - 2b, 2V6% 9
r-OCHs 55.4 3.80 s 4’-C - 3V5'
)-0H - 11.25 s 4 ,4a, 5-C, 6 , 7 - -
7-OCH3 56.1 3.85 s 7-C - 6,8
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5.1.2.3 Structural elucidation of compound ODH.3: (35)-5-hydroxy-7-methoxy-3-(4-
hydroxybenzyl)-4-chromanone
Compound ODH.3 was isolated as a clear oil from the ethanol bulb extract of Ornithogalum 
dubium ‘Hybrid’ and was identified as (35)-5-hydroxy-7-methoxy-3-(4-hydroxybenzyl)-4- 
chromanone
CHsOvj
OH O
ODH.3
Figure 5.1.2.5: Structure for compound ODH.3: (3*S)-5-hydroxy-7-methoxy-3-(4-
hydroxybenzyl)-4-chromanone
The MS [Spectrum 5.1.2.3.1] gave a molecular ion [M+H]^ peak at m/z 301.0, which 
indicated a molecular formula of C17H16O5 for ODH.3 From the formula a double bond 
equivalence of ten was calculated. The FTIR spectrum [Spectrum 5.1.2.3.2] showed 
absorption band at 3399 cm'^ and 1639 cm'^ for OH and C=0 stretches respectively, C-H 
aromatic stretches at 3014 cm'^ and 2975 cm"\ C-H aliphatic stretches at 2931 cm'^ and 2854 
cm '\ C=C aromatic stretches at 1574 cm'^ and 1514 cm'^ and C-0 stretches at 1157 cm'\"^^
The ^H NMR spectrum [Spectrum 5.1.2.3.3] showed the characteristic splitting pattern of the 
3 -benzyl-4-chromanone type homoisoflavonoid for the 2H-2, H-3 and 2H-9. The 2H-2 
proton resonances for compound ODH.3 occurred at ô 4.29 (dd, J=  11.5, 4.2 Hz) and 5 4.13 
(dd, J=  11.5, 7.0 Hz), H-3 occurred at 5 2.81 (m) and 2H-9 occurred at 5 3.16 (dd, J =  13.8,
4.4 Hz) and 2.70 (dd, 13.8, 10.5 Hz). The ^H NMR also showed the typical splitting 
patterns of a m^to-coupled ring A and a j!?ara-disubstituted ring B similar to those of 
compound ODH.l and ODH.2 Also observed on the ^H NMR spectrum was a singlet 
methoxy group resonance at 5 3.81 and a singlet hydroxy group resonance at 5 4.86. The 
hydroxyl proton resonance at ô 4.86 showed correlation in the HMBC spectrum [Spectrum 
5.1.2.3.7] with carbon resonance at ô 115.8 for 3’/5’. This allowed the placement of the 
hyroxy group at C-4’ position and the methoxy at the C-7 position. The placement of the 
hydroxyl goup at the C-4’ and the methoxy at the C-7 positions was also confirmed by the 
correlations in the NOESY spectrum [Spectrum 5.1.2.3.9], which showed correlations 
between the hydroxyl group proton resonance at Ô 4.86 and the proton resonance of 3’/5’ for 
ring B and correlations between the methoxy group proton resonance at 5 3.81 and the proton
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resonance for C-6 and C-8 of ring A. The configuration at the C-3 position was determined 
using ECD and specific rotation analysis. From the ECD specrum, a positive Cotton effect 
(Ac = 0.2) at 289 nm and a negative Cotton effect (Ac -  -1.0) at 307 nm was observed. A 
specific rotation of +14.62 was measured for compound ODH.3. This indicated that the 
absolute configuration of C-3 was S. Compound ODH.3 was found to be (35)-5-hydroxy-7- 
methoxy-3-(4-hydroxybenzyl)-4-chromanone, an enantiomer of a homoisoflavonoid isolated 
previously from Ledebouria graminifolia (scilloideae subfamily) with a specific rotation 
value of -54.6."^ ^
0.5
230 780-0.5
51.5
u  _2
-2.5
-3.5
Figure 5.1.2.6: ECD curve for compound ODH.3
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Table 5.1.2.3: Correlation table for ODH.3: (3*S)-5-hydroxy-7-methoxy-3-(4-
hydroxybenzyl)-4-chromanone
No. ^^ C NMR (125 
MHz) CDCL3
^H NMR (500 MHZCDCL3 J  
in Hz)
HMBC (H->C) COSY NOESY
2 a 69.2 4.29 (dd, J=4.2, 11.5 Hz) 3, 4, 8 a, 9 2b, 3 2b, 3. 9
2 b 4.13 (d,/=7.0, 11.5 Hz) 3,4, 8 a, 9 2a, 3 2b, 3. 9
3 47.1 2.81 - - -
4 198.2 - - - -
4a 1 0 2 .8 - - - -
5 164.7 - - - -
6 95.2 6.06 (d, J= 2.3 Hz) 4a, 5, 7, 8 8 7 -OCH3
7 168.1 - - - -
8 94.1 5.97 (d,J=2.3Hz) 4, 4a, 6,7, 8a 6 7 -OCH3
8a 163.1 - - - -
9a 32.2 3.16 (dd, J= 4.4, 14.0 Hz) r,2V6%2,3,4 9b, 2V6' 2a, 2%/6'
9b 2.70 (dd,J=10.5, 14.0 Hz) r,2V6%2,3,4 9a, 2 V6' 2b, 2 V6'
r 130.2 - - - -
2’ 130.5 7.10(d,J=8.5Hz) r,3V5%4%6% 9 3V5% 9 9,3V5'
3’ 115.8 6.79 (d,J=8.5 Hz) r,2V6%4% 2%/6' 276’, 4’-0H
4’ 154.6 - - - -
5’ 115.8 6.79 (d,/=8.5Hz) r,2V6% 4' 2%/6' 276’, 4’-0H
6’ 130.5 7.10(d,/=8.5Hz) r,3V5%4%9 3V5%9 9,3’/5’
4’-0H 4.86 s 2V6%3V5% 4'-C - 3’/5’
5-OH - 12.1 s 4, 4a, 5-C, 6, 7, 8a - -
7 -OCH3 55.9 3.81 s 7-C - 6,8
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5.1.2.4 Structural elucidation of compound ODH.4: (3i?)-3,5-Dihydroxy-7-methoxy-3-
(4’“hydroxybenzyI)-4-chromanone
Compound ODH.4 was isolated as white needles from the ethanol bulb extract of 
Ornithogalum dibium ‘Hybrid’ and was identified as the new (3i?)-3,5-dihydroxy-7-methoxy- 
3 -(4-hydroxybenzyl)-4-chromanone.
CH3O.
OH 
^ ODH.4
Figure 5.1.2.7: Structure for compound ODH.4: (3R)-3,5-dihydroxy-7-methoxy-3-(4’-
hydroxybenzyI)-4-chromanone
The MS [Spectrum 5.1.2.4.1] gave a [M-H-H20]^ ion at m/z 297.2 which indicated a 
molecular formula of CnHieOô for ODH.4. From the formula a double bond equivalence of 
ten was calculated. The FTIR spectrum [Spectrum 5.1.2.4.2] showed absorption band at 
3412 cm'^ and 1638 cm'^ for OH and C=0 stretches respectively, C-H aromatic stretches at 
3020 cm '\ C-H aliphatic stretches at 2918 cm'^ and 2849 cm"\ C=C aromatic stretches at 
1572 cm'^ and 1514 cm'^ and C-0 stretches at 1158 cm"\"^ ^
The ^H NMR spectrum [Spectrum 5.1.2.4.3] of compound ODH.4 was characterised by a set 
of doublets at 5 4.21 (d, J  = 11.2 Hz) and 6 4.06 (d, J  = 11.2 Hz) for the H-2 proton 
resonances, a set of doublets at 5 2.92 (d, J =  14.0) and 5 2.96 (d, J =  14.1) for the 2H-9 
proton resonances. Also observed was the absence of a complex multiplet at ca. 6 2.8 
observed in the ^H NMR spectrum of compound ODH.l and ODH.3 which indicated the C-3 
substitution as was observed on the ^H NMR spectrum of the C-3 substituted compound, 
ODH.2. The ^^ C NMR spectrum [Spectrum 5.1.2.4.4] of compound ODH.4 was similar to 
that of compound ODH.3, except for the absence of a methine carbon resonance at ô 47.1 and 
the presence of a new quaternary oxygenated carbon resonance at ô 72.4. This therefore 
indicated the presence of a hydroxyl group at the C-3 position, which was confirmed by the 
presence of a hydroxyl group proton resonance at ô 3.39 in the ^H NMR spectrum, which 
showed a correlation in the HMBC spectrum [Spectrum 5.1.2.4.7] with the C-2 and the C-4 
carbon resonances at 6 72.0 and 5 194.4 respectively. It was also confirmed that the hydroxyl 
group was present at the C-3 position by the NOESY experiment [Spectrum S.2.4.9] which 
showed a correlation between the hydroxyl group proton resonance at 5 3.36 and the C-2’/6’
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and the C-9 proton resonances. The configuration at the C-3 position was determined using 
ECD and specific rotation analysis. From the ECD specrum, a positive Cotton effect (As = 
8.2) at 289 nm and a negative Cotton effect (Ae -  -3.6) at 307 nm was observed. A specific 
rotation of +46.5 was measured for compound ODH.4. This indicated that the absolute 
eonfiguration of C-3 was R. Compound ODH.4 was found to be the new (3R)-3,5- 
dihydroxy-7-methoxy-3 -(4 ’ -hydroxybenzyl)-4-ehromanone.
232 232 232
-10
\  (nm)
Figure 5.1.2.8: ECD curve for compound ODH.4
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Table 5.1.2.4: Correlation table for ODH.4: (32?)-3,5-dihydroxy-7-methoxy-3-(4’-
hydroxybenzyl)-4-chromanone
No. ^^C NMR (125 
MHz) CDCI3
^H NMR (500 MHz) 
C D C ls/inH z)
HMBC (H-^C) COSY NOESY
2 a 72.0 4.21 (d ,/=11.2H z) 3, 4, 8 a, 9 2 b 2b, 2V6% 9
2 b 4.06 (d,J=11.2H z) 3,4, 8 a, 9 2 a 2a, 3-OH, 9
3 72.4 - - - -
4 198.4 - - - -
4a 100.7 - - - -
5 164.2 - - - -
6 95.6 6 .1 2 (d, J=2.3H z) 4a, 5, 7, 8 8 7 -OCH3 . 8
7 168.9 - - - -
8 94.8 6.05 (d, J=2.3H z) 4, 4a, 6,7, 8 a 6 6 ’ 7 -OCH3
8 a 163.0 - - - -
9a 41.0 2.92 (d ,J=  14.0). r,2V6% 2, 3 ,4 9b, 2%/6' 2a, 2V6% 4a
9b 2.96 (d, J=14.1). r,2V 6% 2,3 ,4 9a, 2%/6' 2b, 2%/6% 4a
r 126.6 - - - -
T 132.0 7.07 (d, J=8.5H z) 3V5%4%9 3V5% 9 2a, 9, 3V5'
y 115.4 6.77 (d, J=8.5H z) r,2V 6% 4' 2 %/6 ' 276’, 4’-0H
4’ 155.0 - - - -
5’ 115.4 6.77 (d ,/= 8 .5H z) 1% 2V6%4' 2 %/6 ' 276’, 4 ’-0H
6 ’ 132.0 7.07 (d,J=S.5 Hz) 3V5% 4% 9 3V5% 9 2a, 9, 3’/5’
3-OH - 3.39 s 2, 3-C,4 2’/6’, 9
4’-0H 4.66 s 3V5% 4'-C - 3’/5’
5-OH - 1 1 .2 s 4a, 5-C, 6 , 7, - -
7 -OCH3 56.1 3.84 s 7-C - 6 , 8
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5.1.2.5 Structural elucidation of compound ODH.5: (3i?)-3-Hydroxy-7-metlioxy-3-(4-
hydroxybenzyl)-4-chromanone 5-0-)9-D-glucopyranoside.
Compound ODH.5 was isolated as white needles from the ethanol bulb extract of 
Ornithogalum dibium ‘hybrid’ and was identified as the new (3i?)-3-hydroxy-7-methoxy-3- 
(4-hydroxybenzyl)-4-chromanone 5-0-^-D-glucopyranoside.
OH
OH
OH ODH.5
Figure 5.1.2.7: Structure for compound ODH.5: (3i?)-3-Hydroxy-7-methoxy-3-(4- 
hydroxybenzyl)-4-chromanone 5-0-)9-D-glucopyranoside.
The MS [Spectrum 5.1.2.5.1] gave [M + Na]"^  ion at m!z 501.2 which indicated a molecular 
formula of C23H22O11 for ODH.5. From the formula a double bond equivalence of eleven 
was calculated. The FTIR spectrum [Spectrum 5.1.2.5.2] showed absorption band at 3338 
cm'^ and 1730 cm'^ for OH and C=0 stretches respectively and C-H aliphatic stretches at 
2916 cm'^ and 2849 cm'^^^
The ^H NMR spectrum [Spectrum 5.1.2.5.3] showed characteristic proton resonances of the 
me^a-coupled ring A at 5 6.64 (d, J= 2.4 Hz) and 6  6.31 (d, J= 2.4 Hz) for H- 6  and H- 8  
respectively, ^am-disubstituted proton resonances for ring B at ô 7.06 (d, J= 8.5 Hz) and 5 
6.72 (d, J= 8.5 Hz) for H-2’/6’ and H-3’/5’ respectively, typical proton resonances at for 2H- 
2 at 5 4.13 (d, J= 11.2 Hz) and 5 4.01 (d, J= 11.2 Hz), proton resonances for 2H-9 at Ô 2.88 
(d, J =  14.07 Hz) and ô 2.83 (d, J =  14.07 Hz) and one methoxy group at ô 3.88. These 
proton resonances were similar to those of compound ODH.4 except for the absence of the 
hydroxyl proton resonance at ca. 5 11  and the presence of additional proton resonances for 
hydrogens attached to oxygenated carbons implying a possible substitution of a sugar group 
at the C-5 position on ring A. A solvent saturation experiment was carried out to identify the 
anomeric proton resonance [Spectrum 5.1.2.5.4].
The "C NMR [Spectrum 5.1.2.5.5], DEPT [Spectrum 5.1.2.5.6] and HSQCDEPT 
[Spectrum 5.1.2.5.7] spectra showed a total of 23 carbon resonances of which 17 of these 
carbon resonances were attributed to the homoisoflavonoid aglycone, leaving six oxygenated 
carbon resonances to be accounted for. The presence of a carbon resonance at 5 104.5 in the
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NMR spectrum, which correlated to an anomeric proton resonance at ô 4.85 (d, 7.7
HZ) in the HSQCDEPT spectrum [Spectrum 5.1.2.5.7] suggested the presence of a sugar 
unit. The C-5 carbon resonance of ring A showed a correlation in the HMBC spectrum 
[Spectrum 5.1.2.5.8] with the anomeric proton resonance at ô 4.85, hence allowing the 
placement of the sugar unit at the C-5 position. The sugar unit was identified as P-D-glucose 
by using correlations in the NOESY spectrum, which showed correlations between the H-1, 
H-3 and H-5 and correlation between the H-2 and H-4 resonances. Also observed in the 
NOESY spectrum [Spectrum 5.1.2.5.10] was a correlation between the anomeric proton 
resonance at 6 4.85 and the meta- coupled H-6 resonance, confirming the substitution of the 
glucose unit at the C-5 position. The glucose unit was determined to be the P-anomer 
according to the coupling constant of the anomeric proton which was 7.7 Hz."^  ^ The 
configuration at C-3 was determined by comparing the ECD and specific rotation of 
compound ODH.5 and those of previously reported homoisoflavonoids. The ECD spectrum 
displayed a positive Cotton effect (Ac = 2.08) at 287 nm and negative Cotton effect (Ac = - 
1.09) at 313 nm which indicated R configuration which is in agreement with the statement 
that the positive Cotton effect in the 287-295 nm region of the ECD curves of 
homoisoflavonoids is indicative of a 3R configuration for homoisoflavonoids with hydroxyl 
group at the C-3 position. A specific rotation of +7.95 was measured for compound ODH.5. 
This compound was found to be a new glucose derivative of compound ODH.4 and was 
identified as (3R)-3-hydroxy-7-methoxy-3-(4-hydroxybenzyl)-4-chromanone 5-0-P-D- 
glucopyranoside. The 3-benzyl-4-chromanone glycosides are very rare and have only been 
reported once from Ornithogalum caudatum (134-136).^ The homoisoflavonoid glycosides 
reported from Ornithogalum caudatum were found to have negative specific rotation values. 
One of these homoisoflavonoids was a C-5 glucose derivative, but only differed with 
compound ODH.5 on ring B by having a methoxy group at C-4’ position and a negative 
specific rotation value of -18.8.
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Figure 5.1.2.9: ECD curve of compound ODH.5
Table 5.1.2.5: Correlation table for ODH.5: (3i?)-3-Hydroxy-7-methoxy-3-(4-
hydroxybenzyl)-4-chromanone 5-0-y?-D-glucopyranoside.
3. "^C NMR (125 
MHz) CD3OD
^H NMR (500 MHz) J  in Hz) 
CD3OD
HMBC (H ^C ) COSY NOESY
72.6 4.13(d, J= 11.20 Hz) 3, 4, 8a, 9 2 b 2b, 9
4.01 (d ,/=  11.20 Hz) 3, 4, 8a, 9 2 a 2 a,
74.2 - - - -
195.8 - - - -
105.7 - - - -
162.1 - - - -
99.7 6.64 (d, J= 2.4 Hz) 4a, 5, 7, 8 8 7 -OCH3. 1", 5"
168.5 - - - -
97.6 6.31 (d, J= 2.4Hz) 4, 4a, 6,7, 8a 6 6' 7 -OCH3
165.9 - - - -
41.1 2.88 (d,J^ 14.07 Hz) r,2V 6% 2,3 ,4 9b, 2%/6' 2a, 2 V6'
2.83 ( d ,^  14.07 Hz) r,2V6% 2, 3 ,4 9a, 2%/6' 2a, 2 V6'
127.1 - - - -
132.9 7.06 (d, J= 8.5 Hz) 3V5%4' 9 3V5%9 2a, 9,3V5'
116.0 6.72 (d, J= 8.5 Hz) r , 4 ’ 2%/6' 2V6'
157.6 - - - -
116.0 6.72 (d, J= 8.5 Hz) r , 4 ’ 2%/6' 2V6'
132.9 7.06 (d, J= 8.5 Hz) 3V5%4%9 3V5%9 2a, 9, 3V5'
104.5 4.85 (d,J^7.7 Hz) 2", 3», 5 2” 2»3", 5", 6
74.8 3.59 (dd,J^7.7, 9.3 Hz) 3", 1» H ,3" 1", 4"
77.6 3.51 m 5», 2" 2", 4» 1", 5"
71.6 3.43 (t, 7=8.9 Hz) 5", 2" 3", 5» 2", 6»a,6»b
78.8 3.51 m 3», 4", 6" 4", 6"a, 6"b 1», 6"a, 6"b
a 62.8 3.92 (dd,v^4.0, 12.2 Hz) - 5", 6"b 5", 6"b
b 3.74 (dd,7=6.2, 12.2 Hz) 5” 5", 6»a 5», 6"a
DCHs 56.6 3.88 s 7-C - 6 ,8
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5.1.2.6 Structural elucidation of compound ODH.6: (3i?)-3-Hydroxy-7-methoxy-3-(4-
hydroxybenzyl)-5-0-/9-D-glucopyranosyl-(l—>6)-^-D-glucopyranoside-4-chromanone (3-
Hydroxy-7-methoxy-3-(4-hydroxybenzyl)-5-0-)9-D-gentiobiose-4-chromanone)
Compound ODH.6 was isolated as a greenish oil from the ethanol bulb extract of 
Ornithogalum dibium ‘Hybrid’ and was identified as the new (3i?)-3-hydroxy-7-methoxy-3- 
(4-hydroxybenzyl)-5-0-y5-D-glucopyranosyl-(1^6)-y5-D-glucopyranoside-4-chromanone also 
known as (3R)-3 -hydroxy-7-methoxy-3 -(4-hydroxybenzyl)-5- O-y^-D-gentiobiose-4-
chromanone.
•OH
HO
OH
OHHO ODH.6
Figure 5.1.2.10: Structure for compound ODH.6: (3i?)-3-Hydroxy-7-metlioxy-3- 
(4-hydroxybenzyl)-5-0-p-D-glucopyranosyl-(1^6)-p-D-glucopyranoside-4-
chromanone
The MS [Spectrum 5.1.2.6.1] gave [M + Na]^ ion at m/z 663.3, which indicated a molecular 
formula of C29H36O16 for ODH.6. From the formula, a double bond equivalence of twelve 
was calculated. The FTIR spectrum [Spectrum 5.1.2.6.2] showed absorption band at 3399 
cm'^ and 1726 cm'^ for OH and C=0 stretches respectively, C-H aromatic stretches at 2953 
cm '\ C-H aliphatic stretches at 2916 cm’^  and 2849 cm '\ C=C aromatic stretches at 1578 cm' 
 ^ and 1467 cm'^ and C-0 stretches at 1383
The ^H NMR spectrum [Spectrum 5.1.2.6.3] showed similar proton resonances as those of 
compound ODH.5 except for additional proton resonances for hydrogens attached to 
oxygenated carbons and the extra oxygenated carbon resonances in the ^^ C NMR spectrum 
[Spectrum 5.1.2.6.4]. A disaccharide unit was suggested by the presence of a pair of 
anomeric proton resonances at 5 4.87 and 5 4.37 which correlated in the HSQCDEPT 
spectrum [Spectrum 5.1.2.6.6] with the anomeric carbon resonances at ô 104.0 and 5 105.3 
respectively. The HMBC spectrum [Spectrum 5.1.2.6.7] showed a correlation between the 
C-5 carbon resonance (8 162.0) and the anomeric proton resonance at 8 4.87, revealing the 
site of glycosidation as the C-5 position. This was also confirmed by the correlation in the
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NOESY spectrum [Spectrum 5.1.2.6.9] between the anomeric proton at 4.87 and the H-6 
proton resonance at 5 6.66. The correlations in the NOESY spectrum confirmed the presence 
of two glucose units. The site of glucose-glucose linkage was supported by glycosidation 
shift of ca. Ô 70 of the C-6” resonance in a glucose unit. The C-6” carbon resonance at 5 70.7 
showed a correlation in the HMBC spectrum with the anomeric proton resonance at 6 4.37 
for C-1”’, which indicated a possible glucose-glucose linkage between C-6” and C-1”’. The 
glycosidic linkage was also confirmed by the correlations in the NOESY spectrum 
[Spectrum 5.1.2.6.9] between the anomeric proton resonance at 5 4.36 for H-1”’ and the 
proton resonance for H-6”. The ^H NMR and ^^ C NMR resonances therefore suggested a p- 
gentiobiose unit as per the reported data."^  ^ The ECD spectrum displayed a positive Cotton 
effect (Ac = 1.70) at 287 nm and negative Cotton effect (Ac = -2.7) at 311 nm which indicated 
R configuration which is in agreement with the statement that the positive Cotton effect in the 
287-295 nm region of the ECD curves of homoisoflavonoids is indicative of a 3R 
configuration for homoisoflavonoids with hydroxyl group at the C-3 position. A specific 
rotation of +74.36 was measured for compound ODH.6. There has been only one report of 
the 3-benzyl-4-chromanone type glycosides with disaccharide sugar units attached at the C-5 
position on ring A (135).  ^ However, these homoisoflavonoids differed from compound 
ODH.6 in that they possess disaccharide units of glucose and rhamnose, a methoxy group at 
C-4’ position on ring B and negative specific rotation values, which indicated that the 
hydroxyl group at C-3 was in a-position.^ Compound ODH.6 was therefore identified as 
(3R)-3-hydroxy-7-methoxy-3-(4’-hydroxybenzyl)-4-chromanone 5-O-^-D-gentiobiose.
ÂA52A. 34S 3US
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Figure 5.1.2.10: ECD curve of compound ODH.6
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Table 5.1.2.6: Correlation table for ODH.6: (37?)-3-Hydroxy-7-methoxy-3-(4-
hydroxybenzyI)-5-(9-)9-D-gIueopyranosyI-(1^6)-)9-D-gIucopyranoside-4-chromanone
). NMR (125 
MHz) CD3OD
^H NMR (500 M H z )/in  
Hz) CD3OD
HMBC (H ^ C ) COSY NOESY
72.6 4.12(d,/=11.3 Hz) 3 2 b 2b,
4.01 (d ,/=  11.3 Hz) 3 2 a 2 a,
74.2 - - - -
196.0 - - - -
105.7 - - - -
162.0 - - - -
100.0 6 .66  (d, /=  2.4 Hz) 4a, 5, 7, 8 8 7-OCH3. 1”
168.5 - - - -
97.2 6.31 (d ,/= 2 .4  Hz) 4a, 6 , 8a 6 7 -OCH3
165.8 - - - -
41.1 2.82 ( d , /=  14.1 Hz) r,2V 6% 3,4 9b 2%/6’
2.87 (d ,/= 1 4 .1 H z ) 1%2V6% 3 ,4 9a 2%/6’
127.1 - - - -
132.9 7.05 (d ,/= 8 .5 H z) 4’ 9 3V5' 9,3V5'
116.0 6.71 (d ,/= 8 .5 H z) l ’, 4 ’ 2%/6' 2V6'
157.8 - - - -
116.0 6.71 (d ,/= 8 .5 H z) r , 4 ’ 2%/6’ 2V6'
132.9 7.05 (d ,/= 8 .5 H z) 4 % 9 3V5' 9,3V 5’
104.0 4.87 5 2” 2”3”, 5”, 6
74.8 3.59 (d d ,/= 7 .5 ,9 .0  Hz) 1»3„ 1”, 3” 1”
77.5 3.50(t, J = 8 .9 H z) 2", 4”, 2”, 4» 1”
71.8 3.45 m 3", 5" 3”, 5” 6”a
77.6 3.79 m 3”, 4”, 6” 4”, 6'% 6”b 6”a,
a 70.7 4.19(dd,/=2.0, 11.6 Hz) - 5", 6”b 6”b, r ”
b 3.87 m 5” 5”, 6”a 6%  1'”
105.3 4 .3 7 (d ,/= 7 .9 H z) 6” 2», 2”% 5”% 3”% 6"
75.3 3.24 (d d ,/= 7 .9 , 9.1Hz) 3”% 4'” 1”% 3"’ 1”’
78.2 3.36 m 5”’ 2"% 4’” 1’”
78.2 3.30 m 5„, 3”% 5'” 6’”
71.7 3.30 m 3”% 4”' 4"% 6"%6"'b 6”% 6”'b
a 63.0 3.87 m - 5’” 5”% 6”’b
b 3.67 (d ,/= 5 .7 , 11.5 Hz) - 5’” 5”% 6”’a
)CH3 56.7 3.90 s 7-C - 6 ,8
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5.1.3 CONCLUSIONS
The phytochemical investigation of Ornithogalum dubium ‘Hybrid’ yielded six 
homoisoflavonoids ODH.1-ODH.6
OH
ODH.1 ODH.2
OH
OH
OH
ODH.4
ODH.3
OH
OHOH
HO
OHHO OHOH HO
OHHOOHHO ODH.5
ODH.6
All homoisoflavonoids isolated from Ornithogalum Dubium ‘Hybrid’ are the 3-benzyl- 
chromanone type. Compound ODH.l ODH.2 and ODH.3 are the C-3 enantiomers of 
homoisoflavonoids isolated previously from Eucomis bicolar, Ornithogalum longibracteatum 
and Ledebouria graminifolia respectively. Compounds ODH.4, ODH.5 and ODH.6 are new 
homoisoflavonoids. Compound ODH.5 was found to be a glycose derivative of compound 
ODH.4 with the sugar unit attached to the C-5 position. Compound ODH.6 was found to be 
a homoisoflavonoid glycoside with a disaccharide glucose units linked together at the C-6 ” 
and C-1’” positions and attached to the C-5 position on ring A of the homoisoflavonoid. The
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occurrence of homoisoflavonoids in the Omithogaleae tribe is rare. The homoisoflavonoid 
glycosides have been reported once from the Omithogaleae tribe. The known 
homoisoflavonoid glycosides have been isolated previously from Ornithogalum caudatum 
(compounds 134-136) and were the first glycosides attached to a 3 -benzyl-4-chromanone 
skeleton.^ The configuration at the C-3 position of all the homoisoflavonoids isolated from 
Ornithogalum dubium ‘Hybrid’ were determined using electronic circular dichroism and 
specific rotation. The results of ECD analysis showed a positive Cotton effect at the regions 
ca. 280 nm and negative Cotton effects at the regions ca. 315 nm. These results were 
indicative of the ?>S configuration for homoisoflavonoids with hydrogen at the C-3 position 
and 3R configuration for the homoisoflavonoids with hydroxyl group at the C-3 position. 
The signs of the specific rotations of the homoisoflavonoids isolated from Ornithogalum 
dubium ‘Hybrid’ were positive. A search in the literature indicated negative specific rotation 
for the a configuration at C-3^ and positive specific rotation for the (3 configuration at the C-3 
position."^^
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5.2 The chemistry of Ornithogalum ponticum ‘Sochi’
5.2.1 Introduction
Ornithogalum ponticum ‘Sochi’ is a horticultural hybrid belonging to the Omithogaleae tribe 
of the Scilloideae subfamily. There are no reports on the chemistry and ethnomedical uses of 
Ornithogalum ponticum ‘Sochi’.
Picture 17: A photograph of Ornithogalum ponticum ‘Sochi’ (Photograph from
http://www.dixexport.com)
The bulbs of Ornithogalum ponticum ‘Sochi’ were purchased from 
http://www.dixexport.com. From this study three known cardenolides OPS.l, OPS.2 and 
OPS.3 were isolated. Compounds OPS.l A and OPS.2 A are acetylated derivatives of 
compound OPS.l and OPS.2 respectively. The stmctural elucidation of compounds isolated 
from Ornithogalum ponticum ‘Sochi’ is described below.
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5.2.2 RESULTS
5.2.2.1 Structural elucidation of compound OPS.l: 3p-(0-a-L-Rhamnoside)-5p,14p-
dihydroxy-19-oxocardenoIide.
Compound OPS.l was isolated as a colourless oil from the ethanol extract of the bulbs of 
Ornithogalum ponticum ‘Sochi’. It was identified as the known 3P-(O-a-L-rhanmoside)- 
5p, 14p-dihydroxy-19-oxocardenolide, also commonly known as convallatoxin, isolated 
previously from Ornithogalum umbellatum of the Scilloideae su b fam ily ,Antiaris toxicaria 
of the Moraceae family and Saussurea Stella of the Asteraceae family."^^
CH(
OHHO
OH OHHO
OPS.l
o
Figure 5.2.2.1: Structure for compound OPS.l: 3p-(0-a-L-rhamnoside)-5p,14p- 
dihydroxy-19-oxocardenoIide.
The MS spectrum [Spectrum 5.2.2.1.1] gave a molecular ion [M-H]^ peak at m/z 549.5, 
which indicated a molecular formula of C29H42O10 for OPS.l. The IR spectrum [Spectrum
5.2.2.1.2] for compound OPS.l showed absorption bands at 3390 and 1735 cm'^ assigned to 
OH and C=0 stretches respectively."^^
The NMR spectrum of OPS.l [Spectrum 5.2.2.1.3] showed characteristic proton 
resonances of a five-membered lactone or 2-furanone (butenolide) ring at ô 5.91 s, 5.02 (dd, J  
= 18.2, 1.7 Hz) and 6  4.93 (dd, J -  18.2, 1.7 Hz), a singlet methyl proton resonance at 5 0.86 
and an aldehyde proton resonance at 5 10.06. Also observed in the ^H NMR spectrum were 
six proton resonances at 5 4.70 (brs), 5 4.10 (dd, 9.1, 6.5 Hz), 6  4.04 (brs), ô 3.82 (t, J  =
3.5 Hz), 5 3.78 (dd, 3.9, 1.7 Hz) and 5 3.50 (dd, J=  9.1, 3.2 Hz) for hydrogens attached to 
oxygenated carbons and a doublet methyl proton resonance at 1.26 (d, J =  6.5 Hz).
The NMR [Spectrum 5.2.2.1.4] DEPT [Spectrum 5.2.2.1.5] and HSQCDEPT 
[Spectrum 5.2.2.1.6] spectra displayed twenty-nine carbon resonances for compound OPS.l,
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which included a lactone carbonyl carbon resonance at Ô 178.3, two double bond carbon 
resonances at 5 177.4 and 5 118.1, an anomeric carbon resonance at 5 102.7 and eight 
resonances for carbons attached to oxygen at 5 86.1, 5 77.9, ô 75.5, 5 75.2, 5 72.7, ô 72.0, ô 
71.3 and ô 66.9. The NMR spectrum showed that compound OPS.l contained two 
methyl, an aldehyde, ten methylene, nine methine and six fully substituted carbon resonances 
(Table 5.3.2.1). This information suggested that compound OPS.l was a cardenolide 
glycoside. The double bond proton resonances at Ô 5.91 and oxymethylene proton 
resonances at ô 5.02 and ô 4.93 which corresponded with carbon resonances at 6  118.1 and Ô
75.5 in the HSQCDEPT spectrum were assigned to H-22 and the two H-21 protons of the 
butenolide ring respectively.^® These three proton resonances showed correlations in the 
HMBC spectrum [Spectrum 5.2.2.1.7] with a carbonyl carbon resonance at ô 178.3 assigned 
to C-23. In addition, the H-22 resonances showed correlations in the HMBC spectrum with a 
fully substituted double bond carbon resonance at ô 177.4 assigned to C-20. The allylic 
proton resonance at ô 2.83 (m) which corresponded to a carbon resonance at 5 51.9 in 
HSQCDEPT spectrum was assigned to H-17 due to a correlation observed in the NOESY 
spectrum [Spectrum 5.2.2.1.10] with H-22.
The H-17 resonance showed coupling with two proton resonances at ô 2.16 assigned to the 
two H-16 protons in the COSY spectrum [Spectrum 5.2.2.1.8], which, in turn, showed 
coupling with proton resonances at 5 2.17 and 5 1.71 assigned to the two H-15 protons. The 
carbon resonances for C-15 and C-16 occurred at 5 19.5 and ô 28.1 respectively. The methyl 
proton resonance at ô 0.86 showed a correlation in the HMBC spectrum [Spectrum 5.2.2.1.7] 
with carbon resonances at 5 40.7 (CH2), 5 50.9 (C) and 5 86.1 (C) which were assigned to C- 
12, C-13 and C-14 respectively. The methyl group resonance was therefore assigned to C-18. 
The two H-12 proton resonances occurred at ô 1.48 and 5 1.45. These two resonances were 
coupled to methylene proton resonance at 6  2.08 and 5 1.65 ascribed to 2H-11. These proton 
resonances was seen to be coupled in the COSY spectrum to a methine proton resonance at 5
1.71, corresponding to H-9, whose carbon resonance occurred at 5 40.5. The H-9 proton 
resonance, in turn, was seen to be coupled in the COSY spectrum with proton resonance at ô
1.93, which, in turn, corresponded in the HSQCDEPT spectrum with the carbon resonance at 
Ô 42.8 for C-8 . The aldehyde proton resonance at 6  10.06 showed a correlation in the HMBC 
spectrum with a quaternary carbon resonance at 5 56.4 (C-10). This allowed the placement of 
the aldehyde at the C-19 position. The other remaining quaternary carbon resonance at ô 75.2 
was assigned to C-5.
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Following the biosynthetic pathways of cardenolides, one oxygen atom was placed at the C-3 
position. The H-3 proton resonance occurred at ô 4.04 and was seen to correlate in the 
NOESY spectrum [Spectrum 5.2.2.1.10] with the anomeric proton at ô 4.70 (s). The sugar 
unit was therefore placed at the C-3 position and was identified as the a-anomer based on the 
broad singlet resonance of the anomeric proton. A correlation was observed in the COSY 
spectrum between H-1’ and H-2’, H-2’ and H-3’, H-3’ and H-4’, H-4’ and H-5’ and H-5’ and 
3H-6’. This indicated a sugar unit with a methyl group at the C- 6  position and was 
determined to be a-L-rhamnose based on correlations in the NOESY spectrum, which was 
seen between H-1’ and H-2’, H-2’and H-3’, H-3’ and H-4’, H-4’ and H-5’. A correlation in 
the NOESY spectrum was also seen between H-3 and H-ip and H-2p. A half-peak width of 
H-3 was found to be 8.5 Hz. A search in the literature for a cardenolide with an aldehyde at 
the C-9 position and a rhamnose sugar at the C-3 position gave the 3 P-(O-a-L-rhamnoside)- 
5p, 14p-dihydroxy-19-oxocardenolide. (convallatoxin). A specific rotation value of + 23.9 for 
compound OPS.l was measured.
The 3 P-((9-a-L-rhamnoside)-5p,14p-dihydroxy-l 9-oxocardenolide (convallatoxin) has been 
tested against cancer cell lines and is known to possses potent growth inhibitory activity 
against the BGC-823 human gastric cancer cell line and Bel-7402 human hepatoma cell lines 
with IC 50 values of < 1
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Table 5.2.2.1: Correlation table for OPS 1: 3p-(0-a-L-rhamnoside)-5p,14p-dihydroxy-
19-oxocardenolide.
NO. NMR (125 
MHz) CD3OD
NMR (500 M Hz)/in 
Hz) CD3OD
HMBC
(H-^C)
COSY NOESY
1 32.6 2.14 m IP IP
1.65 m la la
2 37.8 1.54 m 2P 2 p
2 . 2 1  m 2 a 2 a
3 77.9 4.04 (brs, Wi/2 = 8.5 Hz) 2a, 2p, 4a, 4p IP, 2 p ,4 p ,r
4 26.2 1.95 m 3,4P 4P
1.60 m 3, 4a 4a
5 75.2 - -
6 23.4 1.54 m 6 p 6 p, 7a
1.31 m 6 a 6 a, 7P
7 25.4 2 . 1 2  m 6 a, 6p,7P, 8 6 a, 7P
1.30 m 6 a, 6p,7a, 8 6 P, 7a
8 42.8 1.93 m 7a, 7p, 9 7P,18
9 40.5 1.71 m 8 , 1 1 a, lip 1 1 a, 1 2 a
1 0 56.4 - -
11 37.6 2.08 m 9, lip , 12a, 12P 9 , 1 1 3
1.65 m 9, 11a, 12a, 12P 1 1 a
12 40.7 1.48 m 11a, lip, 12P 1 2 3 , 18
1.45 m 1 1 a, lip, 1 2 a 1 2 a, 18
13 50.9 -
14 8 6 .1 -
15 19.5 2.17m 15P, 16a, 16P, 17 153, 17
1.71 m 15a, 16a, 16p, 17 15a
16 28.1 2.16 m 15a, 15P, 16P, 17 163, 17
2.16 m 15a, 15p, 16a, 17 16a, 17
17 51.9 2.83 m 16a, 16p 1 2 a, 16a, 16p, 2 2
18 16.3 0 . 8 6  s 12,13,14,17 8 , 1 2 3 , 2 1 , 2 2
19 2 1 0 . 1 10.06 s 10 la ,ip ,9
2 0 177.4 - -
2 1 75.5 5.02 (dd,J=18.2, 1.7 Hz) 23 2 1 b, 2 2 18,21b
4.92 (dd, J=18.2, 1.7 Hz) 23 2 1 a, 2 2 2 1 a
2 2 118.1 5.91 s 20, 23 2 1 a, 2 1 b 17, 18
23 178.3 - -
r 102.7 4.70 brs 2% 3, 5' T 2% 3
T 72.7 3.78 (dd, J = 3.9, 1.7 Hz) \ \ V V
V 72.0 3.82(t, J = 3.5Hz) 2 % 4' 4’
4’ 71.3 3.50 (dd, J = 9.1,3.2Hz) 3% 5’ 3% 5% 6 ’
5’ 66.9 4.10(dd, J = 9.1,6.5Hz) 4% 6 ' 4% 6 ’
6 ’ 18.0 1.26 (d, J = 6.5 Hz) 4% 5’ 5’ 4% 5’
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S.2.2.2 Structural elucidation of compound OPS.IA: 3p-[2’,3’,4’-Tri-t?-acetyl-0-a-L-
rhamnoside]-5p,14p-dihydroxy-19-oxocardenoIide.
Compound OPS.IA is an acetylated derivative of compound OPS.l isolated from the ethanol 
extract of the bulbs of Ornithogalum ponticum ‘Sochi’. Compound OPS.l was acetylated to 
aid in its structural elucidation. The acetylated derivative was identified as 3p-[2’,3’,4’-tri-0- 
acetyl-0-a-L-rhamnoside]-5p,14p-dihydroxy-19-oxoeardenolide.
0
CHO
OH
GAc OHAcO
OPS.IA
Figure S.2.2.2: Structure for compound OPS.IA: 3p-[2’,3’,4’-Tri-0-acetyI-0-a- 
L-rhamnoside]-Sp,14p-dihydroxy-19-oxocardenoIide.
The MS spectrum [Spectrum 5.2.2.2.1] gave a [M + Na]  ^ion at m/z 699.5 which indicated a 
molecular formula of C35H48O13 for OPS.IA. The IR spectrum [Spectrum S.2.2.2.2] for 
compound OPS.IA showed absorption bands at 3497, 1745 and 1621 em'^ assigned to OH, 
C=0 stretches of an acetate and C=C stretches respectively. As was observed in compound 
OPS.l, the NMR spectrum of OPS.IA [Spectrum 5.2.2.2.3J showed characteristic proton 
resonances of a five membered lactone, 2-furanone (butenolide) at 4.95 (dd, J =  18.2, 1.7 
Hz), 4.84 (dd, J=  18.2, 1.7 Hz) and 5.89 (s). A singlet methyl proton resonance at ô 0.87, an 
aldehyde proton resonance at 5 10.14 and an oxymethine proton resonance at 5 4.48 (5-OH) 
were also observed. In addition proton singlets for the methyl groups of the acetates at 5 
2.14, 6  2.09 and 5 2.02 were also seen. The proton resonances of the rhamnose unit of 
compound OPS.IA were shifted downfield as compared to those of compound OPS.l.
The NMR [Spectrum S.2.2.2.4], DEPT [Spectrum S.2.2.2.5] and HSQCDEPT 
[Spectrum S.2.2.2.6] spectra for compound OPS.IA displayed five carbonyl resonances of 
which three are for the acetate carbonyls, one for the aldehyde and one for the 2 -furanone. 
Also observed was a quaternary oxygenated carbon resonance at 5 73.6, which correlated in 
the HMBC spectrum [spectrum 5.2.2.2.7J with hydroxyl proton resonance at 5 4.48, which, 
in turn correlated with carbon resonances at 36.2 and 37.5 for C-4 and C- 6  respectively. This
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confirmed that compound OPS.l contained a hydroxyl group at the C-5 position. OPS.IA 
was found to be 3p-[2’,3’,4’-tri-0-acetyl-0-a-L-rhamnoside]-5p,14p-dihydroxy-19- 
oxoeardenolide. A specific rotation value of + 16.08 for compound OPS.IA was measured.
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Table 5.2.2.2: Correlation table for OPS.IA: 3p-[2’,3’,4’-Tri-0-acetyI-0-a-L-
rhamnoside]-5p,14p-dihydroxy-19-oxocardenoIide.
o. NMR (125 
MHz) CDCI3
NMR (500 M Hz)/in 
Hz) CDCI3
HMBC
(H->C)
COSY NOESY
18.3 2.19m ip, 2 a, 2 P IP
1.82 m la, 2 a, 2 p 19
25.5 1.99 m la, ip, 2P,3 3
1.49 m 2a, la, ip, 3 3
78.4 4.05 (brs, Wi/2 = 8.5 Hz) 2a, 2P, 4 2a, 2P, 4P, r
36.2 2.05 m 3,4P 3, 4P, 5-OH
1.71 m 3, 4a 3, 4a, 5-OH
73.6 - -
OH 4.48 4,6 -
37.5 1.74 m 6 P, 7a, 7P 6 P, 7a
2.16 m 6 a, 7a, 7p 6 a, 7P, 5-OH
24.4 2.13 m 6 a, 6p,7p, 8 6 a, 7P
1.28 m 6 a, 6P,7a, 8 6 P, 7a
42.3 1.89 m 7a, 7P, 9 7P,18
39.5 1.54 m 8 , 1 1 a, lip 11a, 17
1 55.2 - -
22.5 1.55 m 9, llp,12a,12p 9, lip
1.25 m 9, 11a, 12a, 12p 1 la
39.7 2 . 1 0  m 11a, lip, 12P 12P
1.69 m 1 1 a, lip, 1 2 a 1 2 a
49.5 - -
85.4 - -
39.7 2 . 1 0  m 15P, 16a, 16p, 17 15P
1.69 m 13, 14, 16 15a, 16a, 16p, 17 15a
i 32.3 2.17m 17 15a, 15P, 16P, 17 16P, 17
1.91 m 17 15a, 15P, 16a, 17 16a, 2 1 b
50.6 2.77 (dd,/=9.3, 5.3Hz) 13,14,20,21,22 16a, 16P 9,16a,16P,21a,22
15.8 0.87 s 12,13,14,17 - 8 , 2 1 a, 2 1 b, 2 2
207.9 10.14 s 10 - IP, 5-OH, 8 , lip
174.0 - - -
73.6 4.95 (dd,/=18.2, 1.7 Hz) 20,22, 23 2 1 b, 2 2 8 , 17, 18,21b, 22
4.84 (dd,/=18.2, 1.7 Hz) 20,22,23 2 1 a, 2 2 8 , 18, 2 1 a, 2 2
118.2 5.89 s 20,21, 23 2 1 a, 2 1 b 16a, 16P, 17, 18
174.4 - - -
98.9 4.79 brs 2% 3, 3% 5’ 2 ’ 3
70.3 4.87 (dd,/=3.9, 1.7 Hz) 3% 4% 2’-C l ’,3 ’ 5% 6 ’
■CH3 20.9 2.14 s 2’-C - -
■c 169.7 - - - -
66.6 5.31 (t, J= 3.5 Hz) r , 4 ’,3 ’-C 2% 4’ 4’
•CH3 2 1 . 0 2.09 s 3’-C - -
■c 170.2 - - - -
69.7 4.90 (dd, 7=10.0,3.3 Hz) 3% 5% 6%4’-C 3% 5’ 3% 5% 6 ’
■CH3 2 1 . 1 2.02 s 4’-C - -
■c 170.0 - - - -
63.1 4.25(p,/ =  6.3 Hz) - 4% 6’ la, 2a, 4’, 6 ’
17.3 1.26 (d,/=6.3Hz) 4% 5’ 5’ 2% 4% 5’
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S.2.2.3 Structural elucidation of compound OPS.2: 3p-((?-a-L-Rliamnoside)-5p,lla,14p-
trihydroxy-19-oxocardenoIide.
Compound OPS.2 was isolated as a colourless oil from the ethanol extract of the bulbs of 
Ornithogalum ponticum ‘Sochi’. It was found to be the 1 la-hydroxy derivative of compound 
OPS.l. and identified as the known 3P-(0-a-D-rhamnoside)-5p, 11 a, 14p-trihydroxy-19- 
oxocardenolide isolated previously from Ornithogalum umhellatum}^
c h o L  h
■Q
OH1
OH ^OHHO
OPS.2
0
Figure S.2.2.3: Structure for compound OPS.2: 3p-(0-a-L-rhamnoside)- 
5p,lla,14p-trihydroxy-19-oxocardenoIide.
The MS spectrum [Spectrum 5.2.2.3.1] gave a molecular ion [M + Na]^ ion at m!z 589.3, 
which indicated a molecular formula of C29H42O11 for OPS.2. The IR spectrum [Spectrum
S.2.2.3.2] for compound OPS.2 showed absorption bands at 3398 and 1731 cm'^ assigned to 
OH and C=0 stretches respectively. As was observed in compound OPS.l, the NMR 
spectrum [Spectrum S.2.2.3.3] of OPS.2 showed characteristic proton resonances of a five 
membered lactone or 2-furanone (butenolide) ring at 5 5.00 (dd, J=  18.2, 1.7 Hz), ô 4.94 (dd, 
J=  18.2, 1.7 Hz) and 6  5.92 (s). Also observed in the ^H NMR spectrum was singlet methyl 
proton resonance at 5 0.91, an aldehyde at 5 10.0, seven proton resonances at 5 4.90, 8  4.13, 8
3.94, 8  3.70, 8  3.61, 8  3.44 and 8  3.00 for hydrogens attached to oxygenated carbons. 
Comparison between ^H NMR chemical shifts of this compound with those of compound 
OPS.l showed that there was an extra oxymethine proton resonance at 8  3.94. The NMR 
[Spectrum S.2.2.3.4] and DEPT [Spectrum 5.2.2.3.S] spectra also displayed an additional 
oxymethine carbon resonance at 8  68.5, which corresponded to the oxymethine proton 
resonance at 8  3.94 in the HSQCDEPT spectrum [Spectrum S.2.2.3.6].
The singlet methyl proton resonance at 8  0.91 showed correlations in the HMBC spectrum 
[Spectrum 5.2.2.3.7J with carbon resonances at 8  50.1, 8  51.0, 8  85.4 and 8  51.5 or C-12, C-
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13, C-14 and C-17 respectively. The 2H-12 proton resonances at 5 1.51 and ô 1.71 showed 
coupling in the COSY spectrum [Spectrum 5.2.2.3.8] with the oxymethine proton resonance 
at 5 3.94. This allowed the placement of the addition hydroxyl group at the C-11 position. 
To determine the relative configuration at C-11, correlations in the NOESY spectrum 
[Spectrum S.2.2.3.9] was examined. A correlation was seen between the H-11 resonance 
and the H-8 proton resonance at 5 2.00 and the 3H-18 singlet methyl proton resonance at ô 
0.91. According to the biosynthetic pathway of cardenolides the 3H-18 and H-8 are always 
in the p position. The hydroxyl group was therefore placed in the a position. A specific 
rotation value of + 17.8 for compound OPS.2 was measured. Threre are no reports on the 
biological activity of compound OPS.2.
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Table S.2.2.3; correlation table for OPS.2; 3p-(0-a-L-Rhamnoside)-5p,lla,14p-
trihydroxy-19-oxocardenoIide.
3. '"C NMR (125 
MHz) C D 3O D
'H NMR (500 M H z )/in  
Hz) C D 3O D
HMBC (H ^ C ) COSY NOESY
25.5 2.09 m ip ,2o , 2P 13
1.30 m la, 2a, 2p la
34.9 2.08 m la, 13 , 23,3 2p,3
1.68 m la. Ip, 2a, 3 2a, 3
73.3 4.13 (brs, W i/2=12.5 Hz) 2a, 2 3 , 4 la, 2a, 4a, T
27.4 1.98 m 3, 43 4 3 , 3
1.77 m 3 ,4a 40,3
75.4 - -
38.8 1.92 m 63, 7a, 73 63, 7a
1.62 m 6a, 7a, 7p 6a, 73
27.4 1.96 m 6a, 6 3 ,7 3 , 8 6a, 73
1.76 m 6a, 63,7a, 8 63, 7a
42.2 2.00 m 14 7a, 7 3 , 9 7 3 , 18
46.1 1.74 m 8, 11a, 113 11a, 12a
56.7 - -
68.5 3.94 m 9 , 113 , 12a, 123 8, 12a, 123
50.1 1.51 m 11, 17, 18 11a, 113 , 123 17
1.71 m 9, 11, 13, 14, 17, 18 11a, 113 , 12a 18
51.0 - -
85.4 - -
33.1 2.15 m 14 153 , 16a, 163 153, 17
1.91 m 15a, 16a, 163 15a
27.9 2.15 m 15a, 153, 163, 17 163, 17
1.69 m 15a, 153, 16a, 17 16a, 17
51.5 2.95 m 12 ,20 ,21 ,22 16a, 163 12a, 16a, 163, 22
17.6 0.91 s 12,13,14,17 - 8, 11, 123 , 2 1 a
211.0 10.00 s 10 - 8, 11
177.5 - -
75.5 5.00 (d d ,/= 1 8 .2 , 1.7 Hz) 20 ,22 ,23 21b, 22 18, 153,21b
4.94 (d d ,/= 1 8 .2 , 1.7 Hz) 20 ,22 ,23 21a, 22 18, 153,21a
118.1 5.92 s 17 ,20 ,21 ,23 21a, 21b 153 , 17, 18,21a
177.2 -
97.0 4.90 (d ,/= 4 .1 H z ) 2% 3, 3% 5’ T 2% 3
73.4 3.44 ( d d , / - 9.5, 3.6 Hz) 3’ \ \ V l ’, 4 ’
75.0 3.61 ( t ,/= 9 .5 H z ) 4’ 2% 4 ’ 4 ’
77.4 3 .0 0 (t ,/= 9 .3 H z ) 5% 6’ 3% 5’ 3% 5% 6'
69.6 3.70 m 4’ 4% 6’ 4% 6’
18.2 1.24 ( d ,/= 6 .2  Hz) 4 ’, 5’ 5’ 4% 5’
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S.2.2.4 Structural elucidation of compound OPS.2A: 3p-[2’,3’,4’-Tetra-0-acetyI-0-a-L-
rhamnoside]-5p,lla,14p-trihydroxy-19-oxocardenolide.
Compound OPS.2 A is an acetylated derivative of compound OPS.2. Compound OPS.2 was 
acetylated to aid in its structural elucidation. The acetylated derivative was identified as SP- 
[2 ’ ,3 ’ ,4 ’ -T etra-O-acetyl- 0-P-L-rhamnoside] -5 P, 11 a, 14p-trihydroxy-19-oxocardenolide.
o
OH
GAc OHAcO
OPS.2A
Figure S.2.2.4: Structure for compound OPS.2A: 3p-[2’,3’,4’-tetra-0-acetyl-0-a-L- 
rhamnoside]-5p,lla,14p-trihydroxy-19-oxocardenoIide.
The MS spectrum [Spectrum 5.2.2.4.1] of compound OPS.2A did not show an [M]^ ion 
however ^^ C NMR [Spectrum S.2.2.4.4] and DEPT [Spectrum S.2.2.4.5] spectrum 
suggested a molecular formula of C37H50O15. The IR spectrum [Spectrum S.2.2.4.2] for 
compound OPS.2A showed absorption bands at 3508, 1747 and 1623 cm'^ assigned to OH, 
C=0 stretches of an acetate and C=C stretches respectively. As was observed in compound 
OPS.2, the NMR spectrum of OPS.2A [Spectrum S.2.2.4.3] showed characteristic 
proton resonances of a five membered lactone, 2-furanone (butenolide) at 4.85 (m), 4.77 (m) 
and 5.88 (s). A singlet methyl proton resonance at ô 1.00, an aldehyde proton resonance at Ô 
10.14 and an oxymethine proton resonance at ô 4.37 (5-OH) were also observed. In addition 
proton singlets for the methyl groups of the acetates at 6  2.08, 5 2.05, 6  2.01 and 1.99 were 
also seen. The proton resonances of the rhamnose unit of compound OPS.2A were shifted 
downfield as compared to those of compound OPS.2.
The "C  NMR [Spectrum S.2.2.4.4] DEPT [Spectrum S.2.2.4.5] and HSQCDEPT 
[Spectrum S.2.2.4.6] spectra for compound OPS.2A displayed six carbonyl resonances of 
which three are for the acetate carbonyls of rhamnose, one of the acetate carbonyl of C-11, 
one for the aldehyde and one for the 2-furanone. Also observed was a quaternary oxygenated
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carbon resonance at ô 73.5, which correlated in the HMBC spectrum [Spectrum 5.2.2.4.7] 
with hydroxyl proton resonance at 8 4.37, which, in turn correlated with carbon resonances at
33.5 and 37.5 for C-4 and C-6 respectively. This confirmed that compound OPS.2 contained 
a hydroxyl group at the C-5 position. OPS.2A was found to be 3P-[2’,3’,4’-tetra-0-acetyl-0- 
a-L-rhamnoside]-5p,lla,14p-trihydroxy-l 9-oxocardenolide. A specific rotation value of +
12.1 for compound OPS.2A was measured.
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Table S.2.2.4: correlation table for OPS.2A: 3p-[2’,3’,4’-Tetra-0-acetyI-0-a-L-
rhamnoside]-5p,lla,14p-trihydroxy-19-oxocardenoIide.
• NMR (125 
MHz) CD3OD
^H NMR (500 MHz) J in  
Hz) CD3OD
HMBC (H^C) COSY NOESY
32.5 2.07 m IP, 2 a, 2 P IP, 19
1.73 m la, 2 a, 2 p la, 19, 5-OH
25.8 1.96 m la, ip, 2P,3 3
1.84 m 2a, la, ip, 3 3
72.0 4.19 (brs, Wi/2 = 9.5 Hz) 2a, 2P, 4 2a,2P,4p, r
33.5 1.95 m 3,4P 3, 4P, 5-OH
1.52 m 3, 4a 3, 4a, 5-OH
73.5 - - -
H 4.37 4, 5-C, 6 - 1P,4P,1’,19
37.5 1.73 m 6 p, 7a, 7P 6 P, 7a
1.64 m 6 a, 7a, 7p 6 a, 7P
24.5 2.04 m 6 a, 6p,7p, 8 6 a, 7P
1 .2 0  m 6 a, 6P,7a, 8 6 p, 7a, 8
41.4 2.03 m 7a, 7p, 9 7P,18
41.9 1.84 m 8 , 1 1 a, lip 17
54.8 - -
70.8 5.34 m 9, lip, 12a, 12P 8 , 1 2 a, 1 2 p, 18
:Hs 2 1 . 6 1.99 11-C - -
] 169.5 - - -
44.2 1.98 m 9, 13,14,18 11a, lip, 12P 12P
1.36 m 13 1 1 a, lip, 1 2 a 1 2 a, 11
49.5 - - -
84.5 - - -
37.5 1.73 m 15P, 16a, 16P, 17 15P, 16a, 16p
1.64 m 13 15a, 16a, 16P, 17 15a, 16a, 16p
26.9 2.14 m 15a, 15P, 16P, 17 16p, 17
1.91 m 15a, 15p, 16a, 17 16a, 2 1 a
49.9 2.77 (dd, J=8.6,5.9Hz) 12,13,14,20, 21,22 16a, 16P 16a, 16p,21a, 2 2
16.7 1 .0 0  s 12,13,14,17 - 8 , 2 1 a, 2 1 b, 2 2
208.3 10.14 (d ,J =  1.9 Hz) 1 0 - la. Ip, 5-OH, 8
172.9 - - -
73.5 4.85 m 18,20,22 2 1 b, 2 2 16P, 17, 18,21b, 22
4.77 m 18,20,22 2 1 a, 2 2 8 , 18,21a, 2 2
118.4 5.88 s 17,20,21,23 2 1 a, 2 1 b 16p, 17, 18,21a
174.2 - - -
93.5 5.16(d,J=3.9Hz) 3, 3% 5' 2’ 2% 3, 5,5'
70.8 4.93 (dd,/=10.2,3.9Hz) 3%2'-C l ’,3 ’ l ’,3 ’
% 20.9 2.08 s 2'-C - -
; 170.7 - - - -
70.1 5.39(t,J=9.8Hz) 3'-C, 4' 2% 4' 4% 5,
% 21.1 2 . 0 1  s 3'-C - -
; 170.3 - - - -
73.8 4.81 m 3'4'-C,5' 3% 5' 3% 5% 6 '
Hs 21.1 2.05 4’-C - -
; 170.0 - - - -
66.1 3.92 (p, J=  6.3 Hz) - 4% 6' 3% 4% 6 '
17.5 1 .2 0  (d,/ =  6 .3Hz) 4% 5' 5’ |4 ’,5 ’
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S.2.2.5 Structural elucidation of compound OPS.3: 3p-(0-a-L-Rhamnoside)-
5p,lla,14p,19-tetrahydroxy-card-20(22)-enolide.
Compound OPS.3 was isolated as a colourless oil from the ethanol extract of the bulbs of 
Ornithogalum ponticum ‘Sochi’. It was identified as a cardenolide with a hydroxyl group at 
the C-19 position and was determined to be 3 P-(0-a-L-rhamnoside)-5p,11 a, 14^,19- 
tetrahydroxy-card-20(22)-enolide also known as sarmentologenin-3-O-a-L-rhamnoside 
isolated previously from Convallaria majalis of the Nolinoideae subfamily (Asparagaceae 
family).^^
o
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Figure 5.2.2.S: Structure for compound OPS.3: 3p-(0-a-L-rhamnoside)-5p,lla,14p,19-
tetrahy droxy-car d-20(22)-enoIide.
The MS spectrum [Spectrum 5.2.2.5.1] gave a molecular ion [M + Na]^ peak at m/z 591.3, 
which indicated a molecular formula of C29H44O11 for OPS.3. The FTIR spectrum 
[Spectrum S.2.2.4.2] for compound OPS.3 showed absorption bands at 3419 and 1635 cm'^ 
assigned to OH and C=0 of butenolide stretches respectively. The NMR spectrum of 
OPS.3 [Spectrum S.2.2.4.3] showed characteristic proton resonances of a five membered 
lactone or 2-furanone (butenolide) ring at 5 5.02 (dd, J=  18.2, 1.7 Hz), 8  4.97 (dd, J=  18.2, 
1.7 Hz) and 8  5.94 (s). Also observed in the ^H NMR spectrum was singlet methyl proton 
resonance at 8  0.93 and nine proton resonances at 8  4.88, 8  4.46, 8  4.19, 8  4.12, 8  3.95, 8
3.71, 8  3.62 and 8  3.00 for hydrogens attached to oxygenated carbons. The comparison 
between ^H NMR and NMR [Spectrum S.2.2.4.4] chemical shifts of this compound with 
those of compound OPS.l and OPS.3 showed that the aldehyde had been reduced to a 
hydroxyl group, as was observed by additional oxymethylene carbon resonances at 4.19 (d, J  
= 11.2 Hz) and 3.81 (d, J =  11.2 Hz). The oxymethylene carbon was therefore assigned as C- 
19.
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The relative configuration of the 11-OH was determined using the NOESY experiment 
[Spectrum 5.2.2.4.10]. Just like compound OPS.3, a correlation in the NOESY spectrum 
was observed between proton resonance at 5 1.83 for H-8 and a single methyl proton 
resonance at ô 0.93 for 3H-18. The 11-OH was therefore assigned to a position. A specific 
rotation value of + 137.6 for compound OPS.3 was measured. Compound OPS.3 was 
identified ■ as 3p-(O-a-L-rhamnoside)-5P,lla,14p,19-tetrahydroxy-card-20(22)-enolide 
isolated previously fi-om Convallaria majalis.
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Table S.2.2.5: Correlation table for OPS.3: 3p-(t?-a-L-rhamnoside)-5p,lla,14p,19-
tetrahydroxy-card-20(22)-enolide
NMR (125 
MHz) MeOH
NMR (500 MHZ) J  in Hz) 
MeOH
HMBC
(H-^C)
COSY NOESY
36.9 1.87 m IP, 2a, 2p IP
1.44 m la, 2a, 2P la
27.9 2.01 m la , IP, 2P,3 2P,3
1.72 m la. Ip, 2a, 3 2a, 3
74.3 4.12 (brs, Wi/2=8.03Hz) 2a, 2p, 4 la, 2a, 4a, 1’
35.0 2.08 m 3,4P 4P, 3
1.60 m 3, 4a 4a, 3
75.5 - - -
25.1 1.98 m 6P, 7a, 7P 6P, 7a
1.25 m 6a, 7a, 7p 6a, 7P
30.6 1.26 m 6a, 6p,7p, 8 6a, 73
1.23 m 6a, 6p,7a, 8 63, 7a
41.0 1.83 m 7a, 7p, 9 73,18
45.7 1.77 m 8, 11a, lip 11a, 12a
45.2 - - -
69.1 3.95 m 9, l ip , 12a, 12P 8, 12a, 123
50.6 1.56 m 11a, lip, 12P 17
1.68 m 11a, lip, 12a 18
51.1 - -
86.0 - -
33.4 2.19 m 15P, 16a, 16P 153, 17
1.73 m 15a, 16a, 16p 15a
28.0 2.19 m 15a, 15p, 16P, 17 163, 17
1.90 m 15a, 15p, 16a, 17 16a, 17
51.7 2.96 (t, J= 6.1 Hz) 16a, 16P 12a, 16a, 163, 22
17.8 0.93 s 12,13,14,17 - 8, 11, 12a, 123
68.8 4.19 (d ,J=  11.2 Hz) 19b 8, 19b
3.81 (d ,J=  11.2 Hz) 19a 8,11, 19a
177.9 - - -
75.5 5.02 (dd,J=18.2, 1.7 Hz) 21b, 22 18, 153,21b
4.97 (dd,J=18.2, 1.7 Hz) 21a, 22 18, 153,21a
118.0 5.94 s 21a, 21b 153, 17, 18,21a
177.5 - -
98.2 4.88 2’ 2% 3
73.4 3.46 (dd, J=9.5,3.8Hz) r , 3 ’ l ’,4 ’
75.0 3.62 (t,J=  9.4, 7.0 Hz) 2% 4’ 4’
77.3 3.00 (t, J=  9.3 Hz) 3% 5’ 3% 5% 6’
69.5 3.71 m 4% 6’ 4% 6’
18.2 1.24 (d, J=  6.3 Hz) 4% 5’ 5’ 4% 5’
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5.2.3 CONCLUSIONS
The phytochemical investigation of Onithogalum ponticum ‘Sochi’ yielded three known 
cardenolides, OPS.1-OPS.3. Compounds OPS.l and OPS.2 were acetylated to aid in 
structural elucidation. The acetylated derivatives of compound OPS.l and OPS.2 are 
OPS.IA and OPS.2 A respectively.
CH(
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CHO H
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Compound OPS.l is a cardenolide with an aldehyde at the C-19 position, hydroxyl at the C-5 
position and a rhamnose sugar at the C-3 position. This compound has been isolated 
previously from Ornithogalum umbellatum^^ and has been tested for its anticancer activity
145
against BGC-823 human gastric cancer and Bel-7402 human hepatoma cancer cell lines. It 
was found to possess significant growth inhibition activity with IC50 values of < 1
Compound OPS.2 was found to be a 11-a-hydroxyl derivative of compound OPS.l and has 
also been isolated previously from Ornithogalum umbellatum^^’^ .^ There is no report on the 
biological activity of compound OPS.2. Compound OPS.3 was found to be a C-19-hydroxy 
derivative of compound compound OPS.2 and has been reported previously from 
Convallaria majalis of the Nolinoideae subfamily of the Asparagaceae f am i ly .T h e re  is no 
report on the biological activity of compound OPS.3. The isolation of cardenolides from 
Onithogalum ponticum ‘Sochi’ follows the taxonomical trend of the Ornithogalum genus. 
The compounds isolated from this plant will be submitted to NCI for anticancer screening.
146
5.3 References
1. Martmez-Azorîn, M., Crespo, M. B.,Juan, A. and Fay,M.F. 2011. Molecular 
phylogenetics of subfamily Omithogaloideae (Hyacinthaceae) based on nuclear and 
plastid DNA regions, including a new taxonomic arrangement. Annals o f  Botany 107, 
1-37.
2. Speta, F. 1998. Hyacinthaceae In: Kubitzki. K, ed. The families and genera of 
vascular plants. Berlin: Springer. 261-285.
3. Manning, J.C., Goldblatt, P. and Fay, M. F. 2004. A revised generic synopsis of 
Hyacinthaceae in sub-Saharan Africa based on molecular evidence, including new 
combinations and the new tribe Pseudoprospereae. Edinburgh Journal o f  Botany. 60, 
533-568.
4. Manning, J.C., Forest, F., Fay, M. F., Devey, S., Goldblatt, P., 2009. A molecular 
phylogeny and a revised classification of Omithogaloideae (Hyacinthaceae) based on 
an analysis of four plastid DNA regions. Taxon. 58, 77-107.
5. Mulholland, D.A., Schwikkardab, S. L. and Crouch, N.L. 2013. The chemistry and 
biological activity of the Hyacinthaceae. Natural Products Reports. 30, 1165-1210
6 . Yuping, T., Biao,Y., Jie,H., Tao,w. and Yongzheng, H. 2001. The Chemical
Constituents from the Bulbs of Ornithogalum caudatum. Journal o f  Chinese 
Pharmaceutical Science. 10, 169-171.
7. Mulholland, D.A.,Crouch, N, R., Pohl, T.L. and Ndlovu, E. 2004. A
homoisoflavanone from Ornithogalum longibracteatum
(Omithogaloideae:Hyacinthaceae). Biochemical Systematics and Ecology. 32, 499- 
502.
8 . Tunhai, X., Yajuan X., Dayou. L. and Dongming. X. 2000. Studies on chemical 
constituents from Ornithogalum caudatum Ait. YaoxueXuebao. 35, 32-36.
9. Tang, Y., Yu. B., Hu. J., Wu. T. and Hui. H. 2002. Three New Homoisoflavanone 
Glycosides from the Bulbs of Ornithogalum caudatum. Journal o f  Natural Poducts. 
65,218-220
10. Mrozik, H.; Waud, R. A.; Schindler, O.; Reichstein, T. 1959. Glycosides and
aglycons. CXCVII. Glycosides from the bulbs of Ornithogalum umbellatum.
Pharmaceutica Acta Helvetiae. 42, 683.
147
11. Gasic, G., Simanek, V., Lukic, V., Walterova, D., Kevresan, S., Hanus, V. and Pal, B. 
1989. Chemical studies of Ornithogalum umbellatum L. from Subotica-Horgos sands. 
Zbornik Matice Srpske za Prirodne Nauke. 76, 21-26
12. Azzioui, O., Braemer, L.R. and Paris, M. 1989. C-Glucosylflavones in the genus 
Ornithogalum. Biochemical Systematics and Ecology. 17, 449-450.
13. Waud, R. A. and Boyd. J. 1954. Action of Ornithogalum umbellatum on the heart. 
Journal o f Pharmacology and Experimental Therapeutics. I l l ,  147-151.
14. Kelly, R. B. Daniels, E.G. and Spaulding, L. B. 1965 Cytotoxicity of cardiac principles. 
Journal o f  Medicinal Chemistry. 8 , 547-548.
15. Komissarenko, N. F. 1971. Omithogalin, a cardenolide glycoside from Ornithogalum 
magnum. Khimiya Prirodnykh Soedinenii. 7, 38-40.
16. Komissarenko, N. F. 1972. Cardenolide-containing plants of the flora of the USSR. 
Postep Dziedzinie Leku Rosl, Pr. R ef Dosw. Wygloszone Symp.61-ll
17. Zoz, I. G.; Chernykh, N. A. 1969. Ornithogalum magnum- a new source of cardiac 
glycoside. Farmatsevtichnii Zhurnal (Kiev). 24, 77-78.
18. Komissarenko, N. F. 1969. Omithogaloside, a new cardenolide glycoside from the 
pods of Ornithogalum magnum. Khimiya Prirodnykh Soedinenii. 5, 46-48.
19. Komissarenko, N. F. 1965. Boll cardenolides of Ornithogalum magnum. Khimiya 
Prirodnykh Soedinenii. 156-160.
20. Komissarenko, N. F. 1972. Cardenolides from seeds of Ornithogalum magnum. 
Khimiya Prirodnykh Soedinenii. 397-398.
21. Ferth, R., Baumann, A., Mayer, K. K., Robien, W. and Kopp, B. 1992. Cardenolides 
from Ornithogalum nutans (2n = 30). Part 2. Zeitschrift fuer Naturforschung, B: 
Journal o f Chemical Sciences. 47, 1459-1468.
22. Ferth, R., Baumann, A., Robien, W. and Kopp, B. 1992. Cardenolides from 
Ornithogalum nutans (2n = 28). Part 1. 47, 1444-1458.
23. Ghannamy, U., Kopp, B., Robien, W. and Kubelka, W. 1987. Cardenolides from 
Ornithogalum boucheanum. Planta Medica. 53, 172-178.
24. Komissarenko N. F. and Krivenchuk P. E. 1974. Cardenolides from the flowers and 
bulbs of Ornithogalum gussonii. Khimiya Prirodnykh Soedinenii. 10, 257.
25. Buchvarov, Y., Balabanova-Radonova, E., Radenkova, I. and Vankov, S. 1984. 
Isolation of Ornithogalum cardiac glycosides and polysaccharides from species, 
growing in Bulgaria. Farmatsiya (Sofia, Bulgaria). 34, 33-37.
148
26. Koorbanally, C., Mulholland, D. A. and Crouch, N. R. 2005. A novel 3-hydroxy-3- 
benzyl-4-chromanone-type homoisoflavonoid from Albuca fastigiata 
(Omithogaloideae: Hyacinthaceae). Biochemical Systematics and Ecology. 33, 545- 
549.
27. Oyedemi, S.O., Bradley.G and Afolayan, A.J. 2009. Ethnobotanical survey of 
medicinal plants used for the management of diabetes mellitus in the Nkonkobe 
municipality of South Africa. Journal o f Medicinal Plants Research. 3, 1040-1044.
28. Ndebia E. J., Umapathy E., Nkeh-Chungag, B. N. and Iputo J. E. 2011. Anti­
inflammatory properties of Albuca setosa and its possible mechanism of action. 
Journal o f Medicinal Plants Research. 5, 4658-4664.
29. Okanishi, T., Akahori, A., Yasuda, F., Takeuchi, Y. and Iwao, T. 1975. Steroidal 
components of domestic plants. LXVI. Steroidal sapogenins of sixteen Liliaceae 
plants. Chemical and Pharmaceutical Bulletin. 23, 575-579.
30. Mimaki, Y., Kuroda, M., Sashida, Y., Yamori, T. and Tsumo, T. 2000. Candicanoside 
A, a novel cytotoxic rearranged cholestane glycoside from Galtonia candicans. 
Helvetica Chimica Acta. 83, 2698-2704.
31. Kuroda, M., Mimaki, Y., Sashida, Y., Yamori, T. and Tsumo, T. 2000. Galtonioside 
A, a novel cytotoxic cholestane glycoside from Galtonia candicans. Tetrahedron 
Letters. 41, 251-255.
32. Mimaki, Y., Kuroda, M., Yokosuka, A. and Sashida, Y, 2001. Five new 
polyoxygenated cholestane bisdesmosides from the bulbs of Galtonia candicans. 
Journal o f Natural Products. 64, 1069-1072.
33. Kuroda, M., Mimaki, Y., Yokosuka, A. and Sashida, Y. 2001. Cholestane glycosides 
from the bulbs of Galtonia candicans and their cytotoxicity. Chemical and 
Pharmerceutical Bulletin. 49, 1042-1046.
34. K. du Toit, PhD Thesis, University of Natal, South Africa, 2004
35. Kubo, S., Mimaki, Y., Terao, M., Sashida, Y., Nikaido, T. and Ohmoto, T. 1992. 
Acylated cholestane glycosides from the bulbs of Ornithogalum saundersiae. 
Phytochemistry. 31, 3969-3973.
36. Mimaki Y. 1996. A new cytotoxic cholestane bisdesmoside from Ornithogalum 
saundersiae bulbs. Bioscience, Biotechnology, and Biochemistry. 60, 1049-1050.
37. Mimaki, Y., Kuroda, M., Kameyama, A., Sashida, Y., Hirano, T., Oka, K., Maekawa, 
R., Wada, T., Sugita, K. and Beutler, A. J. 1997. Cholestane glycosides with potent
149
cytostatic activities on various tumor cells from Ornithogalum saundersiae bulbs. 
Bioorganic and Medicinal Chemistry Letters. 7, 633-636.
38. Kuroda, M., Mimaki, Y. and Sashida, Y.1999. Cholestane rhamnosides from the 
bulbs of Ornithogalum saundersiae. Phytochemistry. 52, 445-452.
39. Kuroda, M., Mimaki, Y., Yokosuka, A., Sashida, Y. and Beutler, A. J. 2001. 
Cytotoxic cholestane glycosides from the bulbs of Ornithogalum saundersiae. 
Journal o f Natural Products. 64, 88-91.
40. Buchvarov, Y., Balabanova-Radonova, E., Radenkova, I. and Vankov, S. 1984. 
Isolation of Ornithogalum cardiac glycosides and polysaccharides from species, 
growing in Bulgaria. Farmatsiya. 34, 33-37.
41. Pavia, D. L., Lampman, G. M., Kriz, G. S. and Vyvan, J. R. 2009. Introduction to 
Spectroscopy. 4th ed. Brooks/Cole, USA.
42. Gwynn P. E. 2007. The Chemistry of Heterocyclic Compounds, Volume 31, 
Chromenes, Chromanones, and Chromones.
43. Dai, Y., Harinantenaina, L.,Brodie, P.J., Goetz, M., Shen, Y., TenDyke, K. and 
Kingston, I.G.D. 2013. Antiproliferative Homoisoflavonoids and Bufatrienolides from 
Urginea depressa. Journal o f Natural Products. 76, 865-872.
44. Adinofli. M., Barone. G., Corsaro, M.M. and Mangoni.L. 1988. Absolute 
configuration of homoisoflavonoids from Muscari species. Tetrahedron 44, 4981- 
4988.
45. Heller, W., Andermatt, P., Schaad, W. A., Tamm, C. (1976) Homoisoflavanones 
.IV.New constituents of eucomin series of Eucomis hicolor. Helvetica Chimica Acta, 
59, 2048-2058.
46. Mutanyatta, J., Matapa, G. B., Shushu, D.D. and Abegaz, M.B. 2003. 
Homoisoflavonoids and xanthones from the tubers of wild and in vitro regenerated 
Ledebouria graminifolia and cyotoxic activities of some of the homoisoflavonoids. 
Phytochemistry. 62, 797-804.
47. Roslund, U. M., Tahtinen, p., Niemitzc, M. and Sjoholma, R. 2007. Complete 
assignments of the IH and 13C chemical shifts and H,H coupling constants in NMR 
spectra of D-glucopyranose and all D-glucopyranosyl-D-glucopyranosides. 
Carbohydrate Research. 343, 101-112.
48. Sueyoshi, E., Yu, Q., Matsunami, K. and Otsuka, H. 2009. Three new olefmic 
acetogenin glycosides from leaves of Staphylea bumalda DC. Journal o f Natural 
Medicine. 63, 61-64.
150
49. Jiang, M., Dai, Y., Gao, H., Zhang, X., Wang, G., He, J., Hu, Q., Zeng, J., Zhang, X 
and Yao, X. 2008. Cardenolides from Antiaris toxicaria as Potent Selective Nur77 
modulators. Chemical and Pharmaceutical Bulletin. 56, 1005-1008.
50. Drakenberg, T., Brodelius. P., Mcintyre, D.D. and Vogel, J.H. 1989. Structural studies 
of Digitoxin and related cardenolides by two-dimensional NMR. Canadian Journal o f  
Chemistry. 6 8 , 272-277.
51. Kopp, B. and Kubelka, W. 1982. New cardenolides of Convallaria majalis. Planta 
Medica. 45, 87-94.
151
CHAPTER SIX: BIOLOGICAL ACTIVITIES OF BUFADIENOLIDES
6.1 Introduction
Bufadienolides are widely used in traditional medicine for the treatment of several ailments, 
such as rheumatism, infections, inflammation, and disorders associated the heart/ 
Bufadienolides are known to possess a broad range of bioactivities including cardiotonic, 
immunomodulatory, anti-tumour, analgesic, insecticidal and anti-inflammatory activities. 
Some of the biological activities are described below. ^
6.1.1 Cardiotonic activity
Bufadienolides are known to inhibit the adenosine triphosphate sodium-potassium pump 
(Na^-K^-ATpase), thus indirectly increasing the concentration of intracellular Ca^^\ A 
therapeutic concentration of a bufadienolide causes moderate inhibition of the enzyme 
leading to depolarization of the cell. This causes a decrease in the amount of enzyme 
required to restore the Na^/K^ balance leading to an increase of N a \ The increase in Na^ 
modifies Ca^  ^through the Na' /^Ca '^  ^exchange and allows Na^ to exit the cell in exchange for 
Ca^  ^ leading to an increase in intracellular calcium which, in turn, causes an increase in the 
force of contraction. Due to their cardiotonic activities, bufadienolides have been used in 
traditional Chinese medicine for the treatment of congestive heart failure.^
Studies on bufadienolides such as bufalin, cinobufagin, bufotalin, cinobufotalin, 
resibufogenin and gamabufotalin have shown the cardiotonic effect in the isolated heart of a 
guinea pig. The cardiotonic effect was observed in a concentration dependent manner by the 
inhibition of the Na^-K^-ATpase activity.^
6.1.2 Immunomodulatory activity
Bufadienolides have been shown in animal studies to increase significantly the blood 
lymphocytes, splenic lymphocytes and macrophages count. These findings have suggested 
the possible involvement of bufadienolides in immune defence through the modulation of the 
lymphoid cell. Cinobufagin is an example of a bufadienolide that has been used successfully 
in the reduction and treatment of granulocytopenia during combined therapy. Treatment of
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patients with malignant blood diseases with high doses of cinobufagin, showed a significant 
decrease in infection without a significant change in granulocytes/
6.1.3 Anti-tumour activity
Bufadienolides obtained from plants, animals and by chemical transformations have been 
evaluated for their cytotoxic activities towards a variety of cancer cells including human 
leukemia, lung carcinoma, hepatoma, gastrointestinal and breast cancers/
The anti-tumour mechanisms of bufadienolides that have been reported include cell cycle 
arrest by increasing the expression of P21, inhibition of transcription factors such as NF-kB 
and AP-1, inhibition of P13K/AKT and topoisomerases thus affecting cell differentiation, 
induction of mitochondria mediated and death receptor mediated apoptosis and decreasing 
anti-apoptotic proteins such as BCL-2 and BCL-XL/’^  Na^-K^-ATpase has been considered 
as a target of bufadienolides for their anti-tumour activity, however some anti-tumour 
mechanisms of bufadienolides do not involve the inhibition of the Na" -^K’^ -ATpase, indicating 
that the anti-tumour mechanisms of bufadienolides are complicated/ Bufalin is one of the 
bufadienolides that has been widely studied for its anticancer properties against leukemia and 
melanoma cells. Bufalin is known to induce differentiation in human erytholeukemia K562 
cells and also in human leukemia derived cell lines, HL60, U937, MLl. It is known to inhibit 
the growth of MLl cells at G2 phase of the cell cycle.^ This effect of bufalin on the cell 
cycle is similar to that of topoisomerase inhibitors.^ Studies on the mode of action of bufalin 
showed that it reduces the level and activity of topoisomerase Ila and Iip in human leukemia 
HL60 cells. It also indicated the ability to potentiate the inhibitory activity of cisplatin and 
retinoic acid and also enhanced the induction of apoptosis.^ Bufalin has also been shown to 
inhibit cell proliferation and DNA synthesis of the ovarian endometriotic cyst stromal cell 
line, to induce apoptosis and to cause GO/Gl phase cycle arrest by down regulation of cyclin- 
A, BCL-2 nad BCL-X expression with the upregulation of P21 and Bax expression.^’^
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6.2 Anticancer screening of bufadienolides isolated from Urginavia altissima 
6.2.1 Introduction
Bufadienolides isolated from the bulbs of Urginavia altissima were submitted to the 
Development Therapeutics Program of the National Cancer Institute (DTP-NCI) in the 
United States for determination of their potential anticancer activities.
6.2.2 The in vitro NCI59 anticancer drug discovery screen
The DTP-NCI was started more than 50 years ago as the Cancer Chemotherapy National 
Service Centre to provide in vitro and in vivo screening services and pharmacological and 
formulation resources.^ It has had a significant role in the development of anticancer drugs 
including paclitaxel and bortezomib.^ The NCI screens for potential anticancer drugs by 
utilising a panel of 59 human tumour cell lines derived from various tissue types, chosen to 
represent various tumour types and for their consistent ability to withstand the conditions of 
the assay.^ The human tumour cell lines utilized by the NCI represents nine types of cancers; 
leukemia, melanoma, non-small cell lung cancer, CNS cancer, colon cancer, ovarian cancer, 
renal cancer, prostate cancer and breast cancer. The aim of the NCI screen is to prioritize for 
further assessment, natural products or synthetic compounds that show selective growth 
inhibition of a specific cell line.^
The NCI screening involves a two stage process, which starts with the assessment of the 
compounds against 59 cell lines at a single dose of lOpM.^ The compounds which exhibit 
significant antiproliferative activity and satisfy the predetermined threshold, progress to the 
five dose screen. The dose response produced by a compound results in a biological response 
pattern which can be interpreted using a recognition algorithm known as COMPARE 
(computerised pattem-recognition algorithm), which is provided by the NCI.^^ The 
utilization of the COMPARE programme will be discussed in chapter seven.
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6.3 Anticancer screening results for compounds UA.1 -  UA.10
Compounds UA.1-UA.10 were tested against 57 cancer cell lines to determine their 
inhibitory activities. All the compounds were tested at the one dose concentration level of 10 
pM. The growth percent and lethality of compounds UA.1-UA.10 at the one dose 
concentration level are presented as mean graphs [Figure 6.3.1.1-6.3.10.1]. An example of a 
mean graph is shown in figure 6.3.1.1 below for compound UA.1. The number reported for 
the one dose assay is growth relative to the no drug control and relative to the time zero 
number of cells. This allows the detection of growth inhibition (values between 0-100) and 
lethality (between 0 and -100).^ For example a value of 100 means no growth inhibition. A 
value of of 40 mean 60% growth inhibition. A value of 0 means no net growth over the 
course of the experiment. A value of -40 would mean 40% lethality. A value of -100 means 
all cells are killed.^ The bars projecting to the right indicate that an individual cell line is 
more sensitive than the average cell line in the panel while the bars projecting to the left 
means that an individual cell line is less sensitive than the average cell line in the panel.^ 
Compounds UA.1-UA.9 satisfied the predetermined NCI threshold inhibition criteria and 
were evaluated against 57 cell lines at five concentration levels.
At the five dose concentration levels compounds UA.1, UA.2 and UA.5 were tested at 0.001,
0.01, 0.1 and 10 pM, compound UA.3 at 0.0025, 0.025, 0.25, 2.5 and 25 pM, compounds 
UA.4, UA.6, UA.7 and UA.9 at 0.00158, 0.0158, 0.158, 1.58 and 15.8 pM and compound 
UA.8 at 0.00063, 0.0063, 0.063, 0.63 and 6.3 pM. From the dose-response curves, showing 
logio sample concentration versus the percent growth, 3 endpoints were calculated, as 
illustrated in figure 6.3.2 below using dose-response data for compound UA.1 against the 
central nervous system (CNS) cell line panel: The endpoints are, GI50: the concentration of a 
compound that causes 50% growth inhibition, relative to the no drug control; TGI: the 
concentration that yields no net growth over the course of the assay (total growth inhibition) 
and the LC50 endpoint which calculates the concentration that kills 50% of the cells that were 
present at the time of drug addition. The dose réponse curves that give GI50, TGI and LC50 
for compounds UA.1 -  UA.9 are presented as mean graphs [Figures 6.3.1.2-6.3.9.2]. The 
GI50, TGI, LC50 and their Logio values of the five most sensitive cell lines are also shown in 
table 6.1 below.
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Developmental Therapeutics Program 
One Dose Mean Graph
NSC: D-776655 /1 Cone: 1 OOE-5 Molar Test Date: Jul 22, 2013
Experiment ID: 1307OS38 Report Date: Oct 18,2013
Panel/Cell Line
Leukemia
CCRF-CEM
HL-60(TB)
K-562
MOLT-4
RPMI-8226
SR
Non-Small Cell Lung Cancer 
A549/ATCC 
HOP-62 
NCI-H226 
NCI-H23 
NCI-H322M 
NCI-H460 
NCI-H522 
Colon Cancer 
COLO 205 
HCC-2998 
HCT-116 
HCT-15 
HT29 
KM12 
SW-620 
CNS Cancer 
SF-268 
SF-295 
SF-539 
SNB-19 
SNB-75 
U251 
Melanoma 
LOX IMVI 
M14
MDA-MB-435 
SK-MEL-2 
SK-MEL-28 
SK-MEL-5 
UACC-257 
UACC-62 
Ovanan Cancer 
IGROVI 
OVCAR-3 
OVCAR-4 
OVCAR-5 
OVCAR-8 
NCI/ADR-RES 
SK-OV-3 
Renal Cancer 
786-0 
A498 
ACHN 
CAKI-1 
RXF 393 
SN12C 
TK-10 
UO-31 
Prostate Cancer 
PC-3 
DU-145 
Breast Cancer 
MCF7
MDA-MB-231/ATCC 
MS 578T 
BT-549 
T-47D
MDA-MB-468
Mean
Delta
Range
Growth Percent
- 22^0
-37.25
3.13 
-4142  
-12.85 
-2742
-70.37
-96.02
-7.13
-35.50
-22.72
-73.24
-58.56
2.34 
11.25
1.19
-17.46
-27.98
15.52
0.26
-64.76
-6.86
-98.64
13.04 
3.00
-11.24
-69.04
1.40
4.08
-30.54
-13.14
-27.55
4.35 
-25.30
-3.00
-31.07
-30.02
-15.51
1.13 
-13.34 
-20.82
43.07
-25.39
45.76
-29.17
-28.99
-20.63
-36.29
-86.33
2.88
4 7 2 2
0.95
24.05 
-3.77 
-7.64 
- 8.21
25.39
-22.45
76.19
124.03
Mean Growth Percent - Growth Percent
150 100 50 -50 -100 -150
Figure 6.3.1.1: One dose mean graph of compound UA.1
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Figure 6.3.2: Dose response curve of compound UA.l against CNS cancer cell lines
From the previous studies of anticancer drug development/^ emphasis is placed on selecting 
compounds with nano-molar in vitro anticaneer potency, expecting that they will be 
efficacious and safer based on the assumption that they can be used at lower doses (“the 
nano-molar rule”)/^ In this study, nano-molar activity is observed for compounds UA.l -  
UA.9 for most of top 5 sensitive cell lines (Table 6.3.1.1). Ranking has been done for 
compounds showing GI50 levels of <100 nM (Table 6.3.1.2) and their TGI and LC50 levels are 
correlated. This is because systematic analysis of large scale dose-response data usually 
concentrate on the closely related parameters GI50, LC50 and IC50, and used to draw implicit 
assumption that potency at the mid-point of the dose response curve is the most important 
difference between drugs or between sensitive and resistant cells. From the ranking it is 
observed that:
• Compound UA.6 is the most potent against CNS SF-539 with a GI50 value of 3 nM, 
and TGI and LC50 values are 8 and 23 nM respectively. Compound UA.6 also show 
potency against prostate DU-145, ovarian OVCAR-8 and CNS U251 cell lines.
• Compounds UA.2, UA.3, UA.4, UA.6 and UA.7 showed potency against 5 (CNS, 
prostrate, ovarian, non-small cell lung and renal) of the 9 NCI cell line panels that 
were tested.
• Compounds UA.2, UA.3, UA.4, UA.6 and UA.7 showed potency against 10 of the 
57 NCI cell lines that were tested.
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Table 6.3.2: Ranking for compounds showing G I 5 0  levels of <100 nM
GIso TGI UC50 Cell line Compound
3 8 23 CNS SF-539 UA .6
6 17 68 Prostate DU-145 UA .6
15 47 138 Ovarian OVCAR-8 UA .6
25 51 105 CNSU251 UA .6
26 60 145 Non-small cell lung HOP-62 UA.3
32 72 166 CNS SF-539 UA.3
42 138 562 Renal CAKl-1 UA.3
51 135 >16595 Ovarian SK-OV-3 UA .6
52 229 955 Prostate DU-145 UA.2
56 195 513 Non-small cell lung HOP-62 UA.2
58 182 447 CNS SF-268 UA.2
60 170 692 Ovarian OVCAR-5 UA.3
65 2630 7943 Non-small cell lung A549/ATCC UA.7
66 219 575 CNS SF-539 UA.2
79 275 851 CNS U251 UA.3
91 501 3162 Ovarian OVCAR-3 UA.4
98 1202 5248 Renal CAKl-1 UA.7
At this stage other parameters affecting efficacy and toxicity including physiochemical and 
absorption, distribution, metabolism and excretion properties, off-target effects, and multi­
targeting activities are unknown. Therefore, compounds UA.6 for CNS SF 539, CNS U251, 
prostate DU-145 and ovarian OVCAR-8 and UA.3 for CNS SF 539 and non-small cell lung 
HOP-62 could be proposed for further studies that target these parameters.
The rest of the compounds should not be completely discarded as it is known that some 
anticancer drugs show micro-molar potency but are efficacious and are less toxic compounds. 
Examples include thalidomide, a glutamic acid derivative, used as standard therapy for 
multiple myeloma*^ which was inactive in the NCl-60 screen (G150 >100 pM),^  ^ and only 
slightly reduced the proliferation of multiple myeloma cells (<20%) at high concentrations 
(>100 pM).^^ Also 18 of the 27 alkylating agents, the first anticancer drugs discovered and 
the most commonly used drugs in chemotherapy, are only weakly cytotoxic (G I50 > 20 pM). 
It is noteworthy that actinomycin D, the most potent alkylating agent (G I50 1.4 nM) has 
limited clinical use because of its extreme toxicity.
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6.4 CONCLUSIONS
Generally the results of the anticancer activity for bufadienolides isolated from Urginavia 
altissima indicate that:
• Compounds UA.l-UA.9 were found to be active at the one dose concentration level 
of 10 pM, therefore they were tested at a five dose concentration levels to obtain their 
GI50, TGI, LC50 and their Logio values.
• Of the highly sensitive (top 5) cell lines, all the active compounds displayed high 
percent lethality except compound UA.5 which only inhibited the cancer cells.
• The changes in the functional groups and configuration at the C-3 position affect 
their anticancer activity.
• The a-OH group at the C-3 postion (UA.l) increases the anticancer activity more 
than the P-OH group (UA.7) and this applies also to their C-3 ethoxylated derivatives 
(UA.7 and UA.8).
• Compound UA.l was active against the CNS SF-539, non-small cell lung HOP-62, 
renal cancer UO-31, non-small cell lung NC1-H460 and non-small cell lung 
A549/ATCC lines while compound UA.7 target the non-small cell lung A549/ATCC, 
leukemia HL-60 (TB), leukemia MOLT-4, CNS SF-539 and renal RXF 393 lines.
• The C-3 ethoxylated derivatives, compound UA.2 was active against CNS SF-539, 
non-small cell lung HOP-62, CNS U251, prostate DU-145 and CNS SF-268 while 
compound UA.8 target non-small cell lung A549/ATCC, prostate DU-145, non-small 
cell lung HOP-62, non-small cell lung NC1-H522 and CNS SF-539
• The presence of the glucose unit (UA.3) at the C-3 position increases the anticancer 
activity of bufadienolides. The acétylation of the glucose unit (UA.4) and the 
oxidation of 11-OH to an 0 x0  group (UA.5) was found to lower the activity.
• Compound UA.3 target CNS SF-539, CNS U251, ovarian OVCAR-5, non-small cell 
lung HOP-62 and renal CAKl-1, while its acetylated derivative compound UA.4 
target prostate DU-145, non-small cell lung HOP-62, ovarian OVCAR-3, CNS SF- 
268 and renal CAKl-1
• Compound UA.5 inhibited the growth of the non-small cell lung NC1-H522, renal 
RXF 393, renal ACHN, leukemia MOLT-4 and renal TK-10.
• The oxidation of C H 3  at the C - 1 9  position to C H 2 O H  (UA.6) in glucosylated 
bufadienolides increases the anticancer activity and the oxidation of the C H 3  at the C-
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19 position to an aldehyde, hydrogenation of ^4 and the reduction of 11-hydroxyl 
group (UA.9 and UA.10) decreases the activity,
• Compound UA.6 was active against prostate DU-145, CNS U251, ovarian SK-OV-3, 
CNS SF-539 and ovarian OVCAR-8, whereas compound UA.9 target non-small cell 
lung A549/ATCC, non-small cell lung HOF-62, CNS SF-539, leukemia HL-60 (TB) 
and non-small cell lung NCI-H522
A summary of the effect of substitutes of bufadienolides isolated from Urginavia 
altissima are shown below (Figure 6.3.3).
OH
Double bond at C-4 increases 
activity
Oxidation of OH to oxo group and 
reduction to H2 decreases activity
Oxidation of C H 3  to C H 2 O H  
increases activity while oxidation to 
an aldehyde lowers the activity.
Replacement of a-OH with ethoxy or 
glucose increases the activity. P-OH 
and p-ethoxy groups reduces 
activity.
Figure 6.3.3: Summarized structure-activity relationship of bufadienolides isolated from 
Urginavia altissima with regard to anticancer activity.
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CHAPTER SEVEN: DETERMINATION OF ANTICANCER MODE OF ACTION OF 
BUFADIENOLIDES ISOLATED FROM URGINAVIA ALTISSIMA 
7.1 Introduction
Uncontrolled cell proliferation is a feature of human cancer/ Studies on medicinal plants 
have shown their importance in providing effective anticancer agents/ Bufadienolides from 
plants and animals are known to possess anticancer properties, however their mode of action 
is not fully defined and they are thought to be polypharmacological compounds/ In this 
study the anticancer mechanism of bufadienolides was investigated by using the COMPARE 
algorithm provided by the NCl"  ^ followed by molecular docking studies using the Molecular 
Operating Environment programme (MOE 2012.10). The COMPARE and MOE 
programmes will be discussed in detail below.
7.2 COMPARE (Computerised Pattern-Recognition Algorithm)
COMPARE is a pattern recognition algorithm provided by the NCI and is used for predicting 
the possible mechanism of action of growth inhibition com poundsI t  was developed by Ken 
Pauli during the early stages of the NCI 60 cancer cell line screen. During the development 
of the screen, he recognised that the sensitivity of a cell line to tested compounds formed a 
unique pattern, and that the compounds with similar patterns tended to have similar 
mechanisms of cell growth inhibition."^ An example of the use of COMPARE in suggesting 
the possible mode of action, was the identification of the anticancer mode of action of 
azatoxin."  ^ Azatoxin was rationally designed to inhibit topoisomerase II, but COMPARE 
calculations suggested its anticancer mode of action was the disruption of tubulin 
polymerisation, which was demonstrated experimentally."^
The COMPARE methodology involves the calculation of a linear correlation coefficient 
between the data of all cell lines for the compound of interest (seed) and the sets of data in 
the database to be searched. The results are sorted by the Pearson’s correlation coefficient (r) 
produced between -1 to 1.^  The COMPARE calculation can be modified by a number of 
parameters such as setting the calculations to give positive correlations (standard 
correlations) or the largest negative correlations (reverse correlations). The database that can 
be searched with a COMPARE calculation includes the synthesis database, which consists of 
cell growth inhibition data of approximately 38,000 pure natural products or synthetic 
compounds and the standard agents, which is a set of 175 compounds that have been 
clinically tested in humans for their anticancer activity.^ The other databases are the diversity
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set, consisting o f  1990 compounds available from the NCI on 96 well plates, the natural 
produets extracts which consists o f  15,000 crude natural products extracts, the moleeular 
target database which consists o f  data o f  approximately 200 target levels and the NCI 
mieroarray database containing D N A  measurements/
To determine the possible growth inhibition mechanism o f  bufadienolides isolated from 
Urginavia altissima, a COMPARE analysis was performed for eaeh bufadienolide 
(compounds UA.l-UA.9) using the GI50 mean graphs from the five dose screen. The 
standard agents’ database was used for comparison and to suggest the possible growth 
inhibition mechanism o f  bufadienolides based on the minimum correlations o f  > 0.45 with 
compounds with known modes o f  actions. The count results were set to return a maximum o f  
20 compounds tested on minimum count common cell lines above 40. From the analysis, the 
algorithm returned positive correlations to drugs with modes o f  action in three categories: 
DN A  interacting (alkylating agents), D N A  antimetabolites and topoisomerase II inhibitors. 
Compounds UA.l, UA.2, UA.3, UA.4 and UA.9 correlated to all the three categories o f  mode 
o f  action. Compound UA.6 correlated to alkylating agents and D N A  antimetabolites while 
compounds UA.7 and UA.8 correlated with alkylating agents and topoisomerase inhibitors 
(Figure 7.1).
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Figure 7.1: Bar chart summarizing the top 20 correlations, a with r > 0.45, and known 
mode of action for each of the nine bufadienolides (UA.1-UA.9)
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Compound UA.5 did not correlate to any of the categories at a minimum correlation of 0.45, 
however at a correlation of > 0.2 based on a set count of 20 compounds, compound UA.5 
correlated with compounds belonging to the three categories, with the DNA interacting 
agents (alkylating agents) showing a higher number of correlations (Figure 7.2).
c
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HIH
ALK YLA TING
10
Number of correlations 
Figure 7.2: Bar chart summarizing the top 20 correlations, a with r > 0.2, and known 
mode of action for compound UA.5
Based on the COMPARE results it can be concluded that bufadienolides exert their growth 
inhibitory activity possibly by interacting with the DNA, inhibiting the activity of 
topoisomerases leading to impaired transcription and replication processes and also as DNA 
antimetabolites. In the effort to interpret the possible moleeular mechanism for the 
interaction of bufadienolides with DNA and topoisomerase I and II, molecular docking 
studies were carried out to simulate the possible modes of interaction between bufadienolides 
(compounds UA.l -  UA.I2) and DNA and also between bufadienolides (compounds UA.l -  
UA.12) and the amino acids of both topoisomerase I and II. Compounds U A .ll -  UA.12 
were not tested for their in vitro anticaneer activities.
7.3 Molecular docking studies
Molecular docking is a key tool in structural molecular biology and computer aided drug 
design.^ It is used to predict the binding orientation of a small molecule (ligand) to their 
protein target (receptor) in order to determine the affinity and the possible activity of the 
ligand.^
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The drug target interaction theory was formulated by Fischer to describe the enzyme 
substrate interaction and has been called the lock-and-key model.^ In the model, the receptor 
contains a binding pocket complementary to the ligand in both steric and electronic ways, 
such that a network of favourable interactions between the ligand and the receptor is 
established upon binding (Figure 7.3).^
Ligand
Active site
Ligand-recentor complexReceptor
Figure 7.3: Ligand and receptor interaction
To predict the binding affinity of the ligand to its target, one of the scoring schemes is the 
energy component method, which assumes that the change in the free energy upon binding of 
a ligand to a receptor can be broken down into a sum of individual contribution:^
^Gbind~AGint+AGsoiv+AGconf+AGmotion whcrc AGjnt is the specific ligand-receptor interaction, 
AGsoiv is the interaction of ligand and receptor with solvent, AGconf is the conformation 
change in the ligand and the receptor and AGmotion is the motions in the ligand and the 
receptor during the complex formation.^
The binding free energies of a ligand-protein complex are therefore known to include 
enthalpy (AH) and entropy (AS) which can compensate each other based on the fact that as 
the binding becomes stronger, the enthalpy becomes more negative and entropy tends to 
decrease due to the formation of a tight complex because of hydrogen bonding and van der 
Waals interaction,  ^ Favourable enthalpy therefore requires complementary placement of 
hydrogen bond and acceptor groups at the binding interface. As the binding becomes weaker, 
enthalpy becomes less negative and entropy tends to increase due to an increase in 
conformation freedom. The free energy for the formation of the ligand-receptor complex 
can therefore be calculated as follows:
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AGbind^AH-TAS and under equilibrium conditions the free energy equals to AGbind = AH-TAS 
= -RTlnKA=-RTlnKo
In drug design, molecules with favourable enthalpy and entropy contributions to binding 
energies are regarded as good hits and because of this, docking studies play an important role 
in drug design and determination of the drug mechanism/^ The docking programmes are 
considered as important computational filters to reduce labour and cost needed for the 
development of effective medicinal compounds. They also help in understanding the 
mechanism of action of a drug when used after experimental screening.
In this study, docking studies were carried out using B-DNA and topoisomerase I and II. The 
aim of this was to determine whether bufadienolides isolated from Urginavia altissima exert 
their growth inhibitory activity by interacting with DNA and/or inhibiting the activity of 
enzymes topoisomerase I and II based on the results obtained from the COMPARE 
algorithm.
7.3.1 Molecular docking on compounds UA.1-UA.12 with DNA (deoxyribonucleic acid)
DNA is a linear polymer and consists of pyrimidine bases, cytosine (C), thymine (T), and 
purine bases adenine (A) and guanine (G), as well as P-D-2-deoxyribose sugars and 
phosphate groups. The sugar and the phosphate groups form the backbone of the DNA 
polymer whereby the carbon at the 3’ position of the deoxyribose sugar is connected to the 
carbon at the 5’ position of the next deoxyribose sugar via a phosphate group. DNA is 
essential for several biological processes and its main functions are transcription and 
replication.^^ Transcription is involved in the construction of proteins while replication 
produces copies of DNA. Due to these processes DNA is a target of many anticancer and 
antibiotics agents. The interaction of DNA with drug molecules plays a key role in drug 
design. The binding modes of small molecules with DNA can be covalent binding or non- 
covalent binding, which is the major DNA binding mode and it includes non-specific 
electrostatic interaction and DNA minor or major groove binding.M olecular  docking is 
important in predicting the possible interaction between a drug and the nucleic acid in non- 
covalent binding mode.
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Molecular docking studies on the bufadienolides, compounds UA.l to UA.12 and a control 
compound, 2,5-bis(4'-2"(3,4,5,6-tetrahydropyrimidinyl)phenyl)furandihydrochloride, known 
to interact with DNA and to inhibit the topoisomerases,^"^ were carried out with the B-DNA 
duplex sequence d(CCGGTACCGG) (PDB ID: 3IXN) (figure 7.4) in order to determine 
whether these compounds interact with the DNA and, if so, to determine the atoms involved 
in binding and to determine the ligand conformation as per the pose of the molecule with the 
best binding energy.
Figure 7.4: B-DNA (PDB ID: 3IXN)
7.3.1.1 Results of molecular docking on compounds UA.1-UA.12 with DNA
Molecular docking simulations with B-DNA were performed on bufadienolides (UA.l- 
UA.12) and 2,5-bis-(4'-2"(3,4,5,6-tetrahydropyrimidinyl)phenyl)-furan dihydrochloride as a 
control. The 2,5-bis(4'-2"(3,4,5,6-tetrahydropyrimidinyl)phenyl)furandihydrochloride is a 
dicationic, diaryl furan modeled by Kanagy and Wilson. It is known to bind to the AT- 
rich regions of the minor groove of DNA and has been tested as a potential inhibitor of the 
enzyme topoisomerase II, and has also been considered as an antigiardial agent.
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Flexible ligands, the eontrol and compounds UA.1-UA.12, were docked with both rigid and 
induced fit receptor and the possible active conformations in terms of binding energy were 
obtained for eaeh compound [Tables 7.1-7.18]. The most active conformations of the control 
and bufadienolides are reported in Table 7.3.1.1. The most active conformations of the 
control and bufadienolides formed hydrogen bond interactions with the DNA. The binding 
affinities of bufadienolides were in the range of -11.1268 and -5.4498 kcal/mol in rigid 
receptor docking and between -11.2409 to -5.8014 keal/mol in induced fit docking. Some 
bufadienolides, compounds UA.6, UA.9, UA.10 and U A .ll failed to bind to DNA in both 
cases. Table 7.3.1.1 shows the binding affinities, hydrogen bond interactions, hydrogen 
bond acceptors and the bond distances of the most active conformations of the control and 
bufadienolides. Compounds UA.3, UA.4, UA.5, UA.7 and UA.12 gave lower binding 
energies than the control in rigid receptor docking, while compounds UA.2, UA.3, UA.4, 
UA.5, UA.7 and UA.12 gave a lower binding affinity than the control in induced fit docking 
indicating higher binding affinity to DNA. The docking results indicate that the eontrol and 
compounds UA.l, UA.2, UA.3, UA.4, UA.5, UA.7, UA.8 and UA.12 fit into the curved 
contour of the DNA and forms hydrogen bonds with the DNA bases, the phosphate and 
deoxyribose sugar of the DNA backbone. The functional groups of bufadienolides involved 
in the hydrogen bonding are the 3-OH, 11-OH, 14-OH, 19-CHO, hydroxyl groups of the 
glucose unit, 24-0 and the a-pyrone ring.
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7.3.2 Molecular docking of control and bufadienolides with topoisomerase I/II-DNA 
complex
Topoisomerases are enzymes that play an important role in the regulation of the physiological 
function of the genome/^ They control DNA topology by cleaving and rejoining DNA 
strands, therefore preventing supercoiling of the DNA, which can form deleterious structures. 
The opening of the DNA duplex and the separation of its two strands during transcription and 
replication generate torsional tension on both sides of the open DNA strands.E xcessive  
supercoiling tightens the DNA and prevents further separation of the strands, thereby stalling 
the polymerase. The two major classes of topoisomerase enzymes are the type I and type II 
and are distinguished by the number of DNA strands that they cleave. Topoisomerase I 
produces a break in a single strand of DNA and topoisomerase II breaks both DNA strands. 
Beyond their normal functions, topoisomerase enzymes have become important targets for 
the treatment of cancer. Their inhibition in the cell results in impaired DNA relegation and 
other catalytic cycles, leading to cell death.
In this study, the COMPARE analysis resulted in positive correlations of bufadienolides 
isolated from Urginavia altissima to drugs that inhibit topoisomerase II. In order to gain an 
insight of the binding mode of bufadienolides with topoisomerase I and topoisomerase II, 
moleeular docking analysis was perfomed using topoisomerase I/DNA/drug (PDB ID: 1K4T; 
intercalated drug: topotecan) (Figure 7.5) and topoisomerase II/DNA/mitoxantrone, PDB ID: 
4G0V (Figure 7.6). 2,5-Bis(4'2"(3,4,5,6tetrahydropyrimidinyI)phenyl)furan.dihydrochIoride, 
known to interact with topoisomerase I, was used as a eontrol. Docking analysis of the 
bufadienolides with the targets was performed by MOE 2012 and the electrostatic forces 
were used as descriptors for docking analysis.
Fig. 7.6Fig. 7.5
Figure 7.5: Topoisomerase I/DNA complex (PDB ID: 1K4T) and Figure 7.6: 
Topoisomerase II/DNA complex (PDB ID: 4G0V)
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7.3.2.1 Results for molecular docking of compounds UA.1-UA.12 with topoisomerase 
I/II DNA complex
Molecular docking of the rigid and induced fit topoisomerase I/II DNA complex with flexible 
ligands, the control and bufadienolides, UA.1-UA.12 gave several possible active 
conformations (Tables 7.19-7.50). The most active conformations obtained from docking 
bufadienolides with topoisomerase I/II DNA complex are shown in Tables 7.3.2.1 and 
132.2 . The tables show the hydrogen bond interactions, hydrogen bond acceptors, binding 
energies and bond distances for the most active conformations of the control and 
bufadienolides formed from docking with both the rigid and induced fit topoisomerase I/II- 
DNA complex.
The most active conformations of the control and bufadienolides formed hydrogen bond 
interactions with amino acids of topoisomerase I/II and DNA. Componds UA.6, UA.9, 
UA.10 and U A .ll did not bind to the topoisomerase I/DNA complex and eomponds UA.1, 
UA.6, UA.7, UA.9, UA.10 and U A .ll did not bind to the topoisomerase II/DNA complex. 
Compounds UA.4, UA.5 and UA.12 gave a lower binding energy than the control in the rigid 
topoisomerase I/DNA complex docking while compounds UA.8 and UA.2 gave a higher 
binding energy than the control in the induced fit docking topoisomerase I/DNA complex. 
On the other hand, compounds UA.3 and UA.5 gave lower binding energies than the control 
in the rigid topoisomerase II/DNA complex docking while compounds UA.4, UA.5 and 
UA.12 gave lower binding affinity than the control in the induced fit topoisomerase II/DNA 
eomplex docking. The docking results indicate that the control and bufadienolides interact 
with amino acids, arginine, lysine and asparagine of topisomerase I/DNA and amino acids 
glutamine, lysine, glycine, asparagine and serine of topoisomerase II/DNA complex. The 
functional groups of bufadenolides involved in hydrogen bonding with topoisomerases are 
14-OH, 3-OH, 3-ethoxy, 11-OH, 24-0, the glucose unit and the a-pyrone ring.
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7.4 CONCLUSIONS
In this study molecular docking was performed to simulate the modes of interactions between 
bufadienolides isolated from Urginavia altissima (compounds UA.1-UA.12) and DNA, 
topoisomerase I and II/DNA complex. The results suggested that:
• The DNA binding of bufadienolides (UA.l, UA.2, UA.3, UA.4, UA.5, UA.7, UA.8 
and UA.12) act like groove binders.
• The bufadienolides, UA.6, UA.9. UA.10 and UA.11, do not bind to the DNA and 
topoisomerase I/DNA complex, while compounds UA.l, UA.6, UA.7, UA.9. UA.10 
and U A .ll do not bind to the topoisomerase II/DNA complex suggesting a different 
anticaneer mode of action.
• From the binding energies, the binding affinity of bufadienolides to the DNA and 
topoisomerase I/DNA complex is stronger when the 3-OH is replaced by a glucose 
unit and possesses a double bond at the C-4 position and hydroxyl group at the C-11 
position. The binding affinity of bufadienolides to topoisomerase II is hindered by the 
presence of both a and P 3-OH.
• The oxidation of the methyl group at C-19 to CH2OH (UA.6) was found to hinder the 
binding of bufadienolides to DNA, topoisomerase I and II DNA complexes, and the 
acétylation of the sugar unit lowers the binding affinity to DNA and increases the 
binding affinity to topoisomerase I and II DNA complexes.
• The presence of an aldehyde at the C-19 position and a C-4 double bond is essential 
for DNA and topoisomerase interaction. The bufadienolides lacking the double bond 
at the C-4 position and possessing an aldehyde at the C-19 position (UA.9-UA.il) do 
not generate any binding energies and therefore do not interact with the DNA and 
topoisomerases and therefore suggest a different mode of action.
Several anticaneer modes of action of bufadienolides have been proposed before including 
the inhibition of Na^/K^-ATPase and topoisomerase 11,^  ^however these mode of actions are 
not fully defined. The finding from this study suggest that some bufadienolides can bind to 
DNA and topoisomerase, therefore inhibiting the growth of cancer cell lines. It can be 
concluded that bufadienolides are DNA minor groove binders and topoisomerase inhibitors 
and that changes in the functional groups present can alter their binding affinity. A 
summarised structure relationships of bufadienolides isolated from Urginavia altissima with 
regard to DNA and topoisomerase interaction is presented below (Figure 7.7).
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OH
Oxidation of OH to keto group 
increases the binding affinity to 
DNA and topoisomerase I and II
Double bond at C-4 is essential for 
interactions with DNA, 
topoisomerase I and II.
Oxidation of CH3 to CH2OH hinders 
binding to DNA and topoisomerase I 
and II. Oxidation to aldehyde for 
compound with double bond at C-4 
increases binding affinity.
Replacement o f OH with glucose 
increase binding affinity. Acétylation 
of glucose lowers the binding 
affinity to DNA and increases 
binding affinity to topoisomerase I 
and II. Presence o f a and (3 3-OH 
inhibit binding to topoisomerase II.
Figure 7.7: Effect of functionality of bufadienolides isolated from Urginavia 
altissima on interaction with DNA, topoisomerase I and II.
To determine the correlations between the experimental anticaneer activity of bufadienolides, 
UA.1-UA.12 and their lowest binding energies obtained from rigid docking with DNA, 
topoisomerase I and II, correlation graphs of the binding energy versus logioGIso values of a 
selected non-small lung cancer cell line A549/ATCC and their binding energies were plotted 
(Figures 7.8). No significant squared correlation coefficients were obtained. The results of 
these correlations show that the approach to predict the logioGIso for the docked 
bufadienolides in this study is not valid.
To confirm the findings firom molecular docking, in vitro DNA binding assays such as 
isothermal titration calorimetry, topoisomerase I activity assay based on relaxation of 
supereoiled DNA and topoisomerase II activity based on decatenation of double stranded 
DNA should be done.^^’^ ^
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CHAPTER EIGHT: EXPERIMENTAL 
8.1: Spectroscopic and spectrometric analysis
NMR, FTIR, mass spectrometric analysis, measurement of specific rotations and 
derivatisation of compounds were employed in the identification of the chemical constituents 
of Urginavia altissima, Ornithogalum dubium ‘Hybrid’ and Ornithogalum duhium ‘Sochi’.
8.1.1: Nuclear magnetic resonance spectroscopy (NMR)
NMR experiments were carried out on a 500MHz Bruker AVANCE NMR spectrometer at 
the Department of Chemistry, Faculty of Engineering and Physical Sciences, University of 
Surrey, UK. Spectra was recorded either in deuteriochloroform or deuteriomethanol and the 
chemical shifts were recorded in parts per million (ppm). The deuteriochloroform and 
deuteriomethanol were referenced according to central line at 6 7.26 and 5 4.87 respectively 
in the NMR spectrum and 5 77.23 and 6 49.15 for deuteriochloroform and methanol 
respectively in the ^^CNMR spectrum.
8.1.2: Fourier Transform Infrared Spectroscopy (FTIR)
Infrared spectra were recorded using Perkin-Elmer (2000 FTIR) spectrometer at the 
Department of Chemistry, Faculty of Engineering and Physical Sciences, University of 
Surrey, UK.
8.1.3: Mass spectrometry (MS)
High resolution electro spray ionization mass spectra (HRESIMS) were recorded at Oxford 
University by Collin Sparrow on a Bruker MieroToF mass spectrometer using an agilent 
1100 HPLC to introduce the samples.
8.1.4: Specific rotation
Specific rotations were measured at room temperature in either chloroform or methanol using 
JASCO P-1020 polarimeter at the Department of Chemistry, Faculty of Engineering and 
Physical sciences. University of Surrey, UK.
8.2: Electronic circular dichroism (ECD)
The ECD spectra were measured on a Chirasean CD spectrometer using a 1 mm cell with 
aeetonitrile and methanol as solvents at Department of Chemistry, Faculty of Engineering 
and Physical sciences. University of Surrey, UK.
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8.3: Molecular docking studies
The PDB files of the crystal structures of B-DNA, topoisomerase I and topoisomerase II were 
obtained firom the RCSB protein data bank. Molecule building, minimization and docking 
were carried out using Molecular Operating System (MCE 2012).
8.4: Plant collection, extraction and isolation of compounds 
8.4.1: Plant collection
Urginavia altissima (L. f.) Speta was obtained from a green house collection at the University 
of Graz, Graz, Austria by Wolfgang Wetsehnig fi*om an earlier collection from southern 
Africa. The plants were then personally propagated by Wetsehnig. A voucher specimen 
LM170303/03 has been retained.
The bulbs of Ornithogalum dubium ‘Hybrid’ and Ornithogalum dubium ‘Sochi’ were 
purchased from http://www.dixexport.com.
8.4.2: Extraction of plant materials
The bulbs of Urginavia altissima (3 kg), Ornithogalum dubium ‘Hybrid’ (4 kg) and 
Ornithogalum ponticum ‘Sochi’ (3 kg) were chopped into small pieces for extraction. The 
chopped bulbs were extracted using ethanol by shaking at room temperature for 48 hr s. The 
solvent was removed in vacuo and the crude extract left to dry. The mass of dried crude 
extracts (86 g of Urginavia altissima, 116 g of Ornithogalum dubium ‘Hybrid’ and 200 g of 
Ornithogalum ponticum ‘Sochi’) were recorded.
8.4.3: Isolation and purification of compounds
Thin layer chromatographic analysis and eolunm chromatography over silica (Merck Art. 
9385) were used for the isolation process. Different column sizes ranging from 2-6 cm 
diameter were used for column chromatography. The choice of the columns depended on the 
purification stage and the amount of the samples. The separation of crude extracts were 
carried out over silica (Merck Art. 9385) with DCM/MeOH step gradient starting with 100% 
DCM and gradually increasing the concentration of MeOH from 1% to 50% MeOH (scheme 
1). Further purifications were carried out using lem diameter eolunm packed with either 
silica gel (Merck Art. 9385) in DCM or Sephadex (LH 20) in MeOH/DCM. All column 
chromatographic separations were carried out under gravity. TEC and ^H NMR was used to 
monitor all the fractions collected. Similar fractions were combined and further purified.
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Mixtures which were difficult to separate using gravity column chromatography were 
separated using TLC plates (Merck Art. 554). The sample was lined across the TLC plate, I 
cm from the bottom of the plates. The plates were placed in chromatographic tanks and left 
to develop in the desired solvent systems. The developed plate was detected and marked 
under UV light. The marked portion was scrapped off the plate, dissolved in suitable solvent 
and decanted. Further details on isolation and purification are described in schemes 1, 2 and
3.
8.5: Chemical analysis
8.5.1: Acétylation of hydroxylated compounds
Pyridine (1ml) and acetic anhydride (1ml) were added to the hydroxylated compounds in a 
round bottom flask. The reaction was left for 24 hrs and 5ml of methanol added and removed 
61Î vacuo to remove unreaeted acetic anhydride. 4x5 mis of toluene were added successively 
and evaporated en vacuo to remove the pyridine. Finally 5x5 mis of methanol was added and 
evaporated to remove toluene. Thin layer chromatography (TLC) was then carried out to 
check whether the reaction had gone to completion and also to choose a solvent system to be 
used in the separation of the aeetylated compounds.
8.5.2: Visualization of compounds
8.5.2.1: Visualization by use of UV/Vis light
The compounds were first detected under UV light at 254 nm and by fluorescence under UV 
light at 365 nm. The other compounds which are not detectable were visualized by spraying 
with a chemical reagent, anisaldéhyde.
8.5.3.2: Visualization of compounds with anisaldéhyde
For the preparation of anisaldéhyde, 96% of cold methanol, 2.5 % of H2SO4 and 1.5 % o ïp -  
anisaldehyde was used. To visualize the compounds the developed TLC plates were sprayed 
with the reagent and. A distinctive color of the TLC bands was then observed
8.6 Methodology of the NCI in vitro cancer screen
The methodology of the in-vitro cancer screen can be found on the following website 
http://dtp.nci.nih.gov/branehes/btb/ivelsp.html.
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8.7: Constituents of Urginavia altissima 
8.7.1.: Physical data for compound UA.l
Name: 3a,l ip,14p-trihydroxybufa-4,20,22-trienolide
Yield: 2.9 mg (0.003 %)
Physical description: Colourless oil
Mass spectrum: [M + Na]^/w/z 423.2135 (C24H320sNa) calculated m/z value = 423.214744 
Infrared spectrum: 3418 cm'^ (0-H stretch) and 1715 (C=0 stretch)
= +53.4° (c= 0.0014g/ml, CHCI3)
^H, ^^ C NMR and 2D NMR data: presented in Table 3.2.1 
8.7.2: Physical data for compound UA.2 
Name: 3a-ethoxy-lip, 14p-dihydroxybufa-4,20,22-trienolide 
Yield: 3.9 mg (0.005 %)
Physical description: Colourless oil
Mass spectrum: [M + Na]*^  miz 451.2453 (C26H360sNa) calculated m/z value = 451.246044 
Infrared spectrum: 3448 em"^  (0-H stretch), 1714 (C=0 stretch) and 1660 cm'^ (C=C stretch) 
+60.7° (c= 0.001 Ig/ml, CHCI3)
^H, ^^ C NMR and 2D NMR data: presented in Table 3.2.2 
8.7.3: Physical data for compound UA.3
Name: 3a-(O-P-D-glucopyranoside)-lip,14p-dihydroxybufa-4,20,22-trienolide 
Yield: 9.9 mg (0.012 %)
Physical description: Colourless oil
Mass spectrum: [M + Na]’^ m/z 585.2672 (C3oH420ioNa) calculated m/z value = 585.267568 
Infrared spectrum: 3396 cm'^ (0-H stretch), 1715 (C=0 stretch) and 1629 cm'^ (C=C stretch)
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[a]D^ ‘^^ °= +31.5“ (c= 0.002g/ml, MeOH)
*H, ’^ C NMR and 2D NMR data: presented in Table 3.2.3 
8.7.4: Physical data for compound UA.4
Name : 3 a- [2 ’ ,3 ’ 4 ’ , 6  ’ -tetra-O-aeetyl-O-p-D-glucopyranoside] -11P, 14p-dihydroxybufa-
4.20.22-trienolide 
Yield: 6 . 6  mg (0.008 %)
Physical description: Colourless oil
Mass spectrum: [M + Na]^ wî/z 753.3091 (CsgHsoOMNa) calculated m/z value = 753.309827
Infrared spectrum: 3501 cm'^ (0-H stretch), 1748 and 1714 cm'^ (C=0 stretch) and 1634 cm'^ 
(C=C stretch)
= +64.8° (c= 0.0023 g/ml, CHCI3)
^H, ^^ C NMR and 2D NMR data: presented in Table 3.2.4
8.7.5: Physical data for compound UA.5
Name: 3a-[2’,3’4’,6’-tetra-0-aeetyl-(9-P-D-glueopyranoside]-14P-hydroxy-l 1-oxobufa-
4.20.22-trienolide
Yield: 2.7 mg (0.003%)
Physical description: Colourless oil
Mass spectrum: [M + Na]’^ m/z 751.2938 (C3gH4gOi4Na) calculated m/z value = 751.294176
Infrared spectrum: 3481 cm'^ (0-H stretch), 1745, 1732 and 1715 em'^ (C=0 stretch) and 
1649 cm'^ (C=C stretch)
= +38° (c= 0.0008 g/ml, CHCI3)
^H, ^^ C NMR and 2D NMR data: presented in Table 3.2.5
8.7.6: Physical data for compound UA.6
Name: 3a-(O-P-D-glucopyranoside)-lip,14p,19-trihydroxybufa-4,20,22-trienolide.
Yield: 5.5 mg (0.006 %)
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Physical description: Colourless oil
Mass spectrum: [M + Na]^ w/z 601.2621 (C3oH420nNa) calculated m/z value = 601.262482 
Infrared spectrum: 3390 cm“^ (0-H stretch) and 1732 (C=0 stretch)
= +42.9° (c= 0.0007 g/ml, CHCI3)
^H, ^^ C NMR and 2D NMR data: presented in Table 3.2.6 
8.7.7: Physical data for compound TJA.7 
Name: 3p,lip,14p-trihydroxybufa-4,20,22-trienolide 
Yield: 3.5 mg (0.004 %)
Physical description: Colourless oil
Mass spectrum: [M + Na]^w/z 423.2130 (C24H320sNa) calculated m/z value = 423.214744 
Infrared spectrum: 3427 cm‘^  (0-H stretch) and 1711 (C=0 stretch)
= +51.1° (c= 0.0019 g/ml, CHCI3)
^H, ^^ C NMR and 2D NMR data: presented in Table 3.2.7
8.7.8: Physical data for compound UA.8
Name: 3P-ethoxy-lip, 14p-dihydroxybufa-4,20,22-trienolide.
Yield: 1.8 mg (0.002%)
Physical description: Colourless oil
Mass spectrum: [M + Na]"^  m!z 451.2450 (C26H3 6 0 5 Na) calculated m/z value = 451.246044 
Infrared spectrum: 3445 cm'^ (0-H stretch) and 1738 em'^ (C=0 stretch)
= +34.8° (c= 0.0007 g/ml, CHCI3)
^H, ^^ C NMR and 2D NMR data: presented in Table 3.2.8 
8.7.9: Physical data for compound UA.9 
Name: 3-^ z -19-oxobufalin.
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Yield: 2.0 mg (0.002 %)
Physical description: Colourless oil
Mass spectrum: [M + Na]^m/z 423.2128 (C24H320sNa) calculated m/z value = 423.214744 
Infrared spectrum: 3418 cm‘^  (0-H stretch), 1715 and 1730 cm'^ (C=0 stretch)
=+87.0° (c= 0.0004 g/ml, CHCI3)
^H, ^^ C NMR and 2D NMR data: presented in Table 3.2.9 
8.7.10: Physical data for compound UA.IO
Name: 3a-[2’,3 ’4’,6’-tetra-O-aeetyl-O-p-D-glueopyranoside]-14p-hydroxy-19-oxobufa-
4.20.22-trienolide.
Yield: 1.2 mg (0.001 %)
Physical description: Colourless oil
Mass spectrum: [M + Na]^ w/z 770.8473 (C3gH5oOi4Na) calculated m/z value = 753.309827 
Infrared spectrum: 3445 cm'^ (0-H stretch) and 1747 em'^ (C=0 stretch)
= +32.0° (c= 0 . 0 0 1  g/ml, CHCI3)
^H, ^^ C NMR and 2D NMR data: presented in Table 3.2.10 
8.7.11: Physical data for compound U A .ll
Name: 5a-[2’,3’4’,6’-tetra-0-acetyl-0-P-D-glueopyranoside]-14P-hydroxy-l9-oxobufa-
4.20.22-trienolide -4,20,22-trienolide (seillaglyeoside/seillaren F)
Yield: 3.1 mg (0.004 %)
Physical description: Colourless oil
Mass spectrum: [M + Na]^m/z 751.2946 (C3gH4gOi4Na) calculated m/z value = 751.294176 
Infrared spectrum: 3415 cm'^ (0-H stretch), 1743, 1732, 1715 em'^ (C=0 stretch)
= +47.8° (c= 0.001 g/ml, CHCI3)
^H, ^^ C NMR and 2D NMR data: presented in Table 3.2.11
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8.7.12: Physical data for compound UA.12
Name: 3a-(O-P-D-glueopyranoside)-14p-hydroxy-19-oxobufa-20-22-dienolide 
Yield: 2.1 mg (0.002%)
Physical description: Colourless oil
Mass spectrum: [M + Na]’^ m/z 583.3 (C3oH4oOioNa) calculated m/z value = 583.251918 
Infrared spectrum: 3433 em'^ (0-H stretch) and 1710 cm'^ (C=0 stretch)
^H, ^^ C NMR and 2D NMR data: presented in Table 3.2.12 
8.7.13: Physical data for compound UA.13 
Name: 1 p,6a-dihydroxy-4(l 5)-eudesmene 
Yield: 0.5 mg (0.0006 %)
Physical description: Colourless oil
Mass spectrum: m!z 238 (C15H26O2) calculated m/z value = 238.193280
Infrared spectrum: 3428 em'^ (0-H stretch), 1639 cm'^ and 873 cm"^  (C= C stretches)
= +44° (c= 0.0037 g/ml, CHCI3) literature +45° (e= 0 .0 1  g/ml, CHCb)^^
^H, ^^ C NMR and 2D NMR data: presented in Table 3.2.13 
8.7.14: Physical data for compound UA.14 
Name: 6a-hydroxy-4(l5)-eudesmen-1 -one 
Yield: 1.0 mg (0.001 %)
Physical description: Pale yellow oil
Mass spectrum: [M + Na]^m/z 259 (Ci5H2 4 0 2 Na) calculated m/z value = 259.167400 
Infrared spectrum: 3445 em'^ (0-H stretch) and 1645 cm'^ (C=0 stretch)
+5° literature (e= 0.06 g/ml, CHCl3)^ ^
^H, ^^ C NMR and 2D NMR data: presented in Table 3.2.14
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8.7.15: Physical data for compound UA.15
Name: 3-(4-methoxybenzyl)-5,6,7-trimethoxychroman-4-one 
Yield: 2 mg
Physical description: colourless oil
Mass spectrum: m/z 339.3 [M -H-H 2O] (C20H19O5) calculated m/z value = 339.123249 
Infrared spectrum: 3390 cm'^ (0-H stretch) and 1731 cm’^  (C=0 stretch)
^H, NMR and 2D NMR data: presented in Table 3.2.15 
8.7.16: Physical data for compound UA.16
Name: [2’R,3’Y,4’R,55',5’5]-3’,4’,6’-Trihydroxy-5-hydroxymethyl-2,3,4,5-tetrahydro-5H-
[2,3]bifuranyl-2-one (polybotrin)
Yield: 3.8 mg (0.004%)
Physical description: Colourless oil
Mass spectrum: m!z 254.8 (C9H12O7) calculated m/z value = 232.058303 
Infrared spectrum: 3444 em"^  (0-H stretch) and 1682 cm'^ (C=0 stretch)
= -43.3° (Literature -41.1°, e= 0.15 g/ml)^^
^H, ^^ C NMR and 2D NMR data: presented in Table 3.2.16 
8.7.17: Physical data for compound UA.17
Name: (1 ’R,2’R,3’Y,4’7?)-l ’-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-2,3-diol 
(adenoside)
Yield: 1.5 mg (0.002 %)
Physical description: Colourless oil
Mass spectrum: [M + Na]'^m/z 290.0856 (CioHi3N5 0 4 Na) calculated m/z value = 290.086524 
Infrared spectrum: 3419 em"^  (0-H stretch)
(Literature - 67.7°, c= g/ml, MeOH)^^
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^H, N M R  and 2D N M R  data: presented in  Table 3.2.17
8.7.18: Physical data for compound UA.18
Name: 9-Hydroxy-(10E,12Z)-octadecadienoic aeid ethyl ester 
Yield: 2.6 mg (0.003 %)
Physical description: Colourless oil
Calculated m/z value = 324.266445
Infrared spectrum: 3445 cm'^ (0-H stretch) and 1733 (C=0 stretch)
[a]o^  ^= +36.3 (c= O.OOlg/ml, CHCI3)
^H, ^^ C NMR and 2D NMR data: presented in Table 3.2.18 
8.8: Chemical constituents of Ornithogalum dubium ‘Hybrid’
8.8.1: Physical data for compound ODH.I
Name : (35)-5 -hydroxy-7-methoxy-3 -(4-methoxybenzyl)-4-ehromanone.
Yield: 2.1 mg (0.002%)
Physical description: Colourless oil
Mass spectrum: [M -H J 'tw/z  313.1 (CigHnOs) calculated m/z value = 313.107599 
Infrared spectrum: 3432 cm'^ (0-H stretch) and 1634 (C=0 stretch)
= +2 2 . 6  (c= 0 .0 1  g/ml, CHCI3)
^H, ^^ C NMR and 2D NMR data: presented in Table 5.1.2.1 
8.8.2: Physical data for compound ODH.2
Name: (3R)-5-hydroxy-7-methoxy-3-(4-methoxybenzyl)-4-chromanone.
Yield: 8.4 mg (0.007 %)
Physical description: Colourless oil
Mass spectrum: [M + Na]"^m/z 353.0 (CigHigOeNa) calculated m/z value = 353.100108
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Infrared speetrum: 3467 cm'^ (0-H stretch) and 1638 (C=0 stretch)
= +14.62 (c= O.Olg/ml, CHCI3)
^H, NMR and 2D NMR data: presented in Table 5.1.2.2 
8.8.3: Physical data for compound ODH.3
Name: (36)-5-hydroxy-7-methoxy-3-(4-hydroxybenzyl)-4-ehromanone 
Yield: 8 .8  mg (0.008 %)
Physical description: Colourless oil
Mass speetrum: [M +H]’^ «î/z 301 (C15H27O2) calculated m/z value = 301.107599 
Infrared speetrum: 3399 em"^  (0-H stretch) and 1639 (C=0 stretch)
= +16.99 (c= 0.023g/ml, CHCI3)
^H, ^^ C NMR and 2D NMR data: presented in Table 5.1.2.3 
8.8.4: Physical data for compound ODH.4
Name : (3R)-3,5-dihydroxy-7-methoxy-3 -(4 ’ -hydroxybenzyl)-4-ehromanone.
Yield: 12 mg (0.01 %)
Physical description: white needles
Mass spectrum: [M-H-H2 0 ]'«7/z 297.2 (C17H13O5) calculated m/z value = 297.076299 
Infrared speetrum: 3412 cm'^ (0-H stretch) and 1638(C=0 stretch)
= +46.5 (e= 0.003g/ml, MeOH)
^H, ^^ C NMR and 2D NMR data: presented in Table 5.1.2.4 
8.8.5: Physical data for compound ODH.5
Name: (3R)-3-hydroxy-7-methoxy-3-(4-hydroxybenzyl)-4-chromanone 5-O-p-D- 
glueopyranoside
Yield: 4.3 mg (0.004 %)
Physical description: white needles
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Mass spectrum: [M + Na]^Wz 501.2 (C23H220nNa) calculated m/z value = 501.137282 
Infrared speetrum: 3338 em'^ (0-H stretch) and 1730 (0=0  stretch)
+7.95 (e= 0.015 g/ml, MeOH)
^H, NMR and 2D NMR data: presented in Table 5.1.2.5 
8.8.6: Physical data for compound ODH.6
Name: (3i?)-3-hydroxy-7-methoxy-3-(4-hydroxybenzyl)-5-0-P-D-glucopyranosyl-(1^6)-P- 
D-glueopyranoside-4-chromanone
Yield: 0.7 mg (0.0006 %)
Physical description: Greenish oil
Mass spectrum: [M + Na]'"Wz 663.3 (C29H360i6Na) calculated m/z value = 663.190105 
Infrared speetrum: 3399 em"^  (0-H stretch) and 1726 (C=0 stretch)
= +74.36 (c= 0.001 Ig/ml, MeOH)
^H, NMR and 2D NMR data: presented in Table 5.1.2.6 
8.9: Chemical constituents of Ornithogalum ponticum ‘Sochi’
8.9.1: Physical data for compound OPS.l
Name: 3P-(0-a-L-rhamnoside)-5p, 14p-dihydroxy-19-oxoeardenolide.
Yield:2.6 mg (0.001 %)
Physical description: Colourless oil
Mass spectrum: [M -H]'Wz 549.5 (C 29H 41O 10) calculated m/z value = 549.269973 
Infrared spectrum: 3399 cm‘^  ( 0 - H  stretch) and 1735 ( C = 0  stretch)
= +23.87 (c= 0.003 g/ml, MeOH)
^H, ^^ C NMR and 2D NMR data: presented in Table 5.2.2.1 
8.9.2: Physical data for compound OPS.IA
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Name: 3p-[2’,3’,4 ’-tri-0 -<3ce(y/-(9 -a-L-rhamnoside]-5 p, 14p-dihydroxy-19-oxoeardenolide. 
Yield: 2.4 mg (0.001 %)
Physical description: Colourless oil
Mass spectrum: [M + Na]’^ m/z 699.5 (C35H48O13) calculated m/z value = 699.299262 
Infrared spectrum: 3497 cm'^ (0-H stretch) and 1745 (C=0 stretch)
= +16.08 (c= 0.005 g/ml, MeOH)
^H, ^^ C NMR and 2D NMR data: presented in Table 5.2.2.2 
8.9.3: Physical data for compound OPS.2
Name: .3 P-(0-a-L-rhamnoside)-5 p, 11 a, 14p-trihydroxy-l 9-oxocardenolide.
Yield: 1.6 mg (0.0008 %)
Physical description: Colourless oil
Mass speetrum: [M + Na]^m/z 589.3 (C29H42O11) calculated m/z value = 589.262482 
Infrared speetrum: 3398 em'^ (0-H stretch) and 1731 (C=0 stretch)
= +17.8 (c= 0.007 g/ml, MeOH)
^H, ^^ C NMR and 2D NMR data: presented in Table 5.2.2.3 
8.9.4: Physical data for compound OPS.2A
Name : 3 P- [2 ’ ,3 ’ ,4 ’ -tetra- 0-acetyl- O-a-L-rhamnoside] -5 p, 11 a, 14p-trihydroxy-19- 
oxoeardenolide.
Yield: 1.5 mg (0.0008 %)
Physical description: Colourless oil
Calculated m/z value = 734.314971
Infrared spectrum: 3508 em'^ (0-H stretch) and 1747 (C=0 stretch)
= + 12.5 (c= 0.003 g/ml, MeOH)
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NMR and 2D NMR data: presented in Table 5.2.2.4 
8.9.5: Physical data for compound OPS.3
Name: 3P-(0-a-L-rhamnoside)-5P, 11 a, 14P, 19-tetrahydroxy-eard-20(22)-enolide. 
Yield: 2 mg (0.001 %)
Physical description: Colourless oil
Mass spectrum: [M + Na]"^  Wz 591.3 (C29H44O11) calculated m/z value = 591.278132 
Infrared spectrum: 3419 cm'^ (0-H stretch) and 1635 (C=0 stretch)
[o]d -^^ °= +137.6 (c= 0.001 g/ml, MeOH)
^H, ^^ C NMR and 2D NMR data: presented in Table 5.2.2.5
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